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 Summary 
Malaria is caused by the asexual stages of human parasites of the genus Plasmodium. 
Among the five species pathogenic for humans, P. falciparum is accountable for more than 
500.000 deaths per year in Africa. The emergence of resitances to the actual treatments 
have made the development of new antimalarial medicines a key part of the global 
strategy for malaria eradication. 
P. falciparum infects almost exclusively human erythrocytes. In order to study the human 
malaria disease, a mouse model for P. falciparum infection has been developed. This model 
consist in the xenotransplant of human blood to immunodeficient mice that lacks T, B and 
NK cells (NODscidIL2Rnull), by the daily intraperitoneal injections of human erythrocytes. 
A detailed study of this xenotransplant have been addressed in the present work. A robust 
and reprocible growth of P. falciparum has been obtained in engrafted mice. The 
erythrocytic cycle length determined in the P. falciparum mouse model is smilar to the  
reported in the human host (48±1 hours). It has also been demostrated that the 
transmission to the mosquito host is also possible, confirming the presence of fertile 
sexual stages in the animal model. Three different phases have been identified in the P. 
falciparum humanized mouse model: engraftment with human erytrhocytes, P. falciparum 
infection and growth, and anaemia phase provoked by the massive clearance of infected 
and uninfected human erythrocytes. Throughout the phases, different inflammatory 
cytokines have been observed to be secreted, besides the model have been developed in 
immunodeficient mice. Some of the cytokines explored have shown a similar secretion 
pattern to the one observed for the human host.  
The high reproducibility of the model makes suitable the use of the P. falciparum 
humanized mouse model as a drug discovery tool to test the efficacy of new antimalarial 
drugs in the preclinical phases of the drug development process. In this context, the P. 
falciparum mouse model have been used to achieve the efficacy parametres of new 
antimalarial drugs, so as the phenotypical characteristics of the effect of the treatment on 
the parasite to discriminate different mechanism of action. 
All the similiarities found between the mouse model and the human infection, support that 
the P. falciparum humanized mouse model can be a good surrogate of the natural P. 
falciparum infection and a unvaluable tool for the drug development to assess the malaria 
eradication.
 Resumen 
La malaria está causada por los estadíos asexuales de los parásitos humanos del género 
Plasmodium. Entre las cinco especies patógenas para humanos, P. falciparum es el 
responsable de más de medio millón de muertes al año en África. La aparición de 
resistencias a los tratamientos actuales ha hecho que el desarrollo de nuevos fármacos 
antimaláricos sea crucial para la estrategia global de la erradicación de la malaria. 
P. falciparum infecta casi exclusivamente a eritrocitos humanos. Para poder estudiar la 
malaria human, un modelo murino de la infección de P. falciparum ha sido desarrollado. 
Este modelo está basado en el xenotransplante de sangre humana a ratones 
inmunodeficientes que carecen de células T, B y NK (NODscidIL2Rnull),  mediante la 
inyección diaria de eritrocitos humanos. 
Un estudio detallado de este xenotransplante ha sido realizado en este trabajo. Se ha 
conseguido un crecimiento robusto y reproducible de P. falciparum en los ratones 
xenotransplantados. La duración del ciclo eritrocítico de P. falciparum  determinado en el 
modelo murino de P. falciparum es similar al reportado en el hospedador humano (48±1 
horas). También se ha demostrado la transmisión al hospedador invertebrado (mosquito), 
confirmando la presencia de estadíos sexuales fértiles en el modelo animal. Además, se 
han identificado 3 fases diferentes en el modelo murino; quimerización con eritrocitos 
humanos, infección y crecimiento de P. falciparum y la fase de anemia provocada por la 
eliminación masiva de eritrocitos infectados y no infectados. Durante las distintas fases del 
modelo, diferentes citoquinas inflamatorias son secretadas y cuantificadas, a pesar de que 
el modelo se desarrolla en ratones inmuodeficientes. Algunas de las citoquinas observadas 
han mostrado un patrón de secreción similar al observado en el hospedador humano. 
La alta reproducibilidad del modelo hace posible su uso como una herramienta para 
probar nuevos fármacos antimaláricos en las fases preclínicas del desarrollo farmacéutico. 
En este contexto, el modelo murino de P. falciparum ha sido usado para obtener 
parámetros de eficacia de nuevos fármacos antimaláricos, además de las características 
fenotípicas del efecto del tratamiento en el parásito para poder discriminar diferentes 
mecanismos de acción. 
Todas las similaridades encontradas entre el modelo murino y la infección humana, 
respaldan el hecho de que el modelo de ratón humanizado puede ser un buen sustituto de 
la infección natural de P. falciparum y una herramienta esencial para el desarrollo de 
nuevos fármacos en la consecución de la erradicación de la malaria.  
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23 Introduction 
Malaria: The problem 
Malaria is one of the most deadliest disease in the world, with a high rate of mortality. 
Although malaria was prevalent throughout most of the world, currently is endemic of 
sub-tropical regions in the Asian, African and American continents (figure 1). However, 
malaria remains to be a disease of global health importance with 3.3 billion people at risk 
in more than 100 countries. Actually, it is estimated that anually there are 200 million 
cases and around 600.000 deaths [155]. The more susceptible population to suffer from 
malaria are pregnant women and children under 5 years old. 
 
Figure 1. Malaria global distribution (source CDC). In red is indicated high risk of malaria 
transmission, in yellow medium risk and in green are zones in which malaria is not 
transmited or reported. 
Around 50% of the worldwide population lives in areas with risk of malaria transmission. 
However, the continent which is more punished with this disease is Africa, in which the 
90% of malaria cases are reported. Malaria is usually a serious disease in developing 
countries where the resources are limited, the access to medicines is complicated and 
other serious diseases are common. 
Malaria is caused by the unicellular obligate intracellular protozoan parasite of the genus 
Plasmodium. There are more than 100 kinds of Plasmodium that can infect many animal 
species such as reptiles, birds and various mammals. Among these species, four can cause 
malaria in human beings: P. falciparum, P. vivax, P. malariae and P. ovale. In addition, 
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studies in Southeast Asia have shown that P. knowlesi, a malaria parasite that typically 
involves monkeys as the natural reservoir, can also infects humans [126]. 
Malaria due to P. vivax, P. ovale and P. malariae is less severe than that experienced by P. 
falciparum infections, these three species are accountable of less than 10% of the 
worldwide malaria cases [155]. However, P. falciparum is responsible of the 90% of the 
malaria cases and cause te 99% of deaths associated with this disease. 
The P. falciparum pathophysiological sympthoms ranges from asymptomatic infections to 
the usual malarial symptoms: fever, chills, sweating, headaches and muscle aches. 
However, in a subpopulation of the cases, malaria results in severe life-threatening 
complications such as hypoglycemia, metabolic, acidosis, cerebral malaria, severe malarial 
anaemia and respiratory distress. Most of the reported cases of severe malaria include 
malarial anaemia and cerebral malaria are typically displayed in children. However, adults 
are more likely to present jaundice, renal failure and respiratory distress due to 
pulmunary edema [153]. For this reason, most of the efforts in drug discovery programs 
are focused on the treatment of Pf sympthoms. 
The lack of control of the regimen doses in addition to a delay in the diagnosis of the 
disease, have accelerated the emergence of resistances to the current available drugs. The 
development of new antimalarial medicines and vaccines is a key part of the global 
strategy for malaria eradication. 
The two most widely used antimalarial drugs chloroquine and sulfadoxine-pyrimethamine 
are failing at an accelerating rate in most malaria-endemic regions. Actually, chloroquine 
resistance has spread and contributes to the increase in the malaria-associated mortality. 
Sulfadoxine-pyrimethamine resistance is also leading to unaceptable levels of therapeutic 
failure in many areas in Asia, South America and Africa (figure 2). 
The Artemisinin-based combinations therapies are recommended as first-line treatment 
for malaria, and its implimentation has contributed significantly to reduce the malaria 
burden in many endemic countries and countering resistance to key antimalarial 
medicines [155]. However, the emergence of resistance to artemisinin based treatments 
have been a drawback in the fight against malaria [106]. 
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Figure 2. The emergence of malaria resistances to chloroquine (blue circle), sulfadoxine-
pyrimethamine (green diamond) and other treatments (red star) in Malaria transmission 
areas (yellow). Orange triangles indicate free malaria island in malaria endemic regions 
[157]. 
The development of  new antimalarial drugs has become a new priority to achieve the goal 
of malaria eradication and elimination by 2030, due to the most advanced vaccine, the 
RTS,S, have shown only around 50% of efficacy in children under 2 years old [142]. New 
antimalarial drugs must meet the requirements of rapid efficacy, minimal toxicity, and 
above all a low cost to reach the real affected countries in the poorest regions of the world. 
The eradication programme includes the development of new antimalarial vaccines.  
Plasmodium life cycle 
The protozoa from the Plasmodium genus show a complex life cycle where they present 
different hosts and phenotypic characteristics throughout their cycle (figure 3). 
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Figure 3. Plasmodium life cycle in the human host and mosquito(source CDC). A) 
Exoerythrocytic cycle, where the mosquito release sporozoites that invade hepatic cells and 
develop to schizont, which release thousands of merozoites; B) Erythrocytic cycle, where the 
merozoites released by the hepatic schizont invade RBCs and form a ring that then mature to 
trophozoite and posterior schizont that release more merozoites ready to invade new RBCs, 
some merozoites that invade RBCs are able to develop to the sexual stages of the parasite, the 
gametocytes; C) Sporogonic cycle, where the gametocytes develop to female and male 
gametes after the uptake by the mosquito, inside the mosquito midgut takes place the 
fecundation of the female gamete by the male gamete, and the zygote and posterior ookinete 
is formed, the ookinete develop to a oocyst that forms thousands of sporozoites, which after 
the release migrate to the salivary glands and are ready to be introduced to a new human 
host. 
The main mode of transmission of the disease is by bites from infected female Anopheles 
mosquitoes that have previously had a blood meal from an individual infected with 
malaria. Less common routes of transmission are via infected blood transfusion, 
transplantation, infected needles and from mother to her fetus during pregnancy. 
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In order to complete the life cycle, Plasmodium needs two hosts: the mosquito and the 
mammal host. In the mosquito the sexual reproduction of the parasite takes place and it is 
the vector for the transmission of the disease. In the mammalian host takes place the 
asexual reproduction of the parasite and this phase of the cycle is the responsible of the 
pathophysiology associated to the malaria disease [151]. 
The human infection begins when an infected female Anopheles mosquito bites a person 
and injects salive containing sporozoites, the invasive crescent-shaped form, into the 
dermis. These sporozoites enter into the blood circulation directly or through the 
lymphatic system. Sporozoites find their way through the blood circulation to their first 
target, the liver. The sporozoites enter the liver cells (hepatocytes), where it is formed a 
parasitophorous vacuole that includes the parasite and it is separated from the host cell 
cytoplasma [120]. Inside the hepatocyte the parasite starts dividing leading to a new cell 
type, the schizont. Each schizont gives birth to thousands of merozoites that are packed 
into vesicules (merosomes). The infected hepatocyte is lysed and the merosomes that 
contain the merozoites are released to the blood stream [140]. 
This phase, denominated exoerythrocytic  cycle or exoerythrocytic schizogony has a 
length that range from 5 to 15 days depending on the Plasmodium specie [151]. The 
exoerythrocytic phase is not pathogenic and do not produce symptoms or signs of the 
disease. It is worth mentioning that, concerning P. vivax and P. ovale, sporozoites may not 
follow the reproduction step and stay dormant, in a parasite form known as hypnozoite, in 
the liver. They may be activated after a long time leading to relapses entering the blood 
stream (as merozoites) after weeks, months or even years [56]. 
Once the merosomes are outside the hepatocyte, they head to the pulmonary capilars, 
where within 48-72 hours the contained merozoites are released. These merozoites are 
directed to their second target, the red blood cells, this mark the beginning of the 
erythrocytic phase [14]. 
The blood stage merozoite is the smallest cell within the Plasmodium cycle, and one of the 
smallest eukaryotic cells known (≈1-2 m). The merozoite has the convenient organelle 
repertoire of eukaryotic cells with the cytoeskeletal architecture of an apicoplexan cell, the 
phylum to which malaria parasite belong. This includes an apical complex of secretory 
organelles (micronemes, rhoptries and dense granules), mitocondrion, nucleus and relict 
plastid, apicoplast [18]. 
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The erythrocyte invasion process by the merozoite is very fast (within 30 seconds), and 
takes place through several sucessive steps. Initial interaction involves a recognition 
between the merozoite and erythrocyte, followed by a reorientation that places the 
parasite appex abutting the host cell membrane and provoking a deformation of the 
erythrocyte surface. After a brief pause and major deformation of the erythrocyte 
membrane, the parasite enters and the erythrocyte membrane return to its normal shape 
within 10 minutes (figure 4). During the internalization, the parasite forms a new 
parasitophorous vacuole that isolate the parasite from the erythrocyte cytoplasm. The 
internalized parasite, now refered as a ring, undergoes a rapid and dramatic changes after 
this process [52]. 
 
Figure 4. Invasion of a RBC by a P. falciparum merozoite (adapted from [68]). Invasion is a 
complex multi-stage process. Initial attachment can occur with the merozoite in any 
orientation and involves low-affinity interactions. Subsequent interactions are facilitated by 
proteins that are initially hidden within the apical organelles and are secreted only shortly 
prior to or at the time of attachment. 
Typically, ring morphology is thin discoidal flat-shaped and has a thick rim of cytoplasm 
housing the major organelles, while the centre of the disc is thin and contains few 
structures. Parasite begins to feed on the surrounding RBC haemoglobin and enlarges until 
occupy almost all the RBC, originating a new form metabolically very active, the 
trophozoite. This trophozoite continues the digestion of the RBC haemoglobin. The 
haemoglobin degradation is a nutritional resource for the parasite. As a result of the 
catabolitic process, it is generated cytotoxic wastes, as the haeme group in the form of 
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protoporphyrin . The parasite has developed an strategy to avoid the toxic effects of this 
metabolite, in the cytoplasm takes place the polymerization of the haeme group 
generating inhert brown crystals known as hemozoine, that accumulates within the 
digestive vacuole throughout the erythrocytic phases to avoid the toxicity [49]. However , 
the globin group, from the haemoglobin digestion, is used as a source of aminoacids for the 
reproduction. 
The next cellular stage is the schizont. Technically speaking a schizont is an intracellular 
parasite that is undergoing or has undergone repetitive nuclear divisions. However, the 
synthesis of some of the molecules needed for the parasite multiplication, including DNA is 
known to start in the trophozoite stage. Conversely, ingestion of RBC cytosol lasts until 
late in the schizont period. The nucleus divides about four times to produce about 16 
nuclei. Nuclear division is accompanied by numerous cytoplasmic changes that prefigure 
merozoite formation. Then, a constriction ring separates each merozoite from the residual 
body of the schizont, and the merozoites cluster within the parasitophorous vacuole. 
Finally, the parasitophorous vacuole membrane and RBC membrane are breached and the 
new merozoites, released to the blood stream, are ready to find and invade new RBCs 
[151] (figure 5). This erythrocytic cycle is denominated erythrocytic schizogony and is 
when parasitemia occurs and clinical manifestations appear. The liver phase occurs only 
once, while the erythrocytic phases undergoes multiple cycles, the merozoites release 
after each cycle and created the febrile waves in patients. 
 
Figure 5. Erythrocytic stages of Plasmodium falciparum parasite (adapted from [86]). After 
the invasion of the RBC by the merozoite, this develop to a ring stage (A), later to trophoite 
stage (B) and finally to schizont stage (C), where new merozites are formed and assembled 
(D). The new merozoites are released to the blood stream after RBC and parasitophorous 
membrane rupture (E). 
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Although most of the merozoites that invade the erythrocytic cells develop an asexual 
cycle, a small fraction can differentiate into male and female gametocyte inside the human 
host. These gametocytes are a non pathogenic form of the parasite, and this process is 
known as gametocytogenesis (figure 6). There are five different stages of gametocytes 
depending on the grade of maturation, the stage V is the final stage and the only one able 
to reproduce. This process is a crutial step in the Plasmodium life cycle, as it is required for 
parasite transmission from the human host to the mosquito and thus for the subsequent 
infection of other humans. The commitment to sexual development occurs at some point 
before schizogony, as all merozoites within a mature schizont will either differentiate into 
gametocytes or continue asexual development. However, the mechanisms involved are 
currently unclear [2, 33]. 
 
Figure 6. Plasmodium falciparum gametocytes development (adapted from [66]). 
Gametocytes development is divided in five morphologically distint stages shown as Giemsa 
photographs a) and schematics b). Stage I gametocytes are very similar to trophozoites, 
stage II begin to elongate and acquire a D-shape, stage III elongate further and ends become 
rounded, stage IV continues to elongate but ends are now pointed, and stage V acquire 
crescent shape, at this stage female gametocytes are more elongated and thicker than male.  
When a female Anopheles mosquito bites an infected person, it takes up these gametocytes 
with the blood meal. Following ingestion by the mosquito, gametocytes experience a drop 
in temperature, a change in pH and exposure to xanturenic acid, which together trigger 
their maturation from gametocyte in stage V into gametes in the mosquito midgut. Female 
stage V gametocytes transform to macrogamete and male stage V gametocytes rapidly 
undergo three rounds of DNA replication to form an octoploid nucleus, followed by the 
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assembly of eight flagella to produce microgametes, this process is known as 
gametogenesis (figure 7). 
 
 
Figure 7. Development of malaria parasite in the mosquito midgut (adapted from [102]). 
Stage V gametocytes activate in the mosquito midgut to form gametes, then fertilization 
occurs and the ookinete is formed. This penetrates the midgut epithelium and develop an 
oocyst which forms thousands of sporozoites that are released and migrate to the salivary 
glands waiting for the next mosquito bite to infect a new host. 
This transformation occurs in less than 20 minutes. Then, haploid gametes fuse with 
female macrogamete to form a diploid zygote. The zygote, after the fusion of nuclei and 
fertilization, becomes a ookinete. The ookinete, then penetrates the midgut wall of the 
mosquito where it encysts and form and an oocyst. Inside the oocyst, the ookinete nucleus 
divides to produce thousands of sporozoites. This is the end fo the sporogonic cycle (figure 
7) which lasts from 8 to 15 days , depending on the Plasmodium specie [135]. 
Finally, the oocyst ruptures and the sporozoites are released inside the mosquito cavity 
and actively migrate through the haemocoel to the salivary glands, where they reside until 
the mosquito takes a blood meal, which simultaneously delivers sporozoites to the next 
human host. 
The complexity of Plasmodium life cycle has made the eradication strategy difficult. Drug 
discovery efforts usually focus on the erythrocytic phase, but the development of new 
tools have made possible the search of drugs that are effective in other phases of the 
parasite life cycle in the last years. 
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Mouse models for drug discovery 
An animal model for a human disease is by no means attempting to reproduce the human 
disease with all its complexities in an animal but rather to model specific aspects of a 
disease. When adequately designed and conducted, animal models can give invaluable 
information to our knowledge of biology and medicine, including the discovery and 
development of new drugs. The selection of a validated and predictive animal model is 
essential to address the clinical question. 
To fight Malaria, new drugs are needed. Ideally, new drugs for P. falciparum malaria 
should be efficacious against drug-resistance strains, provide a cure in a resonable time, 
have appropiate formulations for oral use and be affordable as the target population lives 
in developing countries with few resources. 
Most antimalarial drugs that are now in use were not developed on the basis of rationally 
identified targest, but following the identification of antimalarial activity of natural 
products, for example quinine and artemisinin. Recently, an improved understanding of 
the biochemistry of the malaria parasite and the description of the entire P. falciparum 
genome sequence has identified many potential targets for new drugs and helped to know 
more about the mode of action of older drugs. 
Targets that are shared between the parasite and human host offer opportunities for 
chemotherapy if structural differences can be found. Alternatively, targets can be selected 
from enzymes or pathways that are present in the malaria parasite but absent from 
humans. A reverse drug discovery approach can also be used to elucidate the nature of 
previously unidentified target of older antimalarial drugs as a basis for new drug 
discovery development. 
Modern drug discovery can be structured as a series of sequential steps in which the 
properties of drugs as potential medicines are investigated. The drug discovery process is 
typically divided in four stages: hit to lead, lead optimization, preclinical development and 
clinical development (figure 8) [64]. At each step, compounds are evaluatted in different 
assays to understand risk and assess efficacy, toxicity, DMPK (drug metabolism and 
pharmacokinetics) and physicochemical properties as indicators of their potential as 
future drug molecules. The progression from one stage of drug discovery to the next 
indicates that drugs has no evident issues or the risks identified can be managed at a later 
stage in the development process. 
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Figure 8. Two strategies of critical pathways in the drug development progress. (A) Efficacy 
evaluation is performed at the end of each progression step. This strategy of evaluation is 
followed by most current drug discovery programmes. In general, efficacy evaluation relies 
on relatively large experiments (dose–response, abbreviated as D/R, >10 mice per 
compound) designed to estimate the potency of compounds. The compounds tested are 
generally selected after extensive filtering using in silico/in vitro filtering; (B) Efficacy is 
performed at the beginning of each evaluation step. Efficacy evaluation relies on screening 
format assays involving small number of mice per compound (≤3 per compound) aiming at 
detecting improvement or not over a reference compound of the series. In this strategy all in 
silico, in vitro and in vivo data are integrated in decision-making on compounds at early 
stage. 
The hits are usually selected based on the activity shown in vitro against an essential 
target of Plasmodium or the whole parasite itself. The sources of hits are usually high-
throughput molecular or phenotypic screenings, depending whether the objective is to 
inhibit a specific molecular target or the intact parasite/host cell. 
In vitro screens for compound activity are based on the ability to culture P. falciparum in 
human erythrocytes. Detailed standardized protocols for culturing P. falciparum and 
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assaying susceptibility to antimalarial compouns are available worldwide [88, 130]. This 
protocol describes the measurement of the uptake of 3H-hypoxanthine (which is taken up 
by the parasite for DNA synthesis) to determine the level of P. falciparum growth 
inhibition. Usually, parasites are cultured in the presence of different concentrations of 
test compounds. IC50 values can be determined by linear regression analysis on the linear 
segment of the dose-response curves. 
Although 3H-hypoxanthine incorporation is the most commonly used method to assay 
antimalarial activity in vitro, it is costly and generate radioactive waste. Flow cytometry 
can also be used to test candidate antimalarial compounds, and takes advantage of the fact 
that human erythrocytes lack DNA [79]. In this assay, parasite killing kinetics can be 
determined by culturing unlabelled erythrocytes with P. falciparum in the presence of 
antimalarial drugs for  24 or 48 hours. After removing the drug, samples were added to 
pre-labelled erythrocytes with intracellular dye to allow their subsequent identification. 
The ability of viable parasites to re-establish infection in labelled erythrocytes can be 
detected by two-colour flow cytometry after tagging parasite DNA. This simply assay 
provides quite high-throughput but requires expensive equipment. 
The demonstration of efficacy in vivo of the hits detected in vitro is a major goal of the 
initial stages of the drug discovery process. In vivo evaluation typically begins with the use 
of rodent parasites. Of these, P. berghei, P. yoelii, P. chabaudi and P. vinckei have been used 
extensively in drug discovery and early development. These animal models remain a 
standard part of the drug discovery and development pathway. Individual species and 
strains have been well characterized including duration of cycle, time of schizogony, 
synchronicity, drug sensitivity and reticulocytes preference [115, 129, 148]. 
The most widely used initial tests, which uses mainly P. berghei, is the Thompson survival 
assay and the Peters´ 4-day test [114, 143]. The Thompson´s assay requires relatively 
large numbers of animals and/or long observation time. However, in the Peters´4-day test 
the efficacy of four daily doses of compounds is measured by comparison of blood 
parasitemia (on day four after infection) and mouse survival time in treated and untreated 
mice. Rodent infection is initiated by needle passage from an infected to a naïve rodent via 
intravenous or intraperitoneal route using a small inoculum (106-107 infected 
erythrocytes). Compounds can be administered by several routes including 
intraperitoneal, intravenous or oral. The administration of compounds starts from one to 
three hours after infection, when parasite is still below to the limit of detection of 
microscopy or flow cytometry. 
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Recently an in vivo screening approach has been assessed as a strategy to rapidly identify 
starting points for drug discovery projects in early stages of drug development [65]. The 
screening assay used a P. berghei murine model of malaria infection based on parametres 
of human disease, for example, parasitemia in the peripheral blood of patients at the point 
of hospital admission and the parasite reductionn rate (PRR), defined as the ratio of the 
baseline parasite count to that following treatment. Infection is assessed by intravenous 
route from an infected mouse with a small inoculum (107 infected parasite). However, 
compound administration starts two days after the infection, and the treatement length is 
only two days, with one daily dose of compound administered by oral route in a unique 
dose of 50 mg/kg (figure 9). 
 
Figure 9. Comparison of the theoretical growth curves of Plasmodium berghei upon 
intravenous infection at day 0 under (A) a Peters’ 4-day test-type or (B) the in vivo screening 
assay format for the evaluation of the antimalarial efficacy of drugs. The solid curves 
represent the growth of parasites treated with vehicle. The dotted lines represent the growth 
of parasites under arbitrary treatments (×n, denotes arbitrary number of drug dosages) 
leading to ED50, ED90 and ED99, respectively. The parasitemia that marks the limit between 
net growth and net clearance of the parasite circulating in peripheral blood is denoted as the 
NG line. The limit of quantification of parasitemia is denoted as the LQ line. PRR is the 
parasite reduction ratio,  the ratio of the baseline parasite count to that following treatment. 
Compounds identified as active in the in vivo assays can subsequently be progressed 
through several secondary tests. In the dose ranging full 4-day test, compounds are tested 
at a minimum of four different doses to determine ED50 and ED90 values (doses that clear 
50% or 90% of parasite, respectively). The parametres of efficacy are essentially 
measurement of the potency that is, the miligrame per kilograme of body weight 
necessary to achieve a specific biological endpoint. Results are expressed as the rapidity of 
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onset of activity (dissapearance of parasitemia) and time to onset of recrudescence 
(increase of parasitemia). 
When using rodent parasites, several variables need to be considered. Rodent plasmodia 
can differ significantly in their degree of infection, lethality and synchronicity. In addition, 
rodent malaria species can also differe significantly in sensitivity to certain classes of 
compounds. The choice of model may depend on the genetic similarity at the level of the 
molecular target. For example, P. yoelii was chosen to test 4-(1H) pyridones because the 
high sequence homology with P. falciparum for the target cytochrome bc1, which is a key 
protein in the mithocondrial respiratory chain [158]. In other cases, the choice is guided 
by empirical considerations based on the relative sensitivity of each model to the drugs 
tested. Thus, pentamidine and diamidines have been tested in the P. vinckei model because 
P. berghei is almost insensitive to these drugs [5]. 
It is important to note that the drug sensitivity of a given rodent malaria does not always 
mirror that of P. falciparum and can limit the types of researching that can be performed. A 
differential susceptibility to the drug between the human pathogen in vitro and the rodent 
surrogate in vivo is inferred in these situations.  In these cases evaluating the efficacy of 
drugs in non-human primates or humanized mouse models is the only realistic alternative. 
Primate models have provided a final confirmation of the choice of a drug candidate. 
Infections with certain strains of P. falciparum has been well characterized in both Aotus 
and Samiri monkeys [139]. However, these hosts are mostly used in projects seeking 
drugs for radical cure, and their use is not widely extensed due to ethical issues. 
By contrast, P. falciparum mouse model offers a practical alternative that has been 
exploited by several drug discovery projects. For example, the poor activity of some 
triazolpyrimidines against P. berghei dihydroorotate dehydrogenase compare to the P. 
falciparum enzyme prompted researchers to use the Pf humanized mouse model to 
measure efficacy in vivo [40]. Noteworthy, an increasing number of projects employ the Pf 
mouse model at some point during the lead optimization process irrespective to the 
difference in susceptibility between P. falciparum and P. berghei [28, 39, 63, 90, 103]. 
Humanized Mouse Models for Malaria 
The humanized mouse models are crutial in infectious diseases caused by specific human 
pathogens. Malarial parasites have a complex life cycle, and are highly host cell specific. P. 
falciparum infects almost excusively human cells with the expection of new world 
monkeys of the genus Aotus and Samiri. Blood stage parasites are responsible for all 
sympthoms of malaria infection. Therefore, a small animal model for P. falciparum blood 
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stages would enhance understanding of disease pathophysiology, and is critical for 
modelling the complete life cycle in small animals and without the ethics problems that 
entails the use of non-human primates. 
The development of a small animal model for the blood stages of P. falciparum was 
preceded by the discovery of mice with spontanenous immune deficiencies, which allow 
for the engraftment with human cells. The severe combined immunodeficiency (scid) 
mouse harbouring a point mutation in the Prkdc kinase (PrkdcSCID),  which interferes with 
the development of functional B and T lymphocytes, accepts xenogenic grafts of hRBCs and 
was used to establish P. falciparum blood stage infection for up to 2 weeks in the 90s 
[146]. This model established the starting point for the development of a reliable 
humanized mouse model for human malaria. Nevertheless, the initial studies included 
difficulties in obtaining high levels of hRBC chimerism, as well as, the rapid clearance of 
parasite-infected hRBC by the mouse. Some of these problems have been analyzed and are 
mainly due to substantial innate responses still present in immunodeficent mice [8]. 
Macrophages and NK cells are responsible for the clearance of the parasite infected and 
uninfected hRBCs. Additional mutations in mice were explored to increase the 
immunodeficience to reduce the innate immune response  present in scid mice. 
The non-obese diabetic (NOD) mouse dramatically reduced the clearance of human 
haematopoietic cells, in part because of a polymorphism in the signal regulator protein 
alpha (SIRP) gene that enhances binding to human CD47 and diminishes macrophage 
phagocytosis [105]. Natural killer cells also have reduced activity in NOD mice because of a 
defect in the NKG2D receptor [109]. These properties have made the NOD background 
prefered for the development of models that uses xenotransplantation of haematopoietic 
cells. 
Targeted gene deletions have also contributed to the immunocompromised status that is 
required for the development of humanized mouse models. The recombination activation 
gene 1 or 2 (Rag1 or Rag2) is responsible for V(D)J recombination, and thus its elimination 
in mice lend to lack of B and T cells [38]. Similarly, deleting the IL-2 receptor gamma chain 
(IL2R) depletes the common receptor of IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 cytokines, 
eliminating functional T cells and NK cells. In addition, homozygosity for the 2 
microglobulin (2m) allele results in the absence of MHC class I expression, loss of CD8+ T 
cells and NK cell activity. Crosses between these mice have resulted in the NODscid mouse, 
the IL2 mouse (NODscidIL2Rnull), the 2 mouse (NODscid2m-/-), the NOG mouse 
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(NODscidIL2Rtruncated), the Rag2 IL2 mouse (NODRag2IL2Rnull) and the NRG 
(NODRag1IL2Rnull), each  of will be used in this work (figure 10). 
 
Figure 10. The origin of the different immunodeficent strains used for the generation of 
humanized mouse models. The parental mice strains NOD, scid, Rag1 and Rag2 can be used 
for the generation of mice with more immunodeficiencies (NODscid). The knock out of 
different genes, as the 2 and IL2 can increase the immuodeficiency level generating new 
mice strains (2, IL2, NOG, NRG, Rag2IL2)  . The scid, NOG and Rag2IL2 strains can be used 
to generate new mouse strains able to support the xenotransplant of human hepatocytes. 
Liver stages 
The development of a robust humanized model for the hepatic stage of Plasmodium 
depends on the transplantation of functional human hepatocytes into mice. These models 
are based on procedures that kill murine hepatocytes followed by transplantation of 
human hepatocytes. There are three major murine models of liver transplantation: i) scid 
mice transgenic for urokinase–type plasminogen activator under the albumin promoter 
(Alb-uPA) [91]; ii) fumaryl acetoacetate hydrolase-deficient (FAH-deficient) Rag2-/- 
IL2Rnull mice (FRG) [11]; iii) mice that express the HSVtk transgene under the albumin 
promoter onto the NOG background (TK-NOG) [53]. 
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Hepatotoxicity in Alb-uPA mice is caused by the overexpression of urokinase-type 
plasminogen activator, which cleaves plasminogen to form the activate enzyme plasmin. 
These mice can be engrafted with human hepatocytes from day 7 after birth, and the 
degree of engraftment that can achieved is up to 99%. However, Alb-uPA mice are prone 
to haemorrhagic complications and difficult to breed due to homozygous transgenic mice 
are infertile. Though, successful infections of humanized mice with P. falciparum 
sporozoites have been described [93]. 
Conversely, the deficiency of FAH (an enzyme which is essential for tyrosine catabolism) 
in FRG mice leads to liver failure by accumulation of toxic metabolites. The cytotoxic 
effects are avoided by continuos treatment of mice with 2-(2-nitro-4-
trifluoromethylbenzyol)-cyclohexane-1.3-dione (NTBC), an inhibitor of tyrosine 
catabolism upstream of FAH. Upon withadrawal of NTBC and subsequent progressive liver 
injury, FRG mice can be transplanted with human hepatocytes at any age. Although the 
engraftment achieved is more variable than Alb-uPA mice (between 3% and 97%), the 
FRG mice have been used for a succesful complete infection with P. falciparum and P. vivax 
sporozoites, culminated with the release of exoerythrocytic merozoites that are able to 
invade hRBC and initiate a sustainable asexual erythrocytic replication in vitro in the case 
of P. falciparum [94, 147]. 
In the case of TK-NOG mouse strain, the loss of endogenous hepatocytes is inducible by a 
brief exposure to a non-toxic dose of gancyclovir, a method that is rapid and temporally 
restricted, and routinely leads to a subtantial human hepatocytes repopulation (60-80%). 
A double engraftment of TK-NOG mice with human hepatocytes and hRBCs has been 
successfully described and these mice were receptive to infection and maturation by 
sporozoites from two species that infect human, P. falciparum and P. ovale [136]. 
Erythrocytic stages 
The availability of scid mice led to the first attempt in establishing a humanized mouse 
model for erythrocytic stages of P. falciparum. The control of innate immunity is crutial to 
achieve a high degree of reproducibility in etyrhocytic P. falciparum humanized models. 
This innate immunity has been controled by using cases immunomodulatory treatments  
in vivo [7, 13, 98] and/or by selection of immunodeficent mouse strains having impaired 
immunity [5, 63]. 
Different immunomodulatory treatments have been used to inhibit the activity and reduce 
the number of phagocytes in tissues of mice used for P. falciparum infection. The most 
commonly used method is the injection of clodronate encapsulated liposomes (lip-clod). 
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The treatment of humanized mice with lip-clod regimes prior to the injection of human 
erythrocytes in the retro  orbital senus, allow the growth of previously cultured strains 
and clinical isolates of P. falciparum in different murine backgrounds after intraperitoneal 
infection. However, the reproducibility of the infections and the parasite growth were low 
despite the immunosupression treatment [13, 98, 100]. An improvement in the 
immunomodulatory treatment with the addition of a monoclonal antibody NIMP-R14, that 
blocks the polymorphonuclear leukocytes, the change of the mouse strain background, the 
refinement in the techniques of hRBCs injection (addition of human serum), and the 
infection protocol, intravenous injection instead of intraperitoneal, lead to a increase in 
the parasite burden and the reproducibility of P. falciparum infections [7, 8]. 
On the other hand, the use of mice with NODscid background with impaired phagocytic 
activity, has allowed the development of models that do not require immunomodulatory 
treatments. Two major differences in this improved mouse model could account for the 
success: the selection of the mouse background and the in vivo selection of a P. falciparum 
strain that was adapted to replicate within the mouse. In this model, NODscid2m-/- were 
used. The daily intraperitoneal injections of hRBCs, at a 50% hematocrit with 25% of 3.1 
mM Hypoxanthine and 25% Human serum, was able to obtain a hRBC chimerism up to 
99%. Then, the parasite adaptation to grow in mice was performed by intravenous 
injection with parasite-infected erythrocytes, which reduced to below detectable 
parasitemia, but then parasite emerged and established a productive infection 2-3 weeks 
later. Adapted parasites were further transmitted and expanded in vivo and reproducible 
growth of the isolate was observed in all mice tested (figure 10). The significant 
improvement of P. falciparum blood stage replication allowed the experimental testing of 
antimalarials in vivo in a dose-response assay [5]. 
 
Figure 10. Schematic representation of the in vivo adaptation protocol for P. falciparum 
strains in humanized mice. First immunodeficent mice are injected daily with hRBCs in a 
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50% hematocrit suspension. Then, humanized mice are infected with P. falciparum infected 
erythrocytes from in vitro culture. Passages are done from mice to mice until obtain a 
reproducible growth in all mice. Finally, the strain is adapted and freezed to establish a stock 
collection. 
However, the 2 mouse strain retains residula NK cell activity as well as other innate 
immune functions and shows a high incidence of early thymic limphomas, which 
dramatically diminish their life span, a do not allow to perfom long lasting experiments. A 
new mouse strain was then selected to overcome these issues, the NODscidIL2Rnull strain 
[63], several improvements were achieved that have been described in this work. 
The humanized models of P. falciparum asexual erythrocytic stages without 
immunomodulatory treatment have been validated to evaluate the efficacy of new 
antimalarials by measuring dose-response relationships for drugs. However, to the date 
there are no reports describing assays to test the ability of compounds to block 
transmission of P. falciparum gametocytes from humanized mice to mosquitoes, even 
though the presence and transmission of mature gametocytes in humanized mouse 
models with immunosupression treatment has been documented [7, 97]. By contrary, 
until the date neither evidencies of gametocytes production nor transmission to 
mosquitoes have been described for the non-myelodepleted P. falciparum mouse model. 
Although the use of IL2 mice for erythrocytic stages of P. falciparum has been 
transformational in malaria drug discovery, little is known about the mechanisms that 
govern the xenotransplant of hEry. Those mechanisms have been elucidated in this 
experimental work, so as the relevance of the model when used in the drug discovery field 
and the analysis of the potential of the P. falciparum humanized model to be used as a 
powerful tool to elucidate different aspects of the biology of the malaria disease.
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Mice 
Female NODscid microglobulin-/- mice (NOD.Cg-Prkdcscid B2mtm1Unc/J), abbreviated 
deficient for the -microglobulin, are class I deficient, B and T cell deficient, C-5 
deficient (Hc0), and have low NK cells. They were obtained from Charles River 
Laboratories (L´Arbresle, France). 
Female NODscidIL2Rnull mice (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ), abbreviated IL2, deficient 
for the chain of the IL-2 receptor. As a result, these mice lack mature T cells, B cells, or 
functional NK cells, and are deficient in cytokine signaling. These mice were raised and 
maintained in the Charles River Laboratories. IL2 mice were also obtained from Taconic 
(NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac) (Albany, NY, USA) these mice were abbreviated NOG. 
Rag2-/- IL2 rg -/-, H-2kb+ mice (B10;B6-Rag2tm1Fwa Il2rgtm1Wjl), abbreviated Rag2IL2 lack 
functional receptors for many cytokines, including: IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. 
As a consequence lymphocyte development is greatly compromised. The double knockout 
mice lack T, B and NK cells. These mice were obtained from Taconic (Albany New York, 
USA). 
FRG® KO mice (Fah-/- Nod/Scid), abbreviated FRG, has a controllable lethal liver disease, 
which permits a highly efficent repopulation with human hepatocytes. This strain has 
multiple mutations that induce liver disease, T and B cells deficiency and defects in 
macrophage regulation and NK activity. These mice were obtained from Yecuris Inc. 
(Portland, Oregon, USA) 
NOD-Rag1null IL2rnull mice (NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ), abbreviated NRG, deficient 
for the chain of the IL-2 receptor, lack mature T cells, B cells, or functional NK cells and 
show more resistance to radiation than the IL2 mice. These mice were obtained from the 
Jackson Laboratories (Bar Harbour, Maine, USA). 
Pathogen-free CD1 (Hsd:ICR) were obtained from Harlan Interfauna Iberica (Barcelona, 
Spain). 
Animal research was performed in the Laboratory Animal Science acredited by AAALAC 
(Association for Assessment and Accreditation of Laboratory Animal Care) at the Diseases 
of Developing World (DDW), GlaxoSmithKline, sited in Tres Cantos (Madrid). 
Immunodeficient mice were maintained in ventilated racks and cages, and were provided 
with autoclaved tap water and irradiated pelleted diet ad-libitum.  
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All the experiments were ethically reviewed and approved by the DDW Ethical Committee 
on Animal Research and were conducted according to National legislation, European 
Directive 2010/63/EU and GlaxoSmithKline policy on the Care, Welfare and Treatment of 
Laboratory animals. IACUC numbers for studies are PROEX 110/14 and PROEX 110/17. 
Parasite 
Different Plasmodium falciparum strains were used along this study: 3D70087/N9, 
V1/S0176/N10, NF540230/N3, K10275/N3, FCR30325/N2, D100325/N2 and D100325/N3 for the infection 
of immunodeficent mice. These P. falciparum strains were adapted by the Therapeutic 
Efficacy Group (Malaria DPU-DDW Tres Cantos) to grow in vivo in non-myelodepleted 
immunodeficent mice engrafted with human erythrocytes [5, 63]. Mice were injected by 
intravenous route with 20x106 parasitized erythrocytes in a final volume of 0.3 ml. P. 
falciparum strains were mantained by weekly passages from infected mice to engrafted 
mice with this quantity of inoculum. Original P. falciparum strains were obtained from 
MR4, accurate descriptions of the genetic background of these strains can be obtained at 
http://www.beiresources.org. 
P. falciparum thawing 
Cryopreserved parasites kept at -150ºC were thawed immediately by plunging the 
cryovials in a water bath at 37ºC for a few minutes and transfering whole vial content to a 
50 ml sterile tube. Then, slowly add 1 volume (0.2 ml) of 12% NaCl solution dropwise via a 
1 ml syringe attached to a 21G needle to 5 volumes (1 ml) of thawed sample and agitate 
continuosly. Next, slowly 10 ml of 1.6% NaCl solution is added for each ml of thawed 
sample shaking gently and continuosly to allow to mix both solutions. Finally, 10 ml of 
NaCl 0,9% and glucose 0,2% solution is added for each ml of thawed sample, while 
shaking gently and continuously the tube. 
Solution obtained is centrifuged for 5 minutes at 520 g, at room temperature, high 
acceleration speed and medium deceleration speed. Then, supernatant is removed, and 
the pellet is resuspended with 10 ml of RPMI, by adding the solution drop by drop and 
shaking gently. Solution obtained is centrifuged 5 minutes at 520 rpm, room temperature, 
high acceleration speed and medium deceleration speed. Finally, supernatant is removed 
but leaving at least 100 µl of RPMI to keep the sample hydrated. Parasite thawed is kept at 
room temperature until its inoculation. 
Reagents 
Soluble Hypoxanthine 50X (Ref. 41065012), Dulbecco´s PBS (Ref. 14190250),  and RPMI 
1640 (Ref. 31870074) were purchased from Gibco (Paisley, U.K.). Hepes Buffer 1M (Ref. 
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H0887), human serum AB+ (Ref. H4522), 5(6)-carboxyfluorescein diacetate N-
succinimidyl ester (CFSE) (Ref. 21888), DMSO (Ref. D2650), Hypoxanthine (Ref. H9377), 
ribonuclease A (Ref. R6513), fetal bovine serum (Ref. F6178),  bovine serum albumin (Ref. 
A2153), ethylenediaminetetraacetic acid (EDTA) disodium salt solution (Ref. E1161), 
Triton X-100 (Ref. 93443), Lidocaine hydrochloride monohydrate (Ref. L5647), Tripan 
Blue (Ref. T8154), PKH26 kit (Ref. PKH26GL), glutaraldehyde 25% (Ref. G5882), D-glucose 
(Ref. G8270), NaHCO3 (Ref. S5761) and NaCl (Ref. S7653) from Sigma-Aldrich (St. Louis, 
MO, USA). SYTO-16 (Ref. S7578) and YOYO-1 (Ref. Y3601) were from Molecular Probes 
(Leiden, The Netherlands). Biotin-X-NHS (Ref. 203188) and DMF (Ref. 103053) were 
obtained from Calbiochem (La Jolla, CA, USA). Giemsa staining solution (Ref. 
1.09204.0100) was from Merck & Co., Inc. (Whitehouse Station, NJ, USA). TruCount™ tubes 
(Ref. 340334) were obtained from Becton Dickinson (Franklin Lakes, NJ, USA). 
Antibodies 
TER119-PE (Ref. 553673), CD45-PerCP (Ref. 557235), Streptavidin-PE (Ref. 554061),  Rat 
anti-mouse CD45-APC (Ref. 9864), rat anti-mouse GR1-PerCP (Ref. 552093), rat anti-
mouse F4/80-PE (Ref. 565410) were acquired from Pharmingen (San Diego, CA, USA).  
Human blood 
Incomplete donations or erythrocytes concentrates of malaria–negative donors were used, 
they were generously provided by the Spanish Red Cross Blood Bank in Madrid, Spain. 
Blood was stored at 4ºC and in the dark until its use. 
Erythrocytes concentrates were washed twice with washing buffer (RPMI 1640 containing 
25 mM Hepes Buffer and 0.1 mM hypoxanthine) at 860 g during 10 minutes at room 
temperature. Buffy coat was removed by aspiration, and erythrocytes were resuspended 
at 50% hematocrit (RPMI 1640, 25% inactivated human AB serum, 3.1 mM hypoxanthine). 
Finally, blood suspension was warmed at 37ºC for 10 minutes prior to intraperitoneal 
injection to immunodeficient mice. 
The human biological samples were sourced ethically and their research use was in 
accordance with the terms of the informed consents. 
Murine blood 
Murine blood was obtained from IL2 donor mice. According with the standard procedures 
approved by DDW Ethical Committee on Animal Research, mice were euthanized with CO2. 
Then, blood was collected by heart puncture using a heparinized 2 ml syringe with 25G 
needle. Blood was used within the 2 hours after extraction. 
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Mosquitoes 
A colony of Anopheles stephensi mosquitoes was breeded in DDW Insectary facilities (Tres 
Cantos, Spain). Mosquitoes colony were mantained in climate controlled chambers at 
27.5±1ºC: 10D photoperiod and 75±5% relative humidity (Panasonic MLR 352PE). Adults 
were kept in insect rearing cages (30x30x30 cm; Bugdorm®), and had ad libitum access to 
water solution containing 10% glucose + 1% Karo syrup until its use. Mosquitoes selected 
for experimentation were female from 3 to 5 days old. Female mosquitoes were selected 
and transferred to containers (30 mosquitoes each) and put in starvation at least 12 hours 
before the experimentation process. 
Containers used for mosquitoes transfer were cylindrical and had a hole in the middle of 
the wall (covered with double elastic material) to introduce mosquitoes with an aspirator. 
The top of the cylindrical cup was covered with a double mesh to avoid mosquitoes 
escape. 
Erythrocytes biotinylation 
Biotinylation of intact mammalian red blood cells was performed by attachment to the 
amino groups by means of biotin N-hydrosuccinimide ester (biotin-X-NHS). Different 
concentrations of biotin-X-NHS were tested (100, 30 and 5 g/ml) for the setting up of the 
erythrocytes biotin labeling protocol. 1 ml of erythrocytes was incubated for 15 or 30 
minutes in the dark at room temperature. The concentration of 30 ug/ml incubated for 30 
minutes was chosen as the most suitable condition for erythrocytes labeling which 
provides a clear discrimination between positive and negative cells measured by flow 
cytometry in terms of fluorescence intensity values.   
For optimal labeling efficiency, 2 ml of human or mouse blood were washed twice with 10 
ml of 0.9% saline solution and centrifuged at 860g for 10 minutes. Erythrocytes were 
labeled with biotin-X-NHS diluted in DMF (30 l of DMF per every milligram of Biotin-X-
NHS weighted). For every milliliter of washed erythrocytes it was used 1.5 ml of the 
Biotin-X-NHS solution adjusted at 30 g/ml in saline solution. Erythrocytes were 
incubated with the biotin solution during 30 minutes in the dark at room temperature. 
Then, labeled erythrocytes were washed 4 times with saline solution, centrifuged at 650g 
during 5 minutes to remove the excess of biotin. Blood pellet obtained after centrifugation 
was resuspended in 0.3 ml of saline solution and injected to IL2 mice (109 of labeled 
erythrocytes by i.v. route per mouse). 
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5(6)-carboxyfluorescein diacetate N-succinimidyl ester (CFSE) erythrocytes 
labeling 
Different concentrations of CFSE were used for erythrocytes labeling (2000, 500, 150, 50 
and 10 g/ml).  1 ml of erythrocytes were incubated at 15 or 30 minutes in the dark at 
room temperature. The concentration of 50 g/ml and an incubation time of 30 minutes 
was set up as the most appropriated protocol for erythrocytes labeling, determined by 
flow cytometry as the condition with the higher difference in mean fluorescence intensity 
rate between positive and negative populations. 
For the labeling protocol, 2 ml of human or mouse blood erythrocytes were washed twice 
with 0.9% saline solution, centrifuged at 860g during 10 minutes. 1 ml of washed 
erythrocytes were labeled with 1.5 ml of a 50 g/ml CFSE saline solution dissolved in 
DMSO (30 l of DMSO per every milligram of CFSE weighted). Erythrocytes were 
incubated with the CFSE solution during 30 minutes in the dark at room temperature. 
Then, labeled erythrocytes were washed 4 times with 0.9% saline solution, centrifuged at 
650g during 5 minutes to eliminate the excess of CFSE. Finally, buffy coat was removed 
and blood pellet was resuspended in 0.3 ml of saline solution and injected to IL2 mice by 
i.v. route (109 of labeled erythrocytes per mouse). 
Magnetic Separation 
Sincronization of P. falciparum 3D70087/N9 
Malaria parasite generates free haem upon catabolism of host haemoglobin during their 
intraerythrocytic growth cycle. The free haem molecules are polymerized into the 
biomineral beta-haematin (haemozoin). Haemozoin crystals are paramagnetic, and this 
property can be exploited for the purification of late stage parasites as the contain larger 
haemozoin crystals than early stage parasites and uninfected cells. Positive selection of 
trophozoites and schizonts from IL2 infected mice was performed using an AutoMACS cell 
separator (Miltenyi Biotec, Auburn, CA, USA). 
Blood from mice infected with P. falciparum was collected by heart puncture into 15 ml 
conical tubes containing PBS supplemented with 1% Fetal Bovine Serum (FBS) to reach 
5% hematocrit. The protocol was optimized for a cell number of 6x108 parasitized 
erythrocytes using the separation program “depl025” on the AutoMACS cell separator. 
Positive fraction collected in port “pos1” (late stage parasites was centrifuged at 650 g for 
5 minutes, buffy coat was removed and cellular pellet was resuspended in the residual 
liquid. Then, 100x106 mature parasites were injected i.v. into engrafted IL2 mice. Samples 
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of 2 l of peripheral blood were taken at different time points (Times: 0, 7, 14, 21, 28, 35, 
42, 49, 56, 63, 70, 72, 96 and 120 hours after infection) for flow cytometry staining 
(TER119-PE/YOYO-1 protocol). In addition, 2 l of mice blood was collected to do a blood 
smear for Giemsa staining. 
Giemsa staining 
Giemsa solution was prepared at 10% in buffered water, smears were stained during 20 
minutes, dried and analyzed using light microscopy. 
Erythrophagocytosis assay 
Removal of senescent, damaged or diseased erythrocytes from the circulation in vivo 
occurs by a process known as erythrophagocytosis which takes place mainly in the spleen 
by macrophages, but also in the liver and the bone marrow. Assays for the assessment of  
in vivo and in vitro erythrophagocytosis have been used through this study. 
In vivo 
In order to address the in vivo erythrophagocytosis, spleens from IL2 mice were obtained 
at different time points. CD1 mice were used as positive control for the erythropagocytosis 
of human erythrocytes. 
1 ml of human blood was labelled with CFSE (as previously described) and was injected by 
i.v. route in CD1 mice and IL2 mice in different phases of the model: engrafted, infected 
and in anaemia. Mice were euthanized with CO2 at different time points and spleens were 
removed and processed. 
Following sacrifice of each mouse, spleens were removed and placed into individual 15 ml 
conical tubes containing ice-cold RPMI. Spleen cells were obtained by homogenizing the 
organs. For the processing spleen organs were placed into a pot with a 200 mm pore 
diameter mesh on a petri dish containing ice-cold washing buffer (PBS + 10% FBS). All the 
process was done on ice to stop phagocytosis. Spleens received several transversal cuts to 
break the capsule and to allow the release of the spleen cells. Then, spleens were hit 
smothly on the pot with a 5 ml syringe piston and washing buffer were added drop by 
drop to allow the filtering of the cells through the 200 mm mesh to the petri dish. After the 
release of all the cells, they were transferred to a 15 ml conical tube and centrifuged 
during 5 minutes at 4ºC and at 360 g. The supernatant was removed and pellet 
resuspended, in 1 ml of distilled water and the tubes were shacked to allow the lysis of the 
erythrocytes present in the pellet. To stop the lysis, 12 ml of ice cold washing buffer was 
added and the tubes were mantained in ice for 2 minutes to favor the erythrocytes 
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membrane debris go to the bottom. The supernatant, avoiding the membrane debris, was 
transferred to another 15 ml conical tube, centrifuged 5 minutes at 4ºC and 360 g.  The 
process was repeated for eliminating membrane debris, and finally cells were 
resuspended in 5 ml of washing buffer. 
For staining procedure, cells concentration was adjusted to 2x106 cells per mililiter using a 
Neubauer chamber, and a 1/10 dilution of Trypan Blue in 0.9% saline solution to discard 
dead cells. Aproximately 6x105 cells were put in each well for staining and flow cytometry 
analysis. 
In vitro 
To study the in vitro erythrophagocytosis, cells from the peritoneum cavity of naïve IL2 
mice were obtained. 
Removal of peritoneum cells 
According with the standard procedures approved by the ethical committee in GSK 
facilities, mice were euthanized with CO2. Then, 5 ml of ice-cold PBS (with 2 mM EDTA) 
was injected into the peritoneal cavity using a 26G needle attached to a 2 ml syringe. The 
needle was slowly pushed into the peritoneum cavity being careful to not puncture any 
organs. After injection, the peritoneum was gently massaged during 2 minutes to dislodge 
any attached cells to the abdominal wall into the PBS solution. Then, a 25G needle, bevel 
up, attached to a 2 ml syringe was inserted in the peritoneum and the fluid was collected 
while moving the tip of the needle gently to avoid clogging by the fat tissue or other 
organs. As much fluid as possible is collected, and cell suspension is collected in a 15 ml 
conical tube kept on ice until use. 
In vitro culture of peritoneum cells 
Cells obtained from the peritoneum were centrifuged during 5 minutes at 4ºC and 360 g. 
Pellet was resuspended in 1.5 ml of 0.9% saline solution and 500 l of the cell suspension 
was transferred to a well of a 6 well culture plate. Culture plate was coated with 2 ml of 
culture medium (RPMI + 10 mM Glutamine + 2% FBS) per well. 
Erythrophagocytosis assay 
After overnight incubation, the culture medium was removed and wells were washed 4 
times using 1 ml of RPMI per well at room temperature. In each washing step, the plate 
was shaked slightly to allow the resuspension of cells that did not adhere to the plate. 
Then, 1 ml of RPMI was added to each well and the plate was observed under the 
microscope to check that macrophages were adhered. Finally, non-attached cells 
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resuspended in RPMI were removed and 2 ml of culture medium (RPMI + 10 mM 
Glutamine + 2% FBS) was added to each well. 
To study the erythrophagocytosis in vitro, human erythrocytes were labelled using the 
membrane marker PKH26 dye (PKH26 Red Fluorescent Cell Linker Kit). Briefly, 500 l of 
human erythrocytes (aproximately 3000x106 of cells) were put in 1.5 ml of RPMI and were 
washed to remove the proteins from the preservation medium (included in the kit). Cells 
were centrifuged at room temperature during 5 minutes at 400 g. Washing step was 
repeated once. Then, supernatant was removed and human erythrocytes were divided in 
two parts each containing equal volume of packed erythrocytes and distributed in 15 ml 
conical tubes. Next, 1 ml of the diluent C from the kit was added to resuspend the pellet of 
cells. At the same time, PKH26 was prepared in diluent C at a concentration of 8 M. Then, 
1 ml of the PHK26 dilution was added to each tube and mixed with the erythrocytes and 
incubated during 3 minutes and 30 seconds  at room temperature. Finally, the reaction 
was stopped by adding 2 ml of human serum and incubated during 1 minute at room 
temperature. Then, 4 ml of RPMI was added to the erythrocytes and were centrifuged 
during 10 minutes at room temperature at 400 g. Supernatant was removed and cells 
were put in a new 15 ml conical tube. Then, 10 ml of RPMI containing 10% of human 
serum was added and erythrocytes were centrifuged three times during 10 minutes, at 
room temperature at 400 g, and resuspended in 10 ml of RPMI containing 10% human 
serum. 
Erythrocytes labelling was confirmed by flow cytometry after fixation with 10 l of 0.25% 
glutaraldehyde. 
In the 6-well culture plate, 50 l of PKH26 labelled erythrocytes were added to one well 
(erythrophagocytosis). 50 l of non-labelled erythrocytes were added to another well and 
(erythrophagocytosis negative control). The plate was shaked to allow an uniform 
distribution of the erythrocytes. Then, 150 l of human serum was added to each well and 
the plate was incubated at least 2 hours in a ventilated incubator (37ºC and 5% CO2). 
After the incubation, erythrocytes that had not been phagocytosed by macrophages were 
eliminated with 4 washes steps with 1 ml of RPMI at room temperature. Erythrocytes 
binded to macrophages membrane but not internalized were lysed by adding 500 l of a 
hypotonic buffer (155 mM NH4Cl; 5.7 mM K2HPO4; 0.1 mM EDTA) and incubating 5 
minutes. Lysis was stopped by the addition of 2 ml of PBS. Then, the plate was washed 3 
times with 1 ml RPMI. 
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After the washing steps, macrophages were detached from the bottom of the well of the 6-
well plate by the addition of 1 ml of lidocaine solution (4 mg/ml of lidocaine in PBS; 5 mM 
EDTA; 5% Ethanol). Macrophages were incubated 15 minutes on ice with constant and 
gentle pipetting. Then, macrophages were put in a 15 ml conical tube and were 
centrifuged 5 minutes at 4ªC and 400 g. The supernatant was removed and pellet was 
resuspended in the remaining liquid. Half of the volume was used for flow cytometry 
analysis. 
Quantification of cells: Flow Cytometry method with Trucount™ tubes 
For the measurement of cells concentration it was needed 30 l of the sample 
resuspended in 300 l of saline solution in TruCount™ tubes (these tubes contain a known 
number of fluorescent beads). Sample acquisition was done in FACSCalibur (two lasers: 
488 nm and 640 nm) and LSRII (three laser: 488 nm, 640 nm and 355 nm) flow 
cytometers. At least 3000 events in beads region were acquired. Acquired samples were 
analyzed using the CellQuest Pro or FACSDiva program (Becton Dickinson), and the 
following equation was applied to obtain the absolute count of cells of interest in the 
sample: 
 
Cells of interest/ml = (NCA/NBA) x (Beads/ml of acquisition tubes) 
 
NCA = Number of cells of interest acquired 
NBA = Number of beads acquired 
Beads = Number of fluorescent beads that contains the TruCount™ tube used. 
 
The real concentration of cells of interest was calculated by multiplying the cells of 
interest concentration by the dilution factor used. 
Flow cytometry 
Calculation of the percentage of human erythrocytes in mice peripheral blood 
2 l of blood from the lateral tail vein of mice was collected in 0.1 ml of 0.9% saline 
solution containing 5 M of SYTO-16 and 10 g/ml of the mAb TER119-PE. Samples were 
incubated during 20 minutes in the dark at room temperature. Then, samples were fixed 
by adding 10 l of 0.25% GTA during 6 minutes at 4ºC and in the dark. 30l of the sample 
were put in cytometry tubes containing 300 l of saline solution, or in TruCount™ tubes 
when it was needed to determine the concentration of human erythrocytes per microlitre 
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of sample. Samples were acquired in FACSCalibur or LSRII flow cytometers by using the 
acquisition programs CellQuest or FACSDiva, respectively. 
During acquisition, the percentage of human erythrocytes was considered those events 
included in the TER119-PE negative region related to the total cells region previously 
selected in a dot plot of 180º dispersed light (forward scatter-FSC) opposite to 90º 
dispersed light (side scatter-SSC). The percentage of murine erythrocytes was calculated 
as the TER119-PE positive events in a FL1/FL2 dot plot. Compensation of TER119-PE 
emission in FL-1 was done to precisely establish the region of murine erythrocytes. This 
region must be determined by comparison of blood samples from non-chimeric and 
chimeric IL2 mice by increasing compensation of TER119-PE emission in FL-1 until 
obtaining a defined region for mouse erythrocytes. 
Calculation of the percentage of parasitemia of the human parasite P. falciparum in 
IL2 mice peripheral blood  
2 l of mice peripheral blood from the lateral tail vein was collected and stained in the 
same conditions described in the previous section. Then, 30 l of samples were put in 300 
l of saline solution in cytometry or TruCount™ tubes. Samples were acquired in 
FACSCalibur of LSRII flow cytometers. 
During acquisition, the percentage of infected human erythrocytes was considered those 
events negative for the mAb TER119-PE but positive for the DNA dye  SYTO-16 related to 
the total cells region previously selected in a dot plot of 180º dispersed light (forward 
scatter-FSC) opposite to 90º dispersed light (side scatter-SSC). The percentage of infected 
erythrocytes was calculated as the SYTO-16 positive/TER119-PE negative events in a 
FL1/FL2 dot plot. Erythrocytes and leukocytes were gated in logarithmic forward/side dot 
plots. Green and red fluorescence were detected in the corresponding FL-1 and FL-2 
photomultipliers through 530/30 or 585/42 band pass filter, respectively. The mean 
fluorescence channels in FL-1 and FL-2 were adjusted to equal values in the first decade of 
intensity in bivariate logarithmic scale dot plots with non-infected erythrocytes. 
Leukocytes were excluded during analysis in SSC/FL-1 dot plots because they show much 
amount of nucleic acids than infected erythrocytes. 
Compensation of SYTO-16 emission in FL-2 and TER119-PE in FL-1 was achieved to set up 
accurately the region of infected events. This region must be defined by comparison of 
blood samples from uninfected-chimeric and infected-chimeric IL2 mice by increasing 
compensation of SYTO-16 emission in FL-2 until obtaining a defined region for infected 
events. Data analysis was performed by using the CellQuest Pro or FACSDiva software. 
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Detection of biotinylated erythrocytes in mice peripheral blood 
2 l of mice peripheral blood from the lateral tail vein was collected in 0.1 ml of 0.9% 
saline solution containing 0.5 g/ml of Streptavidine-PE (SAV-PE). Samples were 
incubated during 20 minutes in the dark at room temperature. Then, samples were fixed 
by adding 10 l of 0.25% GTA in saline solution and incubated 6 minutes in the dark at 
4ºC. Finally, 30 l of the samples were put in 300 l of saline solution in TruCount™ tubes 
and at least 3000 events were acquired in “beads” region in the FACSCalibur flow 
cytometer. During acquisition, the percentage of biotinylated erythrocytes was considered 
those events included in the SAV-PE positive region related to the total cells region 
previously selected in a dot plot of 180º dispersed light (forward scatter-FSC) opposite to 
90º dispersed light (side scatter-SSC). Data was analyzed by using the CellQuest Pro 
software. Acquisition with TruCount™ tubes was performed for the calculation of the 
concentration of biotinylated erythrocytes per microliter of blood. 
Detection of CFSE-stained erythrocytes in mice peripheral blood 
2 l of blood from the lateral tail vein of mice was collected in 0.1 ml of 0.9% saline 
solution containing 10 g/ml of the mAb CD45-PerCP. Samples were incubated in the dark 
at room temperature. Then, samples were fixed by adding 10 l of 0.25% GTA in saline 
solution and were incubated 6 minutes in the dark at 4ºC. For the flow cytometry 
acquisition 30 l of samples were put in 300 l of saline solution in TruCount™ tubes. At 
least 3000 events in the region named “beads” were acquired in the FACSCalibur flow 
cytometer. During acquisition, the percentage of CFSE erythrocytes was considered those 
events included in the CFSE positive region related to the total cells region previously 
selected in a dot plot of 180º dispersed light (forward scatter-FSC) opposite to 90º 
dispersed light (side scatter-SSC). Data was analyzed by using the CellQuest Pro software. 
Acquisition with TruCount™ tubes was performed for the calculation of the concentration 
of biotinylated erythrocytes per microliter of blood. 
Staining of P. falciparum infected erythrocytes using YOYO-1 
To detect the parasitized human erythrocytes in mice peripheral blood using YOYO-1, a 
modification of the staining protocol for murine parasites was done. Briefly, 2 l of blood 
from the lateral tail vein of IL2 infected mice was collected into 0.1 ml of saline solution 
containing 10 g/ml mAb TER119-PE, in V-bottomed 96-well plates. Samples were 
incubated 20 minutes in the dark at room temperature. Then, cells were washed with 
saline solution and cellular pellets were resuspended with 0.2 ml of 0.025% (v/v) 
glutaraldehyde in saline solution with 1 mM EDTA to fix the cells for at least 16 hours at 
4ºC in dark. Before staining, 40-50 l of fixed cells were put into another clean V-bottomed 
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96-well plate and YOYO-1 staining was performed as described for murine parasites. 
Samples were acquired in FACScalibur flow cytometer. Erythrocytes and leukocytes were 
gated in logarithmic forward/side dot plots. The mean fluorescence channels in FL-1 and 
FL-2 were adjusted to equal values in the first decade of intensity in bivariate logarithmic 
scale dot plots with non-infected human erythrocytes. Leukocytes were excluded during 
analysis in SSC/FL-1 dot plots because they show much higher amount of nucleic acids 
than parasitized erythrocytes. The voltage photomultipliers was set up using non infected 
blood from control mice stained with TER119-PE and YOYO-1 as described above. Samples 
were analyzed using CellQuest-Pro software (BD), and compensation of YOYO-1 emission 
was achieved as described for the SYTO-16/TER119-PE staining. 
Study of in vivo erythrophagocytosis 
For the flow cytometry analysis, 6x105 cells from spleen were put in each well. Cells were 
washed with ice cold PBS (5 minutes, 4ºC and 360 g). Pellet was resuspendended in 35 l 
of staining medium (PBS + 2% FCS + 0.1 % Sodium Azide) + 10 l rat serum, and 
incubated 15 minutes in the dark at 4ºC. Then, add 5 l of the monoclonal antibodies 
previously prepared at 100 g/ml (CD45-APC, GR1-PerCP or F4/80-PE), and incubate 30 
minutes in the dark at 4ºC. Finally, wash twice by adding 150 l ice cold PBS (5 minutes, 
4ºC and 360 g). Resuspend the pellet in 200 l of 1% Paraformaldehyde solution and store 
at 4ºC until acquisition. All the staining procedure was done on ice. 
Samples were acquired using a LSRII Flow cytometer and FACSDiva software. During 
acquisition, leukocytes were considered those events included in the CD45-APC positive 
region related to the total cells region previously selected in a dot plot in a linear scale of 
180º dispersed light (forward-FSC) opposite to 90º dispersed light (side-SSC). The 
erythrophagocytosis was considered those events double positive for CD45-APC and CFSE 
(FL1 detector) in a FL1/FL4 dot plot. No compensation was needed to estabish the 
erythrophagocytosis population. To identify the type of leukocyte that was involved in the 
erythrophagocytosis each monoclonal antibody used in each detector (F4/80 in FL2 or 
GR1 in FL3) was ploted with the FL1 detector (CFSE). 
Study of in vitro erythrophagocytosis 
For the flow cytometry analysis, half of the cells obtained from mice peritoneum cavity 
and incubated with PKH26 labelled human erythrocytes (see in vitro erythrophagocytosis 
section), were put in a well of a 96 wells plate in 100 l of 0.9% saline solution The plate 
was centrifuged 5 minutes at 4ªC and 400 g. The supernatant was removed and cells were 
resuspended in 45 l of saline solution + 5 l of rat anti-mouse CD45-APC monoclonal 
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antibody (prepared at 100 g/ml). Cells were incubated with monoclonal antibody during 
20 minutes at 4ºC. Then, cells were washed to eliminate the excess of antibody and 
resuspended in 200 l of 1% Paraformaldehyde solution and store at 4ºC until acquisition. 
Samples were acquired using a LSRII Flow cytometer and FACSDiva software. During 
acquisition, leukocytes were considered those events included in the CD45-APC positive 
region related to the total cells region previously selected in a dot plot in a linear scale of 
180º dispersed light (forward-FSC) opposite to 90º dispersed light (side-SSC). The 
erythrophagocytosis was considered those events double positive for CD45-APC and 
PKH26 (FL2 detector) in a FL2/FL4 dot plot. No compensation was needed to estabish the 
erythrophagocytosis population. 
Measurement of inflammation cytokines 
Mouse inflammation cytokines IL-6, IL-10, MCP-1, IFN-, TNF and IL-12p70 were 
quantified in IL2 mice using the CBA kit from Becton Dickinson (Ref. 552364). Briefly, 50 
l of mice plasma was mixed with 50 l of the mixed Capture Beads, which contained 
capture beads for each cytokine to be detected and was prepared following the 
manufacturer´s instructions. Then, 50 l of the Mouse Inflammation PE detection reagent 
was added to the samples and were incubated 2 hours in the dark at room temperature. 
For the quantification of the cytokines a standard curve was done by serial 1:2 dilutions of 
the Inflammation Standards using the assay diluent provided in the kit. 
Samples were acquired in a FACSCalibur flow cytometer. The setup process before sample 
acquisition was performed following manufacter´s instructions. Samples were acquired at 
medium speed and at least 8000 events in stopping gate. Cytokines were detected in a 
FL2/FL3 dot plot. The intensity of fluorescence in the FL2 detector indicates the quantity 
of each cytokine present in mice plasma, while the FL3 detector identify each cytokine 
depending on the fluorescence intensity of the capture beads provided in the kit. Once 
acquired, samples were analyzed using the FCAP Array™ software (Becton Dickinson). 
Measurement of erythrocytes half life and distribution volume 
Labelled erythrocytes with Biotin or CFSE were injected in IL2 mice by i.v. route (1x109 
labelled erythrocytes). Then, samples of mice peripheral blood were taken at different 
time points and were stained with SAV-PE or CD45-PerCP (as described before). Samples 
for quantification of labelled erythrocytes were taken in regular periods of time until 
labelled erythrocytes were undetectable by flow cytometry. 
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To determine the volume of distribution (abbreviated Vd) and erythrocytes half life (t1/2), 
a monocompartimental kinetic model was applied. The monocompartment model 
represents the simplest mathematical model of pharmacokinetics and was suitable for this 
study. Erythrocytes do not leave the blood stream except transiently during passage 
through hepatic sinuses and the interstitium in the splenic follicles. The delivery of 
erythrocytes after i.v. injection is fast and uniform. 
The volume of distribution in given by the following equation. 
Vd = Ci/Y 
Vd = Distribution volume. 
Ci = Initial labelled erythrocytes concentration. 
Y = Erythrocyte concentration at time t. 
 
For the calculation of the biological half life (t1/2) of erythrocytes, the formula used 
depends on the clearance kinetics showed by injected erythrocytes. 
When the concentration of labeled erythrocytes decreases with the time in an exponential 
way, erythrocytes clearance fit to a one-phase exponential decay function. In this case, the 
formulas applied to do the calculations are the following one: 
Y = a0 x e-kt+c 
Y = Erythrocytes concentration at time t. 
a0 = Labelled erythrocytes concentration at time 0. 
k = Clearance constant. 
t = Time. 
c = Constant (limit of detection of the quantification method). 
 
t1/2 = 0.693/k 
t1/2 = Half life of labelled erythrocytes. 
k = Clearance constant. 
 
If the erythrocytes clearance fit to a lineal regression function, distribution volume and 
half life were calculated using the following formulas: 
Y = b + mt 
Y = Labelled erythrocytes concentration at time t. 
b = Labelled erythrocytes concentration at time 0. 
m = Slope. 
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t = time. 
 
The formula applied for the calculation of the distribution volume was the same that in the 
case of one-phase exponential decay. 
t1/2 = -b/2m 
t1/2 = Half life of labelled erythrocytes. 
b = Labelled erythrocytes concentration at time 0. 
m = Slope. 
 
Compound formulation 
Formulations can profundly impact drug release, absorption and metabolism, which 
influence the resulting pharmacokinetic profile and the associated pharmacodynamic 
response. Physicochemical properties of compounds determine the vehicle formulations. 
Compounds were orally administered and most of them were formulated three days prior 
to the administration.  
Atovaquone, GSK932121, Proguanil, Sulfadoxine and Lumefantrine were prepared in 1% 
Methylcellulose; Primaquine, Chloroquine, Amodiaquine and Quinine were dissolved in 
0.9% saline solution; Mefloquine was prepared in a distilled water solution containing 
0.2% Methylcellulose and 0.4% Tween-80; Pyrimethamine formulation was prepared 
using a dionised water solution with 0.5% Hydroxypropylethyl cellulose, 0.4% Tween-80 
and 0.5% benzyl alcohol; Dihydroartemisinin was formulated in 5% DMSO and 20% 
Captisol distilled water solution; Piperaquine was dissolved in MiliQ water and Artesunate 
was daily prepared in a MiliQ water solution containing 3% Tween-80 and 7% Ethanol 
and pH 7. All compounds were administered orally at a dose volume of 20 ml/kg, except 
Artesunate and Dihydroartemisinin that were administered at 10 ml/kg. Compounds were 
obtained from the GSK Compound Management Database. 
Pharmacokinetics analysis 
After oral dosing, blood samples (20 l) were collected from the lateral tail vein of mice at 
different time points, 0.5, 2, 4, 6, 8 and 23 hours post dosing. All the blood samples were 
diluted in 20 l of MiliQ water and stored at -80ºC until analysis. 
Mice blood samples were analyzed for each compound after protein precipitation and 
liquid/liquid extraction, the samples were assayed by LC/MS using ESI in Q1 M+1 mode 
conditions by selected inon monitoring in an API 2000 mass spectrometer (Applied 
Biosystems Sciex, Foster City, CA) coupled to a HPLC chromatograph (Agilent HP1100 
Series , Agilent Technologies Spain). Quantification was conducted by comparison to 
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calibration curves. Blood concentrations versus time data were analyzed by non-
compartemental analysis (NCA) methods using WinNonlin® Professional Version 6.3 
(Pharsight Corporation, Mountain View, CA) and GraphPad Prism 6.0 (GraphPad 
Software). 
Gametocyte production 
P. falciparum NF54 asexual-stage culture was performed as described by Trager and 
Jensen [145]. Cultures synchronized at the ring stage were used to start gametocyte 
cultures (day 0) at 1% parasitemia and 4% hematocrit in 200 mL final volume. Complete 
culture medium (RPMI 1640 supplemented with 25 mM HEPES, 50 µg/ml hypoxanthine, 2 
g/liter NaHCO3 and 10% pooled human male type A+ serum) was totally replaced daily for 
14 days without fresh erythrocyte addition. To ensure a stable temperature at 37°C, which 
is crucial for gametocyte production and maturation, pre-warmed medium and a slide 
warmer were used. Sexual-stage development was monitored microscopically by Giemsa-
stained thin blood smears, at day 7 asexual stages and stage I to III gametocytes were 
detected and at day 14 mostly gametocytes present were at stage IV and V. 
Exflagellation assay 
Engrafted IL2 mice were infected with Plasmodium falciparum NF54 strains. Parasite 
strains were thawed using the thawing method set up for humanized mice blood 
(described above). 20x106 infected erythrocytes were injected i.v. in IL2 chimeric mice. 
Thawing was done two weeks before mosquito feeding. At least 1 in vivo passage of P. 
falciparum erythrocytic stages was done from infected mice to engrafted mice by i.v. route 
with 20x106 infected erythrocytes. From day 3 until day 30 after infection with the P. 
falciparum strain, daily samples from peripheral blood of P. falciparum NF54 infected mice 
were taken. 2 l of blood was put in a 0.5 ml eppendorf containing 10 l of ookynete 
medium (RPMI medium containing hypoxanthine, bicarbonate and xanthurenic acid), after 
10 minutes of incubation in the dark at room temperature, exflagellation is checked under 
a light microscope using the 100X objective. When exflagellation occurs, the movement of 
the male gamete is easily detected. 
Mice anesthesia 
Anesthetic procedure is performed only by trained personnel. Mice are anesthetized with 
150 l of a solution of Ketamine/Xylazine (80 mg/kg and 15 mg/kg, respectively) by 
intraperitoneal route. These mice are injected intraperitoneal with 3 mg/kg Midazolam 15 
minutes before injecting anesthetics to induce a deep sedation state that lasts at least 40 
minutes. A tear solution is applied to mice eyes to avoid dryness during the anesthesia. 
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Mice are covered with a thermal blanket to avoid the loss of temperature during 
mosquitoes feeding. 
Mosquitoes feeding assay 
Female mosquitoes of Day 3 to 5 days old are put in starvation at least 12 hours before the 
feeding. Then, mice ventral zone is exposed to the mesh of the mosquitoes´ containers for 
the feeding. Mosquitoes are fed with anesthetized mice during 20 minutes in a dark 
chamber at 26.5±1ºC of temperature. After feeding, mosquitoes are put in an incubator 
(12 hours of dark/light cycle, 26.5±1ºC and 75-80% humidity) and each mouse returned 
to its cage unde red warm light until their recovery from anesthesia. 
Mosquitoes are fed with soaked cotton with 10% glucose and 1% Karo syrup, which is put 
in the top of the mesh and is changed every day until the mosquitoes dissection takes 
place. Mosquitoes are not manipulated during the 7 days of incubation. 
Mosquitoes dissection 
At day 7 or 10 after mosquitoes were fed with mice, mosquitoes´ containers were taken 
out from the incubator and put in a CO2 chamber, with the CO2 flux at maximum level, 
during 1 minute to induce an anesthesia. Then, mosquitoes´ cups were taken out from the 
chamber. After checking that all mosquitoes were down in the bottom of the container and 
that there were no mosquitoes in the hole of the container, ethanol 70% is poured through 
the hole until all mosquitoes were immersed. After 1 minute, the mesh of the container 
was cut with a scalpel and the mosquitoes were taken out one by one using entomological 
forceps for catching the mosquitoes by the proboscis. Quickly, mosquitoes were 
transferred to a petri dish on humidified paper filter. Then, mosquitoes´ heads were cut off 
with the scalpel. Mosquitoes bodies were transferred to another petri dish with filter 
paper soaked in distilled water. Finally, the petri dish was sealed with parafilm and it was 
placed into the fridge at 4ªC until dissection. 
Midguts were obtained from mosquitoes under a stereo microsope. Mosquitoes bodies 
were removed from the fridge and put in a drop of PBS 1X on a slide. Under the scope 
vision mosquitoes were dissected by holding firmly the mosquito by the thorax with one 
forceps and by the terminalia (approximately the 7th segment) with a second pair of 
forceps. Then, gently the terminalia was pulled away from the abdomen. The midgut 
should be detached to the final abdomen, and the ovaries should stay in the abdomen. To 
obtain the midgut, the last abdominal segment and the malpigian tubules were removed 
by entomological forceps. 
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Picture from Anopheles method MR4 
Oocyst count 
Anopheles stephensi midguts containing P. falciparum oocysts were stained with 0.1% 
mercurochrome solution for 15 minutes and then were placed separately in the wells of a 
12-well glass slide containing one drop of mercurochrome solution. The slide is covered 
with a cover slip and midguts can be observed under the microscope using the 10X 
objective which allows the oocysts count. 
Statistics 
Sample sizes for comparative experiments were calculated to detect a decrease of 50% in 
the mean of control group. Typically, the level of Type I error  was set at 0.05, meaning 
that we are 95% confident and a power of 80% (Type II error  at 0.2). For the 
comparison of the kinetics curves, the area under the curve (AUC) was calculated to take 
into account the temporal dimension of data. The variables weight, percentage of 
chimerism in pheripheral blood and the percentage of parasitemia against time (AUC0→t) 
followed a normal distribution. The comparision among the averages of each experimental 
group was analyzed using Student´s t test, an Analysis of Variances (ANOVA) followed by 
post hoc test such as Dunnett´s, Tukey´s or Games-Howell´s post test, depending on the 
experiment. The homogeneity of the variance was calculated with the Levene´s test. The 
variability of the data was expressed as the standard deviation (SD) or as the standard 
error mean (SEM). The statistical analysis was performed using the GraphPad 6.0 software 
for Windows. Probability values larger than 0.05 were considered non-significant.
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Characterization of the GSKPfHu mouse model 
Engraftment of immunodeficent IL2 mice with human eythrocytes 
P. falciparum parasite infects almost exclusively human erythrocytes. The most successful 
method for generating a human erythroid chimeric mouse is through regular infusions of 
humans red blood cells. Immunodeficent mice have emerged as an enabling technology for 
studying human malaria. In the non-myelodepleted model with 2 mice previously 
described [5], the engraftment of mice was achieved by the daily intraperitoneal injections 
of 1 ml of human erythrocytes  at 50% hematocrit (RPMI 1640, 25% decomplemented AB 
human serum, 3.1 mM hypoxanthine). The 2 mouse strain retains residuel NK cells 
activity and shows a high incidence of developing early thymic lymphomas, which 
dramatically diminish their life span. These characteristics are a serious problem for 
adressing long term studies. However, the generation of a new immunodeficent mice 
which overcome the  2 deficiencies, open an new possibility for the improvement of the 
GSKPfHu mouse model. 
The ability of IL2 mice to be engrafted with human red blood cells was compared with the 
2 mice for the improvement of the murine model of P. falciparum malaria. Both mice 
strains received daily intraperitoneal injections of 1 ml of human blood at 50% 
hematocrit. As shown in figure 11 the kinetics of engraftment of IL2 mice fit to a one-phase 
exponential association function (R2=0.92), the time of engraftment required to obtain at 
least 40-50% of human erythrocytes in mice peripheral blood was 6.8 ± 0.1 days (n=80 
mice). These data were similar to that found in the engraftment of 2 (R2=0.76), the time 
of engraftment needed to obtain 40-50% of human erythrocytes in mice peripheral blood 
was 6.9 ± 0.4 days (n=142 mice), also shown in figure 11. 
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Figure 11. Comparison of engraftment kinetics of human erythrocytes in IL2 and 2 mice (A 
and B, repectively). The percentage of human erythrocytes was calculated by flow cytometry 
as TER119-PE- events. Data are the mean percentage ± standard error of the mean of 142 2 
mice and 80 IL2 mice. Only errors bars that extend beyond the symbols are shown. 
Consequently, the IL2 mice can be engrafted with human erythrocytes by intraperitoneal 
daily injections of 1 ml of human erythrocytes (50% hematocrit). Nevertheless, to reach a 
50% of human erythrocytes in mice peripheral blood it was needed around 10 days of 
daily blood injections, which means around 5 ml of human erythrocytes per mouse to be 
engrafted. 
Infection of engrafted IL2 mice with the human parasite P. falciparum 3D7 
strain 
The susceptibility of the IL2 mice engrafted with human erythrocytes to infection by 
competent P. falciparum 3D7 was also compared to the 2 mice, which was shown to 
support blood-stage infection of P. falciparum but at low levels, less than 2% [5]. Two 
cohorts of engrafted IL2 or 2 mice (10 mice/cohort) were infected intravenously with 
20x106 parasitized erythrocytes obtained from donors mice infected with a P. falciparum 
3D7 strain, adapted to grow in vivo in engrafted mice [5]. Mice were infected after 10 days 
of receiving daily intraperitoneal injections of human blood (50% hematocrit). 
Parasite growth in both mice strains was monitored during 52 days. The parasite growth 
peak was obtained around day 7 after parasite infection, in IL2 mice this peak was around 
12-14% of parasitemia, which means 10-fold higher than that found in 2 mice (figure 12). 
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Figure 12. Parasite growth after infection by i.v. with 20x106 infected hE with P. falciparum 
(Pf3D70087/N9 strain) in IL2 (open circles) and 2 (close circles) mice. All mice were injected 
i.p. with hE daily from day 0 to day 52. Data are the mean ± standard error mean of five mice 
per data point. Only errors bars that extend beyond the symbols are shown. The percentage 
of parasitemia was calculated by flow cytometry as SYTO-16+ and TER119-PE- population. 
Murine and human erythrocytes dynamics were also studied during the parasite growth. 
The erythrocytes dynamics were similar in engrafted IL2 and 2 mice, as shown in figure 
13A and 13B. Both mice strains showed a selective clearance of human erythrocytes after 
the parasite reach the maximum peak of parasitemia. Concurrent to this human 
erythrocytes clearance, an increase in the percentage of murine erythrocytes was 
observed. During the clearance of human erythrocytes, parasite cannot be detected by 
flow cytometry (limit of detection of the technique 0.01%) in 2 mice, while in IL2 mice, 
parasite growth can be detected in spite of a reduction in the percentage of human 
erythrocytes. 
 
 
Figure 13. Dynamics of mouse (close circle) and human erythrocytes (open circle) from day 0 
to day 52 of 2 (A) and IL2 (B) mice. Mice received daily i.p. injection of hE throughout the 
experiment and were infected by i.v. route, at day 10 of blood injection, with 20x106 infected 
hE. Data are the mean ± standard error mean of five mice per data point. Only errors bars 
that extend beyond the symbols are shown. The quantification of mouse (TER119-PE+ events) 
and human erythrocytes (TER119-PE- events) was done by flow cytometry, using Trucount™ 
tubes. 
These results indicate that the IL2 mice strain was more susceptible to infection by the P. 
falciparum competent strain than 2 mice. In addition, the results suggest that the massive 
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destruction of human erythrocytes was provoked by the P. falciparum infection that is 
probably triggering a massive immune response in the immunodeficent mice. We have 
denominated this phase of the parasite growth as anaemia phase. 
At this point, the P. falciparum murine model developed in this work with the IL2 mice 
receive the name of GSKPfHu mouse model and can be divided in three different phases: i) 
Engraftment, in which IL2 mice were injected i.p. daily with 1 ml of human erythrocytes 
(50% hematocrit), ii) Infection, were the parasite grows exponentially, and iii) Anaemia, in 
this phase there was a massive destruction of human erythrocytes as the parasite growth 
decreases 10-fold compared with the peak of parasitemia reached at day 17. 
P. falciparum lyfe cycle in IL2 mice 
Once the susceptibility of the IL2 mice strain to the P. falciparum (Pf3D70087/N9) infection 
has been tested, the erythrocytic parasite life cycle was studied in these mice.  Within the 
parasite life cycle a parasite goes through several phases of development after the 
infectionof a red blood cell. The first phase is the ring stage, in which the parasite begins to 
metabolize hemoglobin. The next phase is the trophozoite stage, during which the parasite 
metabolized most of the hemoglobin, gets larger, and prepares to produce more parasites. 
Finally, the parasite divides asexually to form a multinucleated schizont. At the end of the 
cycle, the red blood cell bursts open and the parasites are dispersed to infect more red 
blood cells. 
The P. falciparum parasite growth in the mouse model is asynchronous in which all the 
stages mentioned before are present at the same time. To study the length of the parasite 
life cycle, first this parasite has to be synchronized to start the infection from  the same 
parasite stage and do the follow up at different time points. To attempt this issue, the 
parasite was synchronized in mature stages (late throphozoites and schizonts) by 
magnetic separation, mature stages were observed to have a shorter synchronic window 
than young stages (data not shown). Then, 100x106 infected erythrocytes in mature stages 
were injected by i.v. route to engrafted IL2 mice and parasite growth was monitored by 
flow cytometry and microscopy. 
The parasite growth by flow cytometry was assessed using the TER119-PE/YOYO-1 
staining method (see Material and Methods). The YOYO-1 DNA staining was selected for 
this study instead of SYTO-16, because YOYO-1 is performed with fixed cells and the 
staining procedure can be done within two weeks. On the contrary, SYTO-16 staining has 
to be performed at the moment with life cells. For logistic reasons, some samples points 
were during the night, YOYO-1 was the best option for this type of experiment. 
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The flow cytometry strategy used for the analysis of the different development stages of 
the P. falciparum parasite is shown in figure 14. The DNA quantity of young stages of 
parasite (rings and young trophozoites), is less than in mature stages (late throphozoites 
and schizonts). For this reason, young stages of parasite stay in a low YOYO-1 fluorescence 
intensity. In the process of maturation, the parasite structure acquires complexity and the 
DNA quantity increases, for this reason mature stages of parasite express high YOYO-1 
fluorescence and autofluorescence measured in TER119-PE axis (corresponding to FL-2 
photomultiplier) [148]. 
 
Figure 14. Flow cytometry analysis of peripheral blood samples from IL2 mice infected with 
P. falciparum. Red arrow mean mature stages and blue arrow mean young stages. The Dot 
plot shows two types of erythrocytes: mouse and human. Only human erythrocytes are 
infected. 
To study the whole erythrocytic cycle of P. falciparum, samples from infected mice were 
obtained at different time points  (every 7 hours) during 72 hours after infection with 
mature stages. The most representative dot plots graphs for one parasite cycle from flow 
cytometry analysis and microscopy images are shown in figure 15. The study of these 
images reveals that from 42 to 49 hours after the infection with mature stages, infected 
mice show de novo mature stages in their peripheral blood. In addition, young stages of 
parasite were the longer parasitic phase in the erythrocytic life cycle. These young stages 
remain in peripheral blood from 7 hours to 35 hours after infection, which means 28 
hours of parasite development from young rings to late trophozoites. Therefore, the 
parasite only needs 14 hours for the maturation from late trophozoites to schizonts and 
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for the invasion of new erythrocytes generating new young rings. Of note, parasite 
synchronizity was mantained within the 72 hours. 
 
Figure 15. P. falciparum erythrocytic life cycle after infection with mature stages. Dot plots 
show IL2 infected mouse (one representative mouse) peripheral blood stained with TER119-
PE and YOYO-1 at different timepoints (Time 0, 7, 21, 42 and 49 hours after infection). 
Microscopy photographies are examples of parasites found in Giemsa smears analysis of the 
same mouse and at the same timepoint than the dot plots. 
In conclusion, these results reveal that the P. falciparum Pf3D70087/N9 strain shows an 
erythrocytic life cycle of 49 hours in IL2 engrafted mice. The length of the blood-stage life 
cycle was similar to that found in the natural P. falciparum infection in human beings. 
Study of erythrokinetics of human and mouse eythrocytes in the GSKPfHu 
mouse model 
The GSKPfHu mouse model has been developed as a chimera in which human erythrocytes 
can replace totally the host erythrocytes (it can be obtained engraftment of 98%), this 
means that human erythrocytes are acepted by the mouse host and are used as own. At 
this point, it is important to understand  the process of the engrafment and the absence or 
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presence of rejection of the xenotransplant with human erythrocytes during the 
engraftment phase. In addition, it is also interesting to know the dynamics of erythrocytes 
during the infection and during the anaemia phase, where human erythrocytes are 
massively cleared. 
To study the human and mouse erythrokinetics in the GSKPfHu mouse model. 
Erythrocytes were labelled using CFSE or Biotin to grant the detection of the erythrocytes 
in mice peripheral blood. Human and mouse erythrocytes were labelled using both dyes 
interchangeably. Then, labelled human and mouse erythrocytes were injected by i.v. route 
in IL2 mice in the different phases of the murine model: i) engraftment, ii) infection and 
iii) anaemia. In addition, labelled erythrocytes were also injected by i.v. route in naïve IL2 
mice to study the erythrokinetics. 
After the i.v. injection of 1500x106 labelled erythrocytes, samples of mice peripheral blood 
were taken at different timepoints until labelled erythrocytes were undetetectable. The 
detection of labelled erythrocytes was achieved by flow cytometry as shown in figure 16. 
The quantification of tagged erythrocytes in each phase of the murine model was 
calculated using the TruCount™ tubes formula. 
 
Figure 16. Flow cytometry dot plot of labelled erythrocytes detection in mice peripheral 
blood. Red rectangle includes erythrocytes marked with Biotin and stained with SAV-PE. 
Green square contains erythrocytes tagged with CFSE. Blue square harbours non-labelled 
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erythrocytes. Orange region includes the fluorescence beads from the Trucount™ tubes used 
for the quantification of the erythrocytes. 
Kinetics of human and mouse erythrocytes obtained in naïve mice were different. The 
kinetic of hE in naïve mice fit to a one-phase exponential decay function (R2=0.90), as 
shown in figure 17A. As a result, clearance of human erythrocytes was very fast, they were 
completely eliminated in less than 48 hours. These human erythrocytes showed a half life 
of 5.42 ± 1.98 hours (n=5) in naïve mice peripheral blood. Conversely, mouse erythrocytes 
kinetic adjust to a lineal regression function (R2=0.77), as shown in figure 17B. Half life 
calculated for mouse erythrocytes in naïve mice was 363.59 ± 27.83 hours (n=5). These 
results of mouse erythrocytes half life are included in the normal values obtained for 
healthy mice (from 12 to 24 days), these data confirms that the labelling method do not 
affect the erythrocytes morphology and phisiology. 
 
Figure 17. Kinetics of human and mouse erythrocytes (A and B, respectively) in naïve IL2 
mice. Data are the mean ± SD of five mice per data point. Only errors bars that extend beyond 
the symbols are shown. Note that the X axis are different in each graph. The quantification of 
human and mouse erythrocytes was done by flow cytometry, using Trucount™ tubes. 
Significantly, the kinetics of clearance for both human and mouse erythrocytes during 
engraftment phase fit to a lineal regression function (R2=0.89 for hE and R2=0.95 for mE), 
as shown in figure 18A and 18B, respectively. Labelled erythrocytes were injected at day 
13 after starting engraftment of IL2 with daily i.p. injections of 1 ml of human blood (50% 
hematocrit), to ensure a stable engrafment of hEry in which more than 50% of hEry are 
present in mice peripheral blood. The calculated half life for human erythrocytes in 
peripheral blood of engrafted IL2 mice was considerably largest (253.56 ± 3.02 hours, 
n=5) when compared to that found in naïve mice. At the same time, half life of mouse 
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erythrocytes suffered a light decrease and was similar to human erythrocytes half life, 
258.96 ± 4.74 hours (n=5). 
 
Figure 18. Kinetics of human and mouse erythrocytes (A and B, respectively) in engrafted IL2 
mice. Data are the mean ± SD of five mice per data point. Only errors bars that extend beyond 
the symbols are shown. The quantification of human and mouse erythrocytes was done by 
flow cytometry, using Trucount™ tubes. 
To study the kinetics of human and mouse erythrocytes during the infection phase, at day 
1 after infection (day of infection: day 0) infected mice were injected by i.v. route with 
labelled erythrocytes. In this phase, human and mouse erythrocytes kinetics continued to 
fit a lineal regression function (R2=0.77 and R2=0.52, respectively), as shown in figure 19A 
and 19B.  Although, half life of both types of erythrocytes decreased to 174.71 ± 15.83 
hours (n=4) for mouse erythrocytes and 131.21 ± 4.92 hours (n=4) for human 
erythrocytes. 
 
Figure 19. Kinetics of human and mouse erythrocytes (A and B, respectively) in infected IL2 
mice at day 1 after infection with P. falciparum. Data are the mean ± SD of five mice per data 
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point. Only errors bars that extend beyond the symbols are shown. The quantification of 
human and mouse erythrocytes was done by flow cytometry, using Trucount™ tubes. 
However, the observed hEry kinetics after 1 day post-infection was probably 
understimated due to a low number of labelled erythrocytes detected. For this reason, 
human erythrocytes kinetic was studied in mice at day 3 after infection and this kinetic fit 
to a one-phase exponential decay function (R2=0.87), as shown in figure 20. At this point,  
half life of human erythrocytes is also similar to that found for mouse erythrocytes during 
the infection (at day 1 post-infection), 173.4 (n=5). These results suggests that massive 
clearance of human erythrocytes is not occuring at low parasitemias (around 0.5% at day 
3 after infection). 
 
Figure 20. Kinetics of human erythrocytes in infected IL2 mice, labelled erythrocytes were 
injected at day 3 after infection with P. falciparum. Data are the mean ± SD (n=35, not all the 
mice have the same data point). Only errors bars that extend beyond the symbols are shown. 
The quantification of human was done by flow cytometry, using Trucount™ tubes. 
When the anaemia phase was reached at day 12 after infection, kinetic of human 
erythrocytes clearance fits to a one-phase exponential decay function (R2=0.79) as shown 
in figure 21A. In addition, half life of human erythrocytes was similar to that found in naïve 
mice, 11.86 ± 7.4 hours (n=5). However, kinetic of mouse erythrocytes continues to fit to a 
lineal regression function (R2=0.35), although the adjust of the function was not good 
(figure 21B). Half life of mouse erythrocytes calculated in anaemia phase was 146.62 ± 28 
(n=5). 
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Figure 21. Kinetics of human and mouse erythrocytes (A and B, respectively) in anaemia 
phase of infected IL2 mice, labelled erythrocytes were injected at day 12 after infection with 
P. falciparum. Data are the mean ± SD of five mice per data point. Only errors bars that 
extend beyond the symbols are shown. The quantification of human and mouse erythrocytes 
was done by flow cytometry, using Trucount™ tubes. 
These results reaveal that the dynamics of human and mouse erythrocytes in the GSKPfHu 
mouse model is very complex (figure 22). Mouse erythrocytes were eliminated following a 
lineal regression function in all the phases, but the rate of clearance of these erythrocytes 
depends on the phase of the model. Nevertheless, both the kinetics and the rate of 
clearance of human erythrocytes depend critically on the phase of the GSKPfHu mouse 
model. 
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Figure 22. Half life of human and mouse erythroyctes (open and close circles, respectively) in 
all the phases of the GSKPfHu mouse model: i) naïve (green), ii) engraftment (blue), iii) 
infection (pink) and iv) anaemia (orange). 
During the anaemia phase, a massive clearance of hEry takes place, a further analysis is 
done to understand this phenomeno. At day 27 after infection the quantification of 
parasites in peripheral blood are around 147000 parasites per milliliter of blood. The 
parasite cycle takes 48 hours from the ring stage (young) to the schizont stage (mature), 
for instance parasite multiplies every 48 hours. In addition, the 3D7 strain used in these 
experiments has an average of 12 merozoites per schizont, so in theory each parasite is 
able to infect 12 human erythrocytes every 48 hours. Therefore, around 1.7x106 of human 
erythrocytes per milliliter (147000 parasites x 12 merozoites) are infected within 48 
hours in mice peripheral blood. Nevertheless, at the beginning of the anaemia phase 
around 331x106 labelled-human erythrocytes per milliliter are quantified. However, 48 
hours later, only 4x106 of these human erythrocytes are quantified. Hence, more than 
327x106 human erythrocytes (only labeled erythrocytes were quantified) have been 
cleared in 48 hours, much more than the parasite is able to destroy in its growth (1.7x106 
hEry per milliliter). To summarize, 191 uninfected hEry are destroyed per each human 
erythrocyte consumed by the parasite. 
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In conclusion, there were two phases of the GSKPfHu mouse model in which the rate of 
clearance of human erythrocytes was very high: i) naïve (and first days of engraftment), 
and ii) anaemia phase. These phases can be susceptible for improvement in terms of 
human blood consumption, and further studies for the refinement in the use of the blood 
have been done. In addition, massive clearance of hEry during anaemia phase cannot be 
explained by parasite growth, the majority of hEry cleared are uninfected erythrocytes. 
Measurement of volume of distribution in the GSKPfHu mouse model 
The distrution volume is not defined as a physical volume, but a dilution space. It is 
one of the pharmacological parameter calculated for a drug that gives an idea of  
the distribution in the body of the drug after intravenous injection, if it is retained 
in the tissues or not. Regarding the GSKPfHu mouse model, the “drug” 
intravenously administered is red blood cells and the distribution is the blood 
system without any tissue retention. For instance, in this case the volume of 
distribution calculated is the same as the circulation blood volume of the mice in 
which labelled red blood cells are injected. The importance of this parameter to be 
calculated in the GSKPfHu mouse model is to study if all the phases of the model 
are based in a policytemic state. 
The distribution volume was measured in the different phases of the GSKPfHu 
mouse model: i) engraftment, ii) infection, and iii) anaemia. Also, naïve mice 
distribution volume was studied and used as control mice to establish the basal 
distribution volume. 
Human and mouse erythrocytes were labelled with Biotin or CFSE and were 
injected by i.v. route at the different phases of the model. Then, samples of mice 
peripheral blood were taken at different timepoints for the detection and 
quantificatin of labelled erythrocytes by flow cytometry. Distribution volume was 
calculated using the formula described below. 
Vd = Ci/Y 
Where Vd = Distribution volume, and Ci = Initial labelled erythrocytes 
concentration. 
In naïve mice calculated distribution volume was aproximately 1.19 ± 0.25 ml 
(n=10). In addition, basal concentration of erythrocytes in naïve mice was 
7878.79x106 ± 752.75 erythrocytes/ml (n=10) in peripheral blood. At day 13 after 
 
78 Results 
starting engraftment with daily i.p. injections of 1 ml of human blood (50% 
hematocrit),  distribution volume calculated was 3.5 ± 0.83 ml (n=10), triplicating 
the basal distribution volume. Erythrocytes concentration in engraftment phase 
also suffered an increment, reaching the value of 11814.48x106 ± 1358.83 (n=10) 
in mice peripheral blood. Taking into account the hematocrit and the erythrocytes 
concentration, the mean corpuscular volume (MCV) of erythrocytes can be 
estimated by dividing the hematocrit of these mice (around 80%) by the quantity 
of erythrocytes per microliter. The value obtained in the division was 68 fL, which 
it is found between the range of MCV of mice (45-55 fL) and human (80-100 fL). 
At the beginning of the inftection phase (day 1 after infection), the distribution 
volume calculated was similar to that found in the engraftment phase, 3.44 ± 0.81 
ml (n=8). The concentration of erythrocytes in mice at day 3 after infection was 
also similar to that found in the engraftment phase, 10457.04x106 ± 378.68 
erythrocytes/ml  (n=5). However the distribution volume was slightly lower, 2.79 
± 0.44 ml (n=13), when comparing with the value obtained at day 1 after infection. 
During the anaemia phase, where human erythrocytes were massively cleared, the 
concentration of eythrocytes in mice peripheral blood was reduced to the half of 
concentration found in naïve mice, 4532.41x106 ± 702.4 erythrocytes/ml (n=5). 
The distribution volume calculated in this phase was similar to the value obtained 
in naïve mice, 1.69 ± 0.64 ml (n=10). 
To conclude, distribution volume in IL2 mice depend on the phases of the model. 
The concentration of erythrocytes in mice peripheral blood also depend on the 
phases of the model and it was closely related to the distribution volume, as shown 
in figure 23. 
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Figure 23. Comparison between distribution volume (open circles) and erythrocytes 
concentration (close circles) in all the phases of the GSKPfHu mouse model: i) naïve 
(green), ii) engraftment (blue), iii) infection (pink) and iv) anaemia (orange). 
Study of cytokines involved in all the phases of the GSKPfHu mouse model 
The GSKPfHu mouse model has been developed in immunodeficient mice (lacking T and B 
lymphocytes, and non functional NK cells), without myelodepletion of macrophages. 
However, IL2 mice used in this model can have active macrophages that are involved in 
the clearance of human erythrocytes at the beginning of the engrafment and in the 
anaemia phase, as seen in the previous experiments. Therefore, these mice are able to 
show a kind of innate response mediated by activated monocytes and macrophages in the 
different phases of the model. To explore the role that these active macrophages could 
play, some inflammatory cytokines have been studied in the different phases of the 
GSKPfHu mouse model to elucitate the mechanisms involved in the clearance of human 
erythrocytes: i) engraftment, ii) infection, and iii) anaemia. Levels of cytokines were also 
measured before starting engraftment with human erythrocytes. In addition, results 
obtained were compared with the parental mice strain for IL2 mice, NODscid mice, that 
also lacks T and B lymphocytes, but still have functional NK cells. NODscid mice were also 
engrafted and infected with the P. falciparum parasite. 
Inflammatory cytokines studied in mice were: i) TNF-, ii) IL-12p70, iii) IFN, iv) MCP-1, 
v) IL-10 and vi) IL-6. Using the BD CBA mouse inflamatory kit, cytokines were studied in 
mice plasma and were quantified by flow cytometry. 
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Levels of TNF- in naïve mice were less than 10 pg/ml, these levels remains more or less 
stable throughout the engraftment of mice within 34 days of  blood injection (figure 24A). 
Nevertheless, levels of TNF- increased above 25 pg/ml, reaching one peak during 
infection (at day 16 of blood injection), and another peak in anaemia phase (at day 30 after 
blood injection), as shown in figure 24B. 
 
Figure 24. Levels of TNF- in engrafted mice (A) and infected mice (B). Data are the mean ± 
SEM of five mice per data point in the case of percentage of human erythrocytes (hE) and 
infected human erythrocytes (ihE). Only errors bars that extend beyond the symbols are 
shown. TNF- levels are data from an unique pool of of serum from five mice per data point. 
When measuring levels of IL-12p70 in naïve mice, it was also less than 10 pg/ml, these 
levels were mantained throughout engraftment phase (figure 25A). However, levels of IL-
12p70 increased during infection phase and reached a peak during anaemia phase, above 
100 pg/ml at day 28 after starting blood injection, as shown in figure 25B. 
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Figure 25. Levels of IL-12p70 in engrafted mice (A) and infected mice (B). Data are the mean 
± SEM of five mice per data point in the case of percentage of human erythrocytes (hE) and 
infected human erythrocytes (ihE). Only errors bars that extend beyond the symbols are 
shown. IL-12p70 levels are data from an unique pool of serum from five mice per data point. 
Levels of IFN in naïve mice before starting engrafting process were less than 3 pg/ml, 
these levels were mantained more or less stable throughout engraftment phase (figure 
26A). In addition, levels of IFN were also stable during infection and anaemia phase 
(figure 26B). 
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Figure 26. Levels of IFN in engrafted mice (A) and infected mice (B). Data are the mean ± 
SEM of five mice per data point in the case of percentage of human erythrocytes (hE) and 
infected human erythrocytes (ihE). Only errors bars that extend beyond the symbols are 
shown. IFN levels are data from an unique pool of serum from five mice per data point. 
In naïve mice, measured levels of MCP-1 were approximately 80 pg/ml. During 
engraftment phase, these levels were mantained more or less around 100 pg/ml (figure 
27A). Nonetheless, levels of MCP-1 increased during infection phase reaching a peak at 
around 400 pg/ml, other peaks around 200 pg/ml were reached during infection and 
anaemia phase, as shown in figure 27B. 
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Figure 27. Levels of MCP-1 in engrafted mice (A) and infected mice (B). Data are the mean ± 
SEM of five mice per data point in the case of percentage of human erythrocytes (hE) and 
infected human erythrocytes (ihE). Only errors bars that extend beyond the symbols are 
shown. MCP-1 levels are data from an unique pool of serum from five mice per data point. 
Levels of IL-10 in naïve mice were determined at around 35 pg/ml. During engraftment 
phase, levels did not shown a specific pattern, reaching some peaks with a maximum of 
110 pg/ml (figure 28A). In the infection phase, the maximum peak reached was lower than 
engraftment phase (85 pg/ml), as shown in figure 28B. 
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Figure 28. Levels of IL-10 in engrafted mice (A) and infected mice (B). Data are the mean ± 
SEM of five mice per data point in the case of percentage of human erythrocytes (hE) and 
infected human erythrocytes (ihE). Only errors bars that extend beyond the symbols are 
shown. IL-10 levels are data from an unique pool of serum from five mice per data point. 
Measured levels of IL-6 in naïve mice were less than 5 pg/ml, these levels did not suffer 
much variation throughout engraftment phase (figure 29A). Nevertheless, levels of IL-6 
showed a peak during infection phase, around 100 pg/ml at day 14 after starting blood 
injection, as shown in figure 29B. 
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Figure 29. Levels of IL-6 in engrafted mice (A) and infected mice (B). Data are the mean ± 
SEM of five mice per data point in the case of percentage of human erythrocytes (hE) and 
infected human erythrocytes (ihE). Only errors bars that extend beyond the symbols are 
shown. IL-6 levels are data from an unique pool of serum from five mice per data point. 
To summarize, inflammatory cytokines studied in the different phases of the GSKPfHu 
mouse model showed different expression throughout the experiment, where IFN was 
absent during all the phases of the model. In addition, the only cytokine detected during 
the engraftment phase was IL-10. However, during the infection phase most of the 
inflmmatory cytokines studied were involved: TNF, IL-12p70, MCP-1, IL-6 and IL-10. 
Whereas cytokines expressed during the anaemia phase were reduced and only TNF IL-
12p70 and MCP-1 were expressed. A determination of the AUCs for the different cytokines 
studies was assessed to have a better understanding  of the cytokines expression in the 
GSKPfHu mouse model, AUCs of cytokines values obtained througout the experiment were 
compared with the expression of the same cytokines obtained in parental mice strain 
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(NODscid) and in the same conditions of engraftment with hE and infection with P. 
falciparum 3D7 strain (figure 30). 
 
Figure 30. AUC comparison of inflammatory cytokines expression between NODscid and IL2 
mice under the conditions of GSKPfHu mouse model (engraftment with the daily i.p. injection 
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of 1 ml of hE and infection with 20x106 Pf 3D7 infected erythrocytes after 10 days of 
engraftment). AUC is calculated from levels of cytokines obtained from an unique pool of 
serum from five mice per data point. Note that Y axis scale are different in each graphic. 
When comparing AUCs of cytokines expression of IL2 mice with their parental mice strain, 
it can be observed that the expression MCP-1 and IL-10 cytokines stayed more or less the 
same in both mice strain with no significant difference during the engrafment and 
infection procedure. However, TNF- and IL-6 maintained similar expression in the two 
mice strain but it is slightly higher during the infection. In addition, expression of IL-12p70 
was only activated throughout infection and by consequence anaemia phase in IL2 mice. 
Nevertheless, expression of IFN- is lower in IL2 infected mice comparing with the 
parental NODscid. 
Study of erythrophagocytosis in the GSKPfHu mouse model 
In vivo erythrophagocytosis 
It is described that in malaria most of the erythrophagocytosis takes place in the spleen 
[119]. Massive clearance of human erythrocytes in the GSKPfHu mouse model takes place 
mostly in two phases of the GSKPfHu mouse model: naïve and anaemia phase.  In vivo 
erythrophagocytosis of hEry in the spleen was studied in these two phases. Two different 
mice strains were used to address erythrophagocytosis, CD1 mice as control of high 
clearance of human erythrocytes. Whereas, IL2 mice engrafted with human erythrocytes 
were used as control of low clearance of human erythrocytes. 
To study erythrophagocytosis naïve IL2 and CD1 mice were injected with 2.2x108 CFSE-
labelled hEry, mice peripheal blood was collected at different timepoints to quantify CFSE 
labelled hEry, when a significative decrease in this number was detected (more than a half 
of the labelled hEry detected after the injection), spleens were excised. In addition, IL2 
engrafted mouse was injected with the same number of CFSE labelled erythrocytes at day 
14 after starting with the blood injections, spleen was removed 15 hours after injection of 
labelled erythrocytes. Finally, in anaemia phase mice were injected with the same number 
of CFSE labelled hEry by i.v. route at day 10 after P. falciparum infection, then spleens 
were excised at different time points to assess erythrophagocytosis: 7, 14, 15, 24, 32 and 
48 hours after injection. 
Once the spleens were excised, they were desintegrated and cells obtained were used to 
study the erythrophagocytosis by flow cytometry using different monoclonal antibodies: 
CD45, F4/80 or GR-1.  
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Cells from disintegrated macrophages stained with the different monoclonal antibodies at 
the same time using different fluorocromes conjugations. Macrophages that were 
phagocytosing erythrocytes were considered as populations positive for CFSE staining and 
positive for CD45, F4/80 or GR-1 macrophage membrane protein markers in dot plots 
graphics. 
Results obtained showed that in the control CD1 mice, 10% of leukocytes (CD45+ 
population) were phagocytosing CFSE-labelled erythrocytes. From the total leukocytes 
population, the erythrophagocytosis was performed by F4/80+ and GR-1+ active 
macrophages populations, as shown in figure 31A. Accordingly, erythrophagocytosis in IL2 
naïve mice (non-engrafted) was also achieved by the 10% of CD45+ leukocytes. The 
F4/80+ macrophage population and the GR-1+ population were also responsible of this 
erythrophagocytosis, as shown in figure 31B. During engraftment phase there was also 
erythrophagocytosis of CFSE labelled hEry ascertained in the spleen, although calculated 
half life of human erythrocytes was 253.56 hours. In engrafted mice, 9% of CD45+ 
leukocytes were phagocytosing CFSE-labelled hE. In addition, in engrafted mice the 
percentage of phagocytosis on F4/80+ macrophages was higher than GR-1+ population, as 
shown in figure 31C. 
Erythropagocytosis in anemia phase was studied at different time points in order to cover 
the massive clearance of human erythrocytes. The phagocytosis of CFSE-labelled hE was 
detected in all the time points that have been explored. A representative time point in 
which erythrophagocytosis was present was selected to be shown in figure 31D. At 14 
hours after the injection of CFSE labelled erythrocytes, around 5% of CD45+ leukocytes 
were phagocytosing CFSE-hEry. Furthermore, mostly of phagocytosis was performed by 
F4/80+ population. 
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Figure 31. Dot plot graphics from LSRII flow cytometer from erythrophagocytosis study in 
spleen at different phases of the GSKPfHu mouse model. Erythrophagocytosis was studied in 
CD45, F4/80 or GR-1 leukocytes populations (from left to right), and was studied in CD1, IL2 
naïve, IL2 engrafted and IL2 anemic mice (A, B, C and C, respectively). 
In conclusion, erythrophagocytosis in spleen is present in all the phases of the GSKPfHu 
mouse model. Cells populations involved in the phagocytosis of human erythrocytes in IL2 
mice spleen are positive for CD45 (marker for leukocytes), F4/80 (marker for spleen red 
 
90 Results 
pulp macrophages) and GR-1 (marker for inflammatory monocytes) membrane proteins. 
In the case of engrafted and anemic mice the erythrophagocytosis was mostly mediated by 
F4/80+ macrophages. By contrast, in naïve mice, the phagocytosis is assessed equally by 
F4/80+ and GR-1+.  
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Optimization of the GSKPfHu mouse model 
Kinetics of human erythrocytes after intraperitoneal injection 
The results of the erythrokinetics obtained after i.v. injection revealed that in naïve mice 
the clearance of  human erythrocytes was very fast, this massive removal of hE can be 
caused by the rejection of the xenotransplant. The xenotransplant with hE in the GSKPfHu 
mouse model was done by i.p. injections of 1 ml of human blood (50% hematocrit). To 
study the kinetics of human erythrocytes after i.p. injection of 1 ml of human blood 50% 
hematocrit in IL2 mice, several samples from mice peripheral blood were taken at 
different time points after a unique i.p. injection. These samples were analyzed by flow 
cytometry to calculate the concentration of human erythrocytes in mice peripheral blood. 
The analysis of the kinetic revealed the presence of different peaks of absorption of human 
erythrocytes. The first peak was around 6 hours after injection, followed by a small drop in 
the total of human erythrocytes in mice peripheral blood (figure 32). Each mouse received 
3961.68x106 human erythrocytes in the mililiter of human blood injected. The maximum 
peak of human erythrocytes found in mice peripheral blood was 1369.5x106. In 
conclussion, only around the 35% of human erythrocytes injected went through the 
peritoneum to the peripheral blood. 
 
Figure 32. Kinetic of human erythrocytes after i.p. injection of 1 ml of human blood (50% 
hematocrit) in IL2 naïve mice. Data are the the mean ± standard error of the mean of a 
cohort of five mice sampled at different time points. Only errors bars that extend beyond the 
symbols are shown. Quantification of human erythrocytes (TER119-PE- events) was done by 
flow cytometry using Trucount™ tubes. 
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The maximum peak of absorption was reached 12 hours after the intraperitoneal 
injection. This data reveals that exists a rejection of the xenotransplant of human 
erythrocytes in IL2 mice so far as the clearance of human erythrocytes starts as soon as 
the maximum peak of abosorption was reached. This speed of clearance is slower than the 
calculated after i.v. injection of human erythrocytes (5.42 hours), in this case the half life of 
human erythrocytes is around 32 hours. Thus, the injection of 1 ml of human blood at 50% 
hematocrit every 24 hours may be a suboptimal regime for engraftment of IL2 and there is 
still room for improvement of the protocol in terms of engraftment. 
Study of erythrophagocytosis in the GSKPfHu mouse model 
In vitro 
The engraftment of IL2 mice is done with intraperitoneal injections of human blood, and 
the recruitment of monocytes in the peritoneum is common in inflammatory processess 
[133]. For this reason, the ability of IL2 peritoneum cells to perform phagocytosis of hEry 
was assessed. Peritoneal cells were obtained from the peritoneal cavity of  IL2 mice and 
the they were icubated in vitro overnight to allow adhesion to the plate for the 
erythrophagocytosis study. 
Human erythrocytes were labelled with PKH26 membrane staining, and then 3x109 of 
labelled hEry were added to the peritoneum cells culture plate and incubated during 2 
hours at 37ºC in a CO2 incubator. After the incubation, excess of erythrocytes were washed 
and lysed, and peritoneum cells were detached from the bottom of the plate to observe the 
phagocytosis by flow cytometry. 
The, peritoneum cells were incubated with CD45-APC monoclonal antibody (leukocyte 
membrane antibody), during 20 minutes at 4ºC to avoid phagocytosis. Then, cells were 
fixed with 1% paraformaldehyde and acquired in LSR II flow cytometer. Peritoneum cells 
were positive for the CD45 antibody, this means that these cells are leukocytes. Unstained 
hEry were used for phagocytosis control in absence of PKH26 fluorescence (figure 33A). 
Whereas, figure 33B shows peritoneum cells (CD45+) put in culture in the presence of 
PKH26 labelled erythrocytes. 
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Figure 33. Flow cytometry dot plots from in vitro erythrophagocytosis study. Upper dot plots 
(A) shows culture of peritoneal cells in which non-labelled human erythrocytes have been 
added. CD45+ cells are selected on upper-left dot plot, upper-right dot plot represents 
erythrophagocytosis of non-labelled hEry (CD45+-PE- cells). Lower dot plots (B) culture of 
peritoneal cells with PKH26-labelled human erythrocytes added. CD45+ cells are selected on 
lower-left dot plot, lower-right dot plot represents erythrophagocytosis of PKH26-labelled 
hEry (CD45+-PE+cells. Green square shows CD45+cells and red line divides Y axis in negative 
(below the line) and positive (above the line) for PE (PKH26) fluorescence. 
Population included in green box corresponds to CD45 positive cells. This population was 
selected in a SSC-H/APC dot plot, by the selection of cells that express CD45 antibody, 
which is tagged with a APC fluorocrome. To select macrophages that were phagocytosing 
hEry, it was used a PE-H/APC-H dot plot, in which in the X axis (APC)  there was selected a 
population positive for the CD45 antibody, and in the Y axis was selected those CD45+ cells 
that were also positive for PE (PKH26 expression). When the Mean Fluorescence Intensity 
in Y axis (PE-H) of the CD45+ population on the lower right dot plot (figure 33B) was 
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compared with that MFI in the control dot plot (figure 33A), it can be observed that there 
is an increase of these MFI in the Y axis for these  CD45+ cells. This increase means that 
this CD45+ population is showing fluorescence in the PE channel, which correspond to the 
PKH26 expression of labelled human erythrocytes that have been internalized inside the 
CD45+ cells (hEry that had been phagocytosed). 
Fluorescence microscopy was used to confirm that the erythrophagocytosis observed by 
flow cytometry correspond to erythrocytes that have been internalized by the 
macrophages. Fluorescence of the culture plate was observed in an inverted flouorescence 
microscopy, in three different channels: i) UVA to detect DNA of the macrophages stained 
with DAPI; ii) PE for the detection of PKH26 labelled human erythrocytes; and iii) bright 
field to observe the structure of the macrophages. Microphotographies in these different 
channels are shown in figure 34, and exhibit internalized PKH26 hE by macrophages. 
 
Figure 34. Microphotographies of the erythrophagocytosis of labelled PKH26 erythrocytes by 
macrophages. Yellow circles show where the erythrophagocytosis is taking place. From left 
to right: Bright field, DAPI to label macrophages DNA, PE that detects PKH26 erythrocytes 
and the merge of the three fields. 
To conclude, peritoneum cells isolated from IL2 mice are active and are able to 
phagocytose human erythrocytes as it has been checked in an in vitro erythrophagocytosis 
assay. These results supports the hypothesis that hEry are being phagocytosed after the 
intraperitoneal injection and as result only 35% of hEry reach mice pheripheral blood 
after the injection. 
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Optimization of the dosing regime of blood in the GSKPfHu mouse model 
Following empirical protocols previously published, the engraftment of 2 with hEry, used 
in the first implementation of the GSKPfHu mouse model, was achieved by daily 
intraperitoneal injection of 1 ml of hE suspension (50% hematocrit) [5]. This procedure 
led to    50% hE in mice peripheral blood in 10 days, which requires an average of 4 ml of 
hE concentrate per mouse and week for engraftment. 
In previous experiments, it has been hypotethized that the intraperitoneal injection of 1 
ml of hEry (50% hematocrit) every 24 hours may be a suboptimal engraftment protocol, 
and blood dosing regime for engraftment could be reduced using alternative regimes of 
intraperitoneal injections of hEry. 
In order to optimize the use of hEry concentrates in the standard GSKPfHu mouse model, 
different regimes of intraperitoneal injection and volumes of suspension were tested in 
IL2 mice. Briefly, mice were randomly divided in groups of 4 mice each and assigned to 
one of the 9 combinations of 3 different frequency of injection (24, 48 and 72 hours) and 3 
different volumes of hEry suspension for each frequency (0.5, 1 and 1.5 ml) at a 50% 
hematocrit. 
Under these experimental conditions, the best engraftment protocol should be the one that 
achieve    50% hEry in mice peripheral blood in 10 days or less without deleterious effects 
in mice welfare, measured as negative weight increment throughout the experiment. 
Results obtained in this study  lead to the conclussion that the regime used for the 
engraftment of 2 and IL2 mice previosuly published [5, 63], is suitable for engraftment 
without causing damage to mice welfare (AUC0-19=1015.45 ± 131.17). This means, i.p. 
injection of 1 ml of human blood every 24 hours lead to achieve    50% hEry in mice 
peripheral blood in 10 days, as shown in figure 35. In addition, the injection of 1.5 ml of 
human blood every 48 hours also led to   50% hEry in mice peripheral blood in 10 days 
without deleterious effects in mice with similar AUC0-19 (898.45  ± 41.72) (figure 35 and 
36B). However, besides being one of the best regime for IL2 mice engraftment with hE 
(AUC0-19= 925.72  ± 342.66), the regime of 1.5 ml every 24 hours was discarded due to loss 
of weight in mice (figure 36A). No significant differences were observed among these 
three regimes of blood injection after two-way ANOVA test of AUCs.  
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Figure 35. Kinetics of engraftment with hEry in the dosing regimes in terms  of volume and 
time of blood i.p. injection. The percentage of human erythrocytes was calculated by flow 
cytometry as TER119-PE- events. Data are the mean ± standard error of the mean of four 
mice per group. Only errors bars that extend beyond the symbols are shown. 
 
Figure 36. Increment in the body weight of mice injected with different volumes of i.p. hEry 
injections at 24, 48 and 72 hours (A, B and C, respectively).  Data are the mean ± standard 
error of the mean of four mice per group. Only errors bars that extend beyond the symbols 
are shown. 
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In conclusion, in terms of human blood consumption, with the regime of intraperitoneal 
injection of 1.5 ml of erythrocytes suspension (50% hematocrit) every 48 hours, 
approximately 1 ml of human blood can be saved per mouse and week. 
Other regimes of human blood injection for the optimization of blood 
consumption in the GSKPfHu mouse model 
In order to optimize the blood consumption, other protocols for mice engraftment with 
human erythrocytes were explored. One of these protocols it is based on the injection of 
an extra dose of human erythrocytes within 12 hours (time observed before human 
erythrocytes clearance starts after intraperitoneal injection), this regime of blood 
injections may lead to a faster engraftment of mice with human erythrocytes and a 
reduction in the human blood consumption. 
To prove this hypothesis, IL2 mice were randomly divided in groups of 5 mice each and 
assigned to one of the 3 groups tested: i) control group (i.p. injections every 24 hours with 
1 ml of hEry), ii) 1x12h (i.p. injections of 1 ml of hEry every 12 hours until 24 hours, then 
injections every 24 hours) and iii) 2x12h (i.p. injections of 1 ml of hEry every 12 hours 
until 48 hours, then injections every 24 hours). Mice were injected only four days, and 
negative weight increment was used as control of deleterious effect on mice welfare 
throughout experiment. 
 esults obtained in this e periment, revealed that mice injected with human erythrocytes 
from groups ii  and iii  (1 12h and 2 12h, respectively , led to    40-50% of hEry in 
peripheral blood in 4 days (figure 37A). Mice welfare was not affected by the increment of 
i.p. injections at the beginning of the experiment (figure 37B). When comparing AUC of % 
human erythrocytes increment from day 0 to 4, control group showed an AUC0-4=1605 ± 
276.4. Meanwhile, 1x12h had an AUC0-4=2203 ± 835.6 and 2x12h group an AUC0-4=3669 ± 
368, only significant differences were found when comparing control and 1x12h group 
with 2x12h. 
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Figure 37. Kinetics of engraftment with hEry in the different groups tested, compared with 
control group (A). The percentage of human erythrocytes was calculated by flow cytometry 
as TER119-PE- events. Increment in the body weight of the mice in the experimental groups 
throughout the experiment (B). Data are the mean ± standard error of the mean of five mice 
per group. Only errors bars that extend beyond the symbols are shown. 
As conclusion, with these new protocols of engraftment, there is a saving in human blood 
consumption. When using 1x12h protocol, 1 ml of human blood can be saved per mouse 
and week. However, with the 2x12h protocol, only 0.5 ml of human blood can be saved. 
Test different P. falciparum strains to study parasite kinetics and anaemia 
phase 
During the anaemia phase in the GSKPfHu mouse model, there is a massively destruction 
of human erythrocytes, as shown previously. This fast clearance of the human 
erythrocytes could be due to the consumption of the hEry during the exponential growth 
of the P. falciparum 0087/N9 parasite. Different P. falciparum strains were studied in the 
GSKPfHu mouse model to test the capacity of these strains to provoke the anaemia phase 
in mice after infection.  
Various P. falciparum strains of different genetic background have shown a different rate 
of growth. Seven different Pf strains have been selected to perform this experiment based 
on different characteristics: i) V1/S, which is derived from a human isolate in Vietnam, 
resistant to chloroquine, sulfadoxine, pyrimethamine and cycloguanil [26, 116]; ii) NF54, 
that comes from a patient isolate and is the parental of 3D7 strain [24, 118]; iii) D10, this 
strain was collected in Papua New Guinea [21, 32]; iv) Rap I, which is the D10 strain but 
with a truncation by transfection of the Ropthry protein 1 and 2 [16, 25]; v) K1, this strain 
has the same resistances as V1/S, but it was derived from a human isolate in Thailand [23, 
31]; vi) FCR3, that show resistance to chloroquine, atovaquone and cycloguanil [22, 60] 
and vii) 3D7, used as the control of the experiment, and it is a clone from NF54 isolate by 
limiting dilution [20, 50]. P. falciparum strains used in this experiment were expanded in a 
in vitro culture prior to the adaptation in vivo in chimeric NSG mice by performing 
passages from mice to mice and intravenous infections until reproducible growth in all 
mice infected were obtained, as described before [5]. 
To perform the experiment, chimeric IL2 mice with at least 50% of human erythroytes in 
peripheral blood were injected by i.v. route with 20x106 of infected erythrocytes of each 
strain. The percentage of parasitemia and human erythrocytes were measured by flow 
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cytometry at different time points from day 3 to at least day 25 after infection, to cover the 
anaemia phase that takes place around day 15 after infection in the 3D7 control strain. 
When comparing the control strain with each of the other selected strains, we observe that 
the V1/S strain reaches a higher percentage of parasitemia, maximum peak at 30.85%, 
three times higher than the parasitemia peak in 3D7 (10.49%), as shown in figure 38A. 
Besides this increment of parasitemia in the V1/S, the clearance of human erythrocytes 
takes place at the same time and with a similar pattern that the 3D7 strain (figure 39A). 
However, the Rap I parasitemia peak is two times higher the 3D7 control strain (23.15%), 
figure 38C. Moreover, the aneamia phase is delayed in mice infected with this strain, 
therefore human erythrocytes clearance begin at day 25 after infection, 39C. The anaemia 
phase is also delayed in the infection with the NF54 strain, figure 39B. But the parasitemia 
peak reached (6.08%) is almost half the parasitemia peak of the control strain (10.49%), 
figure 38B. 
In three of the Pf strains studied: D10, FCR3 and K1 strains, the massive human 
erythrocytes clearance does not take place throughouth the experiment, figure 39C, 39E 
and 39F. Mice were euthanized at day 25 after infection, so there is not enough data to 
corfirm or reject that hEry clearance is supressed in the infection of these strains. The 
parasitemia peak in the D10 infection was similar to that found in the V1/S infection 
(29.64% and 30.85%, respectively). Whereas, the parasitemia peak for the FCR3 and D10 
was lower to the peak in the control strain (3.77%, 7.3% and 10.49%, respetively), figure 
38C, 38E and 38F. 
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Figure 38. Parasite growth after infection in chimeric IL2 mice by i.v. with 20x106 infected 
hEry at day 0 with different P. falciparum strains compared with the control strain 3D7 
(close circles): V1/S (A), NF54 (B), D10 (C), RapI (D), K1 (E) and FCR3 (F). Data are the mean 
± standard error mean of at least three mice in ecah Pf strain. Only errors bars that extend 
beyond the symbols are shown. The percentage of parasitemia was calculated by flow 
cytometry as SYTO-16+ and TER119-PE- population. 
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Figure 39. Dynamics of human erythrocytes after infection of chimeric IL2 mice by i.v. with 
20x106 infected hEry at day 0 with different P. falciparum strains compared with the control 
strain 3D7 (close circles): V1/S (A), NF54 (B), D10 (C), RapI (D), K1 (E) and FCR3 (F). Mice 
received daily i.p. injection of hEry throughout the experiment. Data are the mean ± standard 
error mean of at least three mice per strain. Only errors bars that extend beyond the symbols 
are shown. The measurement of percentage of human erythrocytes (TER119-PE- events) was 
done by flow cytometry. 
As a conclussion, three of the Pf strains studied also provoke the massive clearance of 
human erythrocytes in the GSKPfHu mouse model (anaemia phase), as the control strain 
3D7. One of these strains, the V1/S resistant strain, cause the anaemia phase at the same 
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point as the control strain. By the contrary, the other two strains that cause anaemia 
showed a delay in the start of this phase when compared with the control strain (3D7). 
One of these strains is the NF54, which is the parental of the 3D7 strain, and the other is a 
modified strain that has a truncation in the ropthry protein (RapI). 
Additionaly, for three of the strains studied (D10, FCR3 and K1) there are not enough data 
to jump to a conclusion about the presence or absence of the anaemia phase in infected 
mice. 
Treatment with antiinflammatory drugs and macrophage depletors to reduce 
the human blood consumption 
It has been shown that in the GSKPfHu mouse model there is an activation of macrophages 
in the different phases of the model, detected by the presence of inflammatory cytokines 
and by the study of the erythrophagocytosis in the spleen and peritoneum. To test if the 
GSKPfHu mouse model could be modulated through the inflammatory answer, different 
classes of anti inflammatory drugs were administered to mice in the different phases of 
the GSKPfHu mouse model (engraftment, infection and anaemia phase). 
The drugs selected for this study were: i) Acetylsalicylic acid (Non-steroideal anti 
inflammatory drug); ii) Dexamethasone (Steroideal anti inflammatory drug); iii) Anti-GR1 
(antibody that blocks granulated differentiation antigen-1). Based on the 
pharmacokinetics properties of the drugs, different doses regimes were chosen. ASA and 
Dexamethasone were administered daily by oral administration, whereas Anti-GR1 was 
administered every 48 hours by i.p. injection. 
During the engrafment phase, IL2 mice received the anti inflammatory treatment as 
described above, starting the same day of the first human blood injection. Mice also 
received daily i.p. human blood injections throughout the experiment. This engraftment 
phase was studied during 14 days. 
In engraftment phase, after studying the acquisition of chimerism curve (figure 40), we 
can observe that only the engraftment curve of mice which received the treatment of 
Dexamethasone at 30 mg/kg is significantly different to the untreated mice (1 way 
ANOVA; Dunnett´s multiple comparisons test of AUCs0→14, p<0.05). 
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Figure 40. Comparison of kinetics of engratment with human erythrocytes in IL2 mice 
treated with anti inflammatory drugs: ASA, Dexamethasone and Anti GR1 (A, B and C, 
repectively) with  the control group (no treatment). All mice were injected i.p. with hE daily 
throughout the experiment and were treated with the corresponding anti inflammatory 
drug. Data are the mean percentage ± standard error of the mean of four mice in each 
experimental group. Only errors bars that extend beyond the symbols are shown. Percentage 
of human erythrocytes was calculated by flow cytometry as TER119-PE- events. 
After 14 days of engraftment, mice were infected. Parasite growth and anaemia phase 
were studied from day 0 to day 25 after infection (day of infection: day 0). During both 
phases mice received daily blood injections and were treated with anti inflammatory 
drugs. Comparing the engraftment curves (figure 41), it was revealed that all treatments, 
except Dexamethasone at 3 mg/kg, show similar parasite growth, without significant 
differences (1 way ANOVA; Dunnett´s multiple comparisons test of AUCs0→25, p<0.05). 
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Figure 41. Comparison of parasite growth after infection by i.v. with 20x106 infected hE at 
day 0 with P. falciparum (Pf3D70087/N9 strain) in IL2 mice treated with anti inflammatory 
drugs: ASA, Dexamethasone and Anti GR1 (A, B and C, repectively) with  the control group 
(no treatment). All mice were injected i.p. with hE throughout the experiment and were 
treated with the corresponding anti inflammatory drug. Data are the mean ± standard error 
mean of four mice in each experimental group. Only errors bars that extend beyond the 
symbols are shown. The percentage of parasitemia was calculated by flow cytometry as 
SYTO-16+ and TER119-PE- population. 
When studying human erythrocytes clearance during infection and anaemia phase, we can 
observe that the massive hEry clearance is showed under all treatments with anti 
inflammatory drugs (figure 42). Although there are visual differences in the curves, the 1 
way ANOVA test of the AUCs0→25 revealed that there are no significant differences among 
the treatments when compared with the control curve (p<0.05). 
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Figure 42. Comparison of the dynamics of human erythrocytes from day 0 to day 25 after 
infection of IL2 mice treated with anti inflammatory drugs: ASA, Dexamethasone and Anti 
GR1 (A, B and C, repectively) with  the control group (no treatment). Mice received daily i.p. 
injection of hE throughout the experiment and were treated with the corresponding anti 
inflammatory drug. Data are the mean ± standard error mean of four mice per experimental 
group. Only errors bars that extend beyond the symbols are shown. Percentage of human 
erythrocytes was calculated by flow cytometry as TER119-PE- events. 
As a conclusion, none of the treatments with anti inflammatory drugs inhibited the 
engrafment of IL2 mice with human erythrocytes, neither the growth of P. falciparum in 
these mice nor the massive clearance of hEry after infection with the parasite. Mice treated 
with Dexamethasone developed ascitis in the peritoneum, probably due to the lack of 
cleaning by the macrophages in the peritoneum after i.p. injections of hEry. 
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Figure 43. Kinetics of human erythrocytes after i.p. injection of 1 ml of human blood (50% 
hematocrit) in IL2 splenectomized (open cirlces) and non-splenectomized (close circles) 
naïve mice, within the first 24 hours (A) and complete kinetic until clearance of hE (B). Data 
are the the mean ± standard error of five mice sampled at different time points. Only errors 
bars that extend beyond the symbols are shown. Quantification of human erythrocytes 
(TER119-PE- events)  was done by flow cytometry using Trucount™ tubes. 
Test different mice strains to improve the engraftment with human 
erythrocytes 
One of the limiting factors in the engraftment process is the human blood. In order to 
improve the model and avoid the anaemia phase after the infection with the parasite, 
different backgrounds of immunodeficient mice were selected to study the engraftment 
with human erythrocytes, the infection with the parasite P. falciparum 3D7 and the 
anaemia phase. Four different mouse strains were tested and compared with the IL2 
control strain: i) Rag2IL2 (lack T, B, NK cells); ii) NOG (lack T and B cells, and decrease NK 
cells activity); iii) FRG (lack T and B cells, defect in macrophage regulation and NK activity, 
induced liver disease and liver was reconstituted with 80% of human hepatocytes); and 
iv) NRG (lack T, B, NK cells). At least 7 mice of each strain (except FRG strain, that 
experiment was done with only 2 mice), were injected i.p. daily with 1 ml of human blood 
(50% hematocrit). When mice achieved   70% of human erythrocytes in peripheral blood, 
they were infected by i.v. route with 20x106 infected erythrocytes. Parasite growth was 
studied at least until day 31 after infection to observe the presence or absence of the 
anaemia phase (massive hEry clearance) in the different mice strains. 
During the engraftment with human erythrocytes, results show that NOG, FRG and NRG 
strains supports the xenotransplant with human erythocytes and can achieve  70% of hEry 
in mice peripheral blood in around 20 days (figure 44B, 44C and 44D). However, hEry did 
not reach mice peripheral blood in Rag2IL2 mice (figure 44A). 
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Mice splenectomy to study xenotransplant rejection 
As shown previously, in the in vivo erythrophagocytosis study, in the spleen there are 
active macrophages populations that are in charge of the clearance of  hEry in the different 
phases of the GSKPfHu mouse model. The excision of the spleen may lead to a decrease in 
the number of hEry clearance. To confirm this hypthesis the kinetics of hEry after an 
unique i.p. injection of human blood was sudied in IL2 mice without spleen (quirurgically 
excised), and was compared with IL2 mice with spleen. 
A group of five mice were splenectomized three weeks before starting the experiment, in 
other to study the role of the spleen in the initial steps of the human erythrocytes 
xenotransplant in the GSKPfHu mouse model. 
Kinetics of hEry after i.p. dosing were studied until 92 hours after injection. Results show 
that in the first twelve hours, in which the acquition of hEry through the peritoneum takes 
place, there are a slight difference between splenectomized and non-splenectomized mice 
(figure 43A). This difference is not statistically significative (Mann Whitney test, p<0.05). 
In addition, after hEry reaches the maximum peak in mice peripheral blood (after 12 
hours, in both cases), hEry are cleared at the same speed in splenectomized and non-
splenectomized mice (30.2 and 31.4 hours, respectively) as shown in figure 43B. 
To conclude, kinetics of hEry after i.p. injection are very similar in splenectomized mice 
when compared with non-splenectomized mice. This result confirm that the spleen may 
not be the main organ involved in the fast clearance of hEry that occurs after the release of 
these erythrocytes in mice peripheral blood from a i.p. injection of human blood (50% 
hematocrit). 
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Figure 44. Kinetics of engraftment with human erythrocytes in different mice strains: Rag2 
IL2 (A), NOG (B), FRG (C) and NRG (D), compared with the control IL2 mice strain (close 
circles). Data are the mean ± standard error mean of at least 10 mice of each strain, except 
FRG mice which data belong to two mice. Only errors bars that extend beyond the symbols 
are shown. Percentage of human erythrocytes was calculated by flow cytometry as TER119-
PE- events. 
Further studies were done with the Rag2 IL2 strain, to understand the absence of hEry in 
peripheral blood.  Rag2IL2 mice received an unique i.p. and i.v. injection of hEry and 
kinetics of absortion and clearance was studied and compared with that obtained in IL2 
mice (figure 45). Clearance of hEry after i.v. injection is slightly faster in Rag2IL2 mice, 
6.97±1.11 hours (n=5) of half life, compared with IL2 mice, 10.75±1.52 hours (n=5) as 
shown in figure 45A. When studying the i.p. injection it was observed that Rag2 IL2 mice 
clearance of human erythrocyes after the release in peripheral blood is much faster than 
the observed in IL2 mice (half life of hEry 15.7 and 57.1 hours, respectively), figure 45B. In 
addition, hEry are completely cleared from mice peripheral blood 48 hours after i.p. 
injection in Rag2IL2 mice. Whereas in IL2 mice, this total clearance of hEry is achieved 96 
hours after the i.p. injection. This results suggests that macrophage activity may be 
increased in Rag2IL2 strain. As a result, human erythrocytes cannot be accumulated in 
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mice peripheral blood, so neither engraftment with human erythrocytes nor infection with 
P. falciparum can not be achieved in this mice strain. 
 
Figure 45. Kinetics of human erythrocytes after i.v. (A) and i.p. (B) injection of human 
erythrocytes in Rag2 IL2 (open square) and IL2 mice (open circles). Data are the mean ± 
standard error of five mice (except Rag2 IL2 i.p. that was done with three mice,  sampled at 
different time points. Only errors bars that extend beyond the symbols are shown. 
Quantification of human erythrocytes (TER119-PE- events)  was done by flow cytometry 
using Trucount™ tubes. 
When studying parasite growth in the different mice strains infected (NOG, FRG and NRG), 
parasite growth can be mantained in mice peripheral blood for 31 days after infection in 
NRG (figure 46C), 34 days in FRG (figure 46B) and 51 days in NOG mice (figure 46A). 
Parasite peak of parasitemia is similar in NRG and NOG mice strains compared with the 
control IL2 strain, around 10%. However, FRG mice parasitemia was variable in each 
mouse studied, one reached 9% of parasitemia peak, but the other did not reach a 
parasitemia higher than 1%. No robust data could be obtained due to the size of the 
population studied. In addition, in this strain, parasite was almost cleared completely 
when the massive hEry clearance took place, around day 20 after infection. 
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Figure 46. Parasite growth after i.v. infection of 20x106 infected hEry in chimeric NOG (A), 
FRG (B) and NRG (C) mice strains  compared with the control IL2 mice strain (close circles). 
Data are the mean ± standard error mean of at least 10 mice of each strain, except FRG mice 
which data belong to two mice. Only errors bars that extend beyond the symbols are shown. 
The percentage of parasitemia was calculated by flow cytometry as SYTO-16+ and TER119-
PE- population. 
During the infection of P. falciparum parasite, around day 10 after infection, massive hE 
clearance took place in all mice strains studied (figure 47). The starting point of the 
anaemia phase was similar to that found in the IL2 control strain. 
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Figure 47. Dynamics of human erythrocytes after infection of chimeric NOG (A), FRG (B) and 
NRG (C) mice, with i.v. injection of 20x106 infected hE at day 0, compared with the control IL2 
mice strain (close circles). Mice received daily i.p. injection of hE throughout the experiment. 
Data are the mean ± standard error mean of at least 10 mice of each strain, except FRG mice 
which data belong to two mice.  Only errors bars that extend beyond the symbols are shown. 
The measurement of percentage of human erythrocytes (TER119-PE- events) was done by 
flow cytometry. 
In conclusion, kinetics of hE engraftment and P. falciparum infection in NOG, FRG and NRG 
mice strain are similar to the IL2 control strain used in the GSKPfHu mouse model. Thus, 
these mice strains can also be used as a P. falciparum malaria mouse model. In addition, in 
the different immunodeficent genetic backgrounds studied the massive hEry clearance is 
also observed. 
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The GSKPfHu mouse model as a researching tool 
A reliable humanized model for erythrocytic stages of Plasmodium falciparum has been 
developed, which shows a reproducible model of infection. The GSKPfHu mouse model 
share some features with the infection of the P. falciparum parasite in the human host such 
as 48 hours erythrocytic cycle and a Severe Anaemia phase, which can not explained by 
the parasite growth. 
Due to this characteristics and the reproducibility of the infections, we can affirm that this 
model can be used as a valuable tool to study different aspects of the pathophisiolgy of the 
infection with the human parasite P. falciparum, for the test of new drugs against malaria 
disease and many other applications that need a metabolic activity of the parasite or the 
host. 
The evaluation of drugs for malaria treatment or drug development, so as studies on 
transmission to the mosquito host are part of the applictions that have been explored in 
this work. 
Drug discovery 
The emergence of parasite drug resistance to currently deployed antimalarials used such 
as chloroquine and artemisinin containing treatments, requires the urgent development of 
new medicines to replace the failing ones. Also, the commitment of the WHO to eradicate 
this disease have made possible to fund new projects to discover and develop a new 
generation of antimalarials with a differentitated mode of action. In the drug discovery 
process the animal models have been crutial to perform the efficacy assays needed in the 
preclinical steps of the drug development. In the case of the malaria, the most widely 
model used is based in a rodent pathogen, Plasmodium berghei, due to the limitations in 
the use of primates for the test of the new drugs in a human parasite. Therefore, the 
development of mouse models for the infection of the human Plasmodium parasite has 
been a major breakthrough in the malaria drug discovery field. 
The GSKPfHu mouse model of P. falciparum asexual erythrocytic stages has played a 
crutial role in development of new drugs against malaria. 
The routinary test used for validation purposes was based on the Peters´4-day test with 
minor modifications [114]. Briefly, the Peters´4 day test consist in the administration of 
compounds starting from one to three hours after the infection, treatment is performed 
during 4 consecutive days once a day administration, the resulting parasitemia is 
measured on the fifth day after infection (24 hours after the last dose administration), and 
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compared to the vehicle-treated controls. The test that is performed with the GSKPfHu 
mouse model is denominated 4-day test and differs from the original Peters´ test in the 
starting parasitemia, mice are infected 3 days before treatment starts (20x106 infected 
erythrocytes inoculum), to obtain a parasitemia detectable at the time of the first 
administration dose. In addition, parasitemia is measured every day of treatment and 24 
hours after finishing the treatment or day 7 after infection (figure 48). Parasitemia is 
measured by flow cytometry, this technique requires very small blood samples (less than 
5 l) and do not interfere with the evaluation of efficacy in vivo. At the same time that the 
efficacy assay is performed, blood samples for the measurement of compound levels is 
blood are taken from mice peripheral blood the first 24 hours of treatment at different 
time points, depending on the PK properties of the compounds, but a general sampling 
scheme is adopted (0.5, 2, 4, 6, 8 and 24 hours). The measurement of the Pharmacokinetics 
of the administered compounds is crutial to increase the knowledge about the efficacy of 
the compounds, it can give a clue if a compund do not show efficacy and it can be measure 
how long a compound is present in mice peripheral blood. Therefore, the 4-day test 
performed in the GSKPfHu mouse model is a simple assay wich allows to obtain 
concomitant information on pharmacokinetics (PK) and parasitological effects, 
pharmacocynamics (PD), of the compounds administered. 
 
 
Figure 48. Schematic representation of the complete experimental process for a 4-day test 
assay. First mice received in the facilities are acclimatization period of 5 days, then the 
engraftment process starts and lasts 2 weeks until mice are infected with 20x106 infected 
parasites. At day 3 after infection, treatment with antimalarial drugs starts and mice receive 
one dose for 4 consecutive days. Finally, parasitemia is measured every day and 24 hours 
after finishing the treatment to establish the parasite clearance curve. 
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The compound therapeutic efficacy can be expressed as the effective dose (mg of 
compound per kg of mouse body weight) that reduced parasitemia by 50% or 90% with 
respect to the vehicle-treated control group. Therefore, typical efficacy parameters 
calculated are the ED50, which is the effective dose where half of the parasite population is 
cleared by the treatment and currently is not very used in drug discovery, and the ED90, 
which in this case is the effective dose that clears 90% of the parasites under treatment. In 
addition, when the compound levels are analyzed simultaneously with the parasite 
clearance, another parameter can be estimated, the AUCED90, which consist in the quantity 
of compound in blood per hour needed to clear the 90% of parasites in peripheral blood. 
The ED90 and AUCED90 parameters obtained are very useful in the critical path of drug 
discovery to prioritize or stop a compound development to the next step. However, the 
final endpoint of an efficacy assay should be the non-recrudescent dose or the cure of the 
animal after the treatment. Recrudescence refers to the emergence of asexual parasites 
belonging to the same population that gave rise to the primary infection. Recrudescence 
can be due to incomplete or inadequate treatment as a result of drug resistance of 
improper choice of drug dose. The WHO values for non-recrudescent compound in malaria 
is the dose at which there no detectable parasite is observed 28 days after treatement is 
finished. For this reason, after the 4-day test against P. falciparum is performed, those 
doses that have been enough efficacious (parasite not detectable or less than 0.3%) are 
kept for a recrudescence period of 28 days after finishing the treatment, in which mice 
receive alternative human blood injections due to the low clearance of hEry observed in 
the absence of parasite. This non-recrudescent dose obtained after the assay is a valuable 
data for the human dose predictions before the clinical assays take place. 
Two examples for a 4-day test with a recrudescence study of drugs in clinical use have 
been detailed in this work for a better understanding of the efficacy assay. The first 
compound selected is Atovaquone, which is a selective inhibitor of cytochorme bc1 from 
the electron transport chain present in P. falciparum mithocondria [15]. Briefly, IL2 
engrafted mice were infected with 20x106 infected erythrocytes at day 0 of the assay. 
Then, treatment with different doses of Atovaquone started at day 3 after infection (0.01, 
0.05, 0.1, 1 and 10 mg/kg), mice received 4 oral doses once a day according to their body 
weight (20 ml/kg).  Samples from mice peripheral blood were taken every day from day 3 
to 7 after infection to measure parasitemia by flow cytometry (SYTO-16/TER119-PE). In 
addition, blood samples for the measurement of atovaquone concentrations were 
collected over the first 24 hours after dosing to establish the 
pharmacokinetics/pharmacodynamics (PK/PD) relationship. Chloroquine was used as a 
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reference drug and was used orally at 10 mg/kg, with the same treatment schedule. Mice 
were also dosed orally with 1% Methylcellulose as a control of parasite growth. Finally, at 
day 7 (24 hours after finishing treatment), mice which received efficacious doses were left 
for a recrudescence study. 
The therapeutic efficacy of Atovaquone against P. falciparum is shown in figure 49A. The 
parasite clearance by Atovaquone treatment is low, at day 7 parasite is still detectable by 
flow cytometry (limit of detection: 0.01%). The parasites grow exponentially in infected 
control animals and the same level of growth was observed in the experimental group of 
0.01 mg/kg/day. However, maximum parasite clearance occurred at or slightly above a 
dose of 0.1 mg/kg/day (figure 49A). Regarding to the drug exposures, there was a dose 
dependent behaviour with a half life of Atovaquone longer than the 23 hours duration of 
observation (figure 49B). Nevertheless, the drug exposure for the lowest dose (0.01 
mg/kg) was under the limit of detection of the technique (2.5 ng/ml). 
The parameters of efficacy estimated in the study are the ED90 and the AUCED90. The ED90 
is calculated by a non-linear fiting to sigmoid dose-response curve of log10 of percentage 
of parasitemia at day 7 after infection versus the dose (figure 49C). The AUCED90 is used to 
estimate the potency and it is determined by non-linear fiting to a sigmoid dose-response 
curve of log10 of percentage of parasitemia at day 7 after infection versus the area under 
the curve of levels of compound obtained during the first 23 hours after the first 
administration, it is assumed that the accumulation during the treatment has not 
significant effect (figure 49D). 
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Figure 49. Therapeutic efficacy of Atovaquone in a 4-day test against P. falciparum 3D70087/N9 
in GSKPfHu mouse model. In A it is represented the evolution of the percentage of 
parasitemia throughout the experiment, from day 3 (starting treatment) to day 7 (24 hours 
after finishing the treatment), data inside the red rectangle are used for the estimation of 
efficacy parameters. In B it is represented the levels of compound measured in mice blood 
during the first 23 hours of treatment. In C it is represented a sigmoideal dose-response used 
for the calculation of the efficacy parameter ED90 (log of %parasitemia at day 7 against log 
of doses administered to mice). In D it is represented a sigmoideal dose-response used for the 
estimation of the efficacy parameter AUCED90 (log of %parasitemia at day 7 against log of 
AUC of the levels measured for compounds at the different doses). In E it is resumed the 
results of the efficacy parameters calculated for Atovaquone (F). Data represented are 
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individual data for two mice for each dose and the mean±SEM of three mice in the case of the 
vehicle treated group. 
The efficacy parameters estimated for the Atovaquone are: ED90 = 0.05 mg/kg and 
AUCED90 = 0.03 mg·h/ml, which means that for killing the 90% of the parasite in mice 
blood it is needed a four day dose treatment of 0.05 mg/kg or a mantained drug level in 
blood of 0.03 g/ml every hour and day of treatment (figure 49E). 
These results mean that around 10% of parasite is still alive after the treatment, for 
instance, 0.05 mg/kg is not a curative dose. To determine a curative dose in a 4-day test, it 
is needed a complementary recrudescence assay. The recrudescence is the final endpoint 
of an efficacy assay in which it is calculated the non-recrudescent dose or cure. To obtain 
this value, mice treated with the doses that reduced the parasitemia below 0.3% at day 7, 
were monitored for up to 28 days after finishing the 4-day treatment to observe the 
emergence of parasites in mice peripheral blood. The recrudescence period has been 
considered based on the assumption that if only one parasite is left in mice blood after 
finishing the treatment, 28 days are enough to observe growth by flow cytometry. In the 
case of the Atovaquone, parasite was detected in all doses before 28 days after treatment 
was acomplished, in the highest dose (10 mg/kg) parasite was detected at day 17 after 
finishing treatment (figure 50). However, although the clearance of the parasite during the 
treatment was the same from at the three highest doses (0.1, 1 and 10 mg/kg), differences 
are observed in the recrudescence period. Indeed the dose of 0.1 mg/kg did not cleared 
the parasite below the limit of detection at day 10 after infection, whereas the doses of 1 
and 10 mg/kg completed the clearance of the parasite and entered into the recrudescence 
study. Finally, at the dose of 1 mg/kg the parasite growth was detected earlier than the 
dose of 10 mg/kg (figure 50). In conclusion, among the regime of doses used in the efficacy 
study of the Atovaquone: 0.01, 0.05, 0.1, 1 and 10 mg/kg there is no a curative dose. 
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Figure 50. Recrudescence study for Atovaquone. Data represented is the percentage of 
parasitemia measured by flow cytometry from day 3 to day 34 after infection, when 
recrudescence study is concluded (day 27 after finishing treatment). Data are the individual 
parasitemia data for two mice for each dose and the mean±SEM of three mice in the case of 
the vehicle treated group. 
The effect of drugs on the parasite population can be characterized by a detailed analysis 
of flow cytometry results.. The SYTO-16/TER119-PE staining can be used for a 
phenotypical study of the parasite populations affected by the treatment. The flow 
cytometry data suggest that the intracellular parasite can develop to a late-stage parasite 
after Atovaquone treatment but fails to form daughter merozoites and to propagate to the 
next generation (figure 51). This drug response is consistent with the primary activity of 
Atovaquone, which inhibits electron transport in the mithocondria but ultimately kills 
Plasmodium through downstream effects on pyrimidine synthesis. These studies have 
important implications for further understanding the mechanism of action of 
antimalarials. 
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Figure 51. Atovaquone 4-day test flow cytometry dot plots. In the X axis of the dot plots it is 
represented the fluorenscence of the DNA dye SYTO-16, more fluorescence intensity means 
more quantity of DNA. In the Y axis it is represented the monoclonal antibody TER119-PE 
which detects mouse erythrocytes. 
The second compound selected is Piperaquine, which is a compound that belongs to the 
aminoquinolone family which mecanism of action is based on the interference with the 
digestion of the hemoglobine by the parasite and targets the food vacuole of the 
trophozoite stage [127]. The therapeutic efficacy assay was performed as described for 
Atovaquone. Mice were dosed orally at 1, 5, 10, 25, 50 and 100 mg/kg for four consecutive 
days. 
In this case, the Piperaquine parasite clearance is fast, at the highest doses tested (25, 50 
and 100 mg/kg) parasitemia is under the limit of detection of the flow cytometry 
technique (0.01%) at day 5 after infection. However, the doses of 5 and 10 mg/kg obtained 
a parasite clearance at day 6 and 7, respectively. In addition, the parasitemia increased in a 
exponential manner at the lowest dose tested (1 mg/kg), comparable to the same growth 
in the infected vehicle-control mice. Of note, a dose dependent response was observed in 
treated mice (figure 52A). Regarding to the blood levels, it was observed a dose dependent 
behaviour with a half life longer than the 23 hours duration of observation (figure 52B). 
The ED90 and the AUCED90 were estimated (figure 52C and D). 
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Figure 52. Therapeutic efficacy of Piperaquine in a 4-day test against P. falciparum 
3D70087/N9 in GSKPfHu mouse model In A it is represented the evolution of the percentage of 
parasitemia throughout the experiment, from day 3 (starting treatment) to day 7 (24 hours 
after finishing the treatment), data inside the red rectangle are used for the estimation of 
efficacy parameters. In B it is represented the levels of compound measured in mice blood 
during the first 23 hours of treatment. In C it is represented a sigmoideal dose-response used 
for the calculation of the efficacy parameter ED90 (log of %parasitemia at day 7 against log 
of doses administered to mice). In D it is represented a sigmoideal dose-response used for the 
estimation of the efficacy parameter AUCED90 (log of %parasitemia at day 7 against log of 
AUC of the levels measured for compounds at the different doses). In E it is resumed the 
results of the efficacy parameters calculated for Piperaquine (F). Data represented are 
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individual data for two mice for each dose and the mean±SEM of three mice in the case of the 
vehicle treated group. 
The efficacy parameters estimated for the Piperaquine are: ED90 = 1.7 mg/kg and AUCED90 
= 0.8 g·h/ml, which means that for killing the 90% of the parasite in mice peripheral 
blood it is needed a four day dose treatment of 1.7 mg/kg or a mantained drug level in 
blood of 0.8 g/ml every hour and day of treatment (figure 52E). 
To determine a curative dose for the Piperaquine in a 4-day test, a recrudescence assay 
was done. Mice treated with the doses that reduced the parasitemia below 0.3% at day 7, 
were monitored for up to 28 days after finishing the treatment to observe the recurrence 
of parasite in mice blood. Five doses were studied in the recrudescence assay for 
Piperaquine, and only one mice treated with 5 mg/kg showed recrudescence within the 28 
days after treatment experiment time. Hence, four doses showed curation after a 4-day 
Piperaquine treatment: 10, 25, 50 and 100 mg/kg in mice infected with the huma parasite 
Plasmodium falciparum (figure 53). 
 
Figure 53. Recrudescence study for Piperaquine. Data represented is the percentage of 
parasitemia measured by flow cytometry from day 3 to day 35 after infection. Data are the 
individual parasitemia data for two mice for each dose and the mean±SEM of three mice in 
the case of the vehicle treated group. 
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In the phenotypic study for Piperaquine when comparing treated mice with the vehicle 
control, it can be observed that treated mice show a population of low quantity of DNA 
that is out of the region of “healthy parasite”, this type of parasite is known as pyknotic 
form and it is known to be a condensed parasite which still contains DNA (figure 54). The 
aminoquinolone-related compound, Piperaquine showed an expected drug response 
response, parasite death during the trophozoite stage and no effect on schizont rupture. 
Piperaquine can inhibit the development of ring stages to pigmented trophozoites 
producing pyknotic cells. 
 
Figure 54. Piperaquine 4-day test flow cytometry dot plots. In the X axis of the dot plots it is 
represented the fluorenscence of the DNA dye SYTO-16, more fluorescence intensity means 
more quantity of DNA. In the Y axis it is represented the monoclonal antibody TER119-PE 
which detects mouse erythrocytes. 
The potential efficacy of new antimalarial drugs can be assessed by the 4-day test. A 
comparison among different drugs under development can be determined. Sigmoideal 
dose-response curves of the log10 of parasitemia against AUC can be compared and 
differences in terms of potency and speed of clearance can be observed (figure 55). In the 
case of the Atovaquone and Piperaquine, although the Piperaquine is a fastest comopound 
in terms of speed of clearance, it is worse than Atovaquone in terms of potency, this means 
that more concentration in blood is needed for Piperaquine to kill the 90% of parasite (1.8 
g·h/ml), when for Atovaquone it is needed 10 times less compound in blood (0.03 
g·h/ml). However, in the recrudescence study it is observed that for the Atovaquone, 
besides being more potent thant Piperaquine, the minimum quantity of compound in 
peripheral blood needed to cure has to be higher than the needed for Piperaquine. 
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Figure 55. Sigmoideal dose response representation. In the X axis it is represented the AUC of 
the levels measurement in peripheral blood. In the Y axis it is represented the log of the 
percentage of parasitemia at day 7 after infection. Data are individual mouse, two mice per 
each dose and three for the vehicle treated mice. 
Phenotypic assay 
The reproducibility growth of the P. falciparum parasite in the GSKPfHu mouse model 
makes easy the study of the effect in parasite growth of potential antimalarial drugs. The 
combination of this reproducibility with the advantage of using flow cytometry techniques 
to quantify the percentage of parasitemia, makes possible the use of the GSKPfHu mouse 
model as a powerful tool for the experimental testing of antimalarials in vivo in a dose-
response assay. 
To study the effect of potential antimalarial drugs, it is important be able to detect parasite 
clearance under treatment with these compounds. To attempt this issue, IL2 mice 
engrafted with human erythrocytes, are infected with 20x106 infected erythrocytes. At day 
3 after infection, when parasite in mice peripheral blood is around 0.3-0.5% treatment 
with compounds starts. Mice receive a daily oral dose during 4 days of the compounds to 
be tested at efficacious doses previously defined (data not shown). Parasitemia is 
measured by flow cytometry (SYTO-16 and TER119-PE staining) during the treatment and 
24 hours after finishing the last dose, to observe parasite clearance under treatment. Flow 
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cytometry technique used has a limit of detection of 0.01%, so we are able to measure one-
log parasite decrease if parasite starts to decrease since the first dose received. 
Different drugs has been tested in the model and depending on the speed of parasite 
reduction, these drugs can be divided in four different categories: i) fast: parasite 
clearance is achieved 24-48 hours after starting treatment; ii) medium: parasite clearance 
is reached 72 hours after starting treatment; iii) slow: parasite is cleared 96 hours, and iv) 
very slow: parasite that do not reach the limit of detection at 96 hours after starting 
treatment (figure 56). 
 
Figure 56. Schematic representation of the percentage of parasitemia of infected mice 
treated orally during four consecutive days, once a day with 4 different standard 
antimalarials that show different parasite clearance speed. Parasitemia was measured by 
flow cytometry as SYTO-16+ and TER119-PE- population. The limit of detection of the 
technique is 0.01%. 
The use of flow cytometry techniques in drug discovery studies can give more information 
about the drugs tested. Different monoclonal antibodies and DNA staining used can give 
different information about the different stages of parasite and populations of 
erythrocytes infected. 
By using the DNA dye YOYO-1, a phenotypical study of the effect on parasite after 
treatment with several standard antimalarial drugs has been done. The combination of the 
YOYO-1 dye with the monoclonal antibody TER119-PE and the bidimensional analysis of 
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the dot plots can define different patterns on parasite effect of the different drugs tested in 
P. falciparum infected IL2 mice. 
IL2 mice engrafted with human erythrocytes were infected with 20x106 infected 
erythrocytes. Then, at day 3 after infection, fourteen anti-malarial drugs with different 
mechanism of action and belonging to different chemical families, were administered to P. 
falciparum infected IL2 mice per oral route at efficacious doses (based on previous 
experiment performed and in bibliography search in the case of proguanil and 
sulfadoxine), once a day during four consecutive days, as described previously. Blood 
samples were obtained 24 hours after the last dose (2 asexual cycles of the parasite), and 
stained with YOYO-1 and TER119-PE as described in material and methods, and analyzed 
using a bidimensional analysis in FL2/FL1 dot plots (figure 57). 
 
Figure 57. Flow cytometry patterns of affected parasite at day 7 after infection. Mice received 
an oral treatment once a day during four consecutive days with 13 standard antimalarial 
compounds and GSK932121 compound. Patterns are compared with healthy parasite shown 
on the vehicle treated dot plot. Patterns are determined using the YOYO-1 /TER119-PE flow 
cytometry analysis.  
The fast parasite clearance of Chloroquine, Artesunate, Amodiaquine, Piperaquine and 
Dihydroartemisinin (figure 58) showed patterns of event distribution of lower intensity at 
YOYO-1 (X axis) than healthy rings obtained from vehicle-treated mice. Parasites were 
pyknotic and vacuolated shrinked trophozoites in giemsa smears (figure 59). Conversely, 
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Atovaquone, Pyrimethamine, Primaquine, Proguanil and GSK932121 rendered YOYO-
1FL2/FL1 showed patterns with most infected events mapping to the trophozoite region, 
with a parasite clearance very slow or slow in the case of Pyrimethamine and Primaquine 
(figure 58). However, in the case of Pyrimethamine and Proguanil events showed in the 
trophozoite region are closer to the schizont region than those found in 
Atovaquone/GSK932121 pattern (figure 57). By contrast, in the case of Primaquine the 
altered trophozites are closer to the younger stages region, this means that the effect is 
concentrated in young trophozoites. Consistent with this observation, blood smears 
unveiled vacuolated trophozoites as the main phenotype remaining in circulation of mice 
treated with Atovaquone or GSK932121. However, trophozoites found in blood smears of 
mice treated with Proguanil or Pyrimethamine were swollen and morphologically 
different to that found in Atovaquone/GSK932121 treatment, in addition Primaquine 
blood smears showed shrinked trophozoites (figure 59), which confirm the differences in 
the cytometry patterns. Noteworthy, Mefloquine, Quinine and Lumefantrine treatment 
showed also altered trophozoites, but there were still some DNA synthesis and re-
infection, shown as envents in the schizont and ring stage region of the cytometry dot 
plots, and confirmed with the microscopy blood smear. In the case of Sulfadoxine, it 
showed no effect in the 4-day treatment assay against P. falciparum in the mouse model at 
the given dose of 100 mg/kg. 
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Figure 58. Parasitemia clearance after 4-day treatment with 14 different standard 
antimalarials. There were found different parasite clearance rate: in open black it is 
represented fast, in red medium, in blue slow and in green very slow parasite clearance. 
Filled black graphics correspond to vehicle and non efficacious treatment. Parasitemia was 
measured by flow cytometry as SYTO-16+ and TER119-PE- population. The limit of detection 
of the technique is 0.01%. 
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Figure 59. Microscopic photographies of P. falciparum infected mice blood smears stained 
with Giemsa. It is shown 4 representative photographies of each smear taken at day 7, 24 
hours after finishing treatment with 14 different antimalarial drugs. 
Transmission studies 
The GSKPfHu mouse model is able to sustain the intraerythrocytic phase of the P. 
falciparum parasite. In the human host, during this asexual infection inside the 
erythrocytes, some of the parasites develop into the sexual stages of parasite 
(gametocytes). These sexual stages are the responsible of the transmission of the malaria 
parasite to the mosquito host, where the parasite sexual reproduction takes place and new 
parasites are formed and are ready to infect new human hosts. 
The objective of the transmission studies is to evaluate the suitability of the GSKPfHu 
mouse model to be used to study the transmission of the human parasite to Anopheles 
mosquitoes. Two different aproaches has been evaluated: i) Natural transmission, where it 
is studied the ability of the P. falciparum in vivo adapted strain NF540230/N3 to develop to 
gametocytes in humanized mice peripheral blood and the infectivity of these gametocytes 
in Anopheles mosquitoes; ii) in vitro/in vivo transmission, where it is studied the ability of 
the GSKPfHu mouse model to sustain the engraftment with in vitro cultured Stage V 
gametocytes, then the infectivity of these gametocytes are studied in Anopheles 
mosquitoes. 
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Natural transmission 
IL2 mice were engrafted with daily i.p. injections of 1 ml of human erythrocytes (50% 
hematocrit). When these mice achieved around 50% of human erythrocytes in peripheral 
blood, mice are injected with 20x106 infected erythrocytes of Pf NF540230/N3 strain. 
Firstly, it is studied the ability of this strain to generate stage V gametocytes and fertile 
male gametes in humanized mice peripheral blood. To attempt this issue, mice infected 
with Pf NF540230/N3 were monitored from day 5 to day 26 after infections. Mice blood was 
collected from the lateral tail vein for flow cytometry study of the parasitemia (2 l), for 
Giemsa staining to study the presence of the different stages of gametocytes (2 l) and for 
the exflagellation assay to study the presence of fertile male gametes (2 l). 
Gametocytes at different stages were detected from day 12 to day 26 (figure 60). In 
addittion, the exflagellation is first detected at day 14 after infection, obtaining the peak at 
day 16 (figure 61A). The exflagellation peak does not match with the peak of parasitemia 
(figure 61B). However, the exflagellation takes place during the anaemia phase where the 
erythrocytes are massively cleared (figure 61C). 
 
Figure 60. Photographies from giemsa stained smears of mouse number 1 peripheral blood 
from day 12 to day 26 after infection. Stages I to V gametocytes are observed. 
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Figure 61. Graphic representations of the exflagellation counts (A), percentage of 
parasitemia (B) and total erythrocytes count (C) during infection with the P. falciparum 
NF54 strain. The exflagellation is checked under a light microscope using the 100X 
objective during a maximum of 10 minutes. The percentage of parasitemia was calculated 
by flow cytometry as SYTO-16+ and TER119-PE- population. The quantification of 
erythrocytes was done by flow cytometry, using Trucount™ tubes. Data represented shows 
the results of two individual mice from the experiment. 
The presence of exflagellation in mice peripheral blood suggests that the gametocytes 
generated by the Pf NF540230/N3 in the GSKPfHu mouse model strain may be fertile. 
To test the infectivity of Pf NF540230/N3 strain gametocytes, IL2 infected mice were put for 
mosquito feeding at different days after infection: 6, 10, 13, 15, 17, 20, 34 and 48. Briefly, 
mice were anesthetized before mosquito feeding. Then, mice were put on the mesh of the 
mosquito container, with 30 female mosquitoes each, to allow biting. Mosquito feeding 
was performed during 30 minutes in dark and at 26.5 ºC. After feeding, mosquitoes were 
incubated during 7 or 10 days in an incubator (12 hours of dark/light cycle, 26.5±1ºC and 
75-80% humidity). 
At day 7 or 10 after feeding, mosquitoes were disected to obtain the midgut for oocysts 
counting after staining with 0.1% mercurochrome solution. Oocsyts were found at 
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different days after infection: 6, 10, 13, 20, 34 and 48 (figure 62). In all cases only 1 oocyst 
was found in each midgut. The prevalence of mosquito infection obtained was around 5%.  
 
Figure 62. Photographies from mercurochrome stained midguts from mosquitoes used for 
mice feeding. Oocysts (black arrows) are observed in mosquitoes fed with mice infected with 
the Pf NF54 strain at different days after infection. 
In conclussion, the gametocytes generated by the P. falciparum NF54 strain able to grow in 
the GSKPfHu mouse model, are able to infect mosquitoes by natural transmission after 
mosquito biting. These results confirm that the GSKPfHu mouse model can be an apropiate 
tool to study the biology of mosquito infection and can be the starting point to develop 
transmission assays. 
In vitro/in vivo gametocytes engraftment 
In this aproach, IL2 engrafted mice, with at least 50% human erythrocytes in peripheral 
blood, are used for the xenotransplant of stage V gametocytes (Pf NF54 strain) from in 
vitro culture. Briefly, around 40x106 stage V gametocytes were injected by i.v. route in IL2 
mice engrafted with human erythrocytes. Mice did not receive daily injections of human 
erythrocytes after the injection of gametocytes and were monitorized until gametocytes 
were cleared from blood (day 7 after injection). Mosquito feeding with xenotransplanted 
mice was done at day 2 after gametocyte injection. 
After the injection, stage V gametocytes can remain in mice peripheral blood for at least 7 
days (figure 63A). Gametocytes are quantified by flow cytometry every day after the 
injection using the SYTO-16/TER119-PE staining (figure 63B). Stage V gametocytes can be 
quantified until day 7 after injection. However, the clearance of these gametocytes starts at 
day 1 after the injection. Half of the gametocytes are cleared from day 0 to 1. Nevertheless, 
clearance decreases after day 1. In addition, the morphology of stage V gametocytes in 
mice peripheral blood is normal (figure 63C). 
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Figure 63. Stage V gametocytes injection in engrafted IL2 mice. In A is represented a graphic 
of the count of stage V gametocytes in mice peripheral blood after injection. The 
quantification is done by flow cytometry by using Trucount™ tubes. Data are the 
mean±standard error of the mean of five mice. In B it is shown a dot plot graphic of the 
SYTO-16/TER119-PE staining and detection of stage V gametocytes. The detection of 
gametocytes by flow cytometry was defined as SYTO-16+ (high fluorescence intensity in FL1), 
and autofluorescence (high fluorescence intensity in FL2 in the SYTO-16+ region), the 
gametocyte population is marked with a red circle. In C it is exhibited a photographies from 
Giemsa smears of stage V gametocytes found in mice peripheral blood after the injection. 
The relative low clearance of stage V gametocytes found in engrafted IL2 mice peripheral 
blood, and the healthy morphology that they show, suggests that these gametocytes are 
fertile, also the presence of exflagellation is also confirmed. 
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At day 2 after injection and in order to test the infectivity of Pf NF54 stage V gametocytes, 
five IL2 injected mice were put for mosquito feeding, as it was described before. 
At day 7 after feeding, mosquitoes were dissected to obtain the midguts to confirm the 
presence of oocysts after staining with 0.1% mercurochrome solution. Oocysts were found 
in mosquitoes from all the containers (figure 64). In all cases 1 oocyst was found in each 
midgut. The prevalence of infection was around 6%, similar to that found in the natural 
transmission. 
 
Figure 64. Photographies from mercurochrome stained midguts from mosquitoes used for 
mice feeding. Oocysts (black arrows) are observed in mosquitoes fed with mice injected with 
the stage V gametocytes (Pf NF54 strain) from an in vitro culture. 
To conclude, IL2 engrafted mice are able to support the xenotransplant of stage V 
gametocytes. These gametocytes while in mice peripheral blood are fertile and are able to 
infect mosquitoes after mosquito biting of mice. These results confirm that the GSKPfHu 
mouse can be used in studies that combine in vitro/in vivo techniques for the study of the 
transmission of the P. falciparum parasite to mosquitoes. 
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Characterization of the GSKPfHu mouse model 
The parasite P. falciparum infects almost excusively human erythrocytes. The specificity of 
P. falciparum for its human host is the major limitation for the development of in vivo 
models to study the erythrocytics stages. The ability of the P. falciparum parasite to infect 
New World monkeys eythrocytes [51], made possible the use of these monkeys as an in 
vivo model to test new antimalarial drugs [67]. The use of non primate monkeys to study 
diseases has been drastically reduced in the last 30 years due to economic/ethical 
restrictions and a limited supply, and they are only used in research when there are no 
suitable alternative methods or species. For this reason, the development of mouse models 
able to support the study of many human diseases has become a crucial tool for 
researching. In the malaria field, the development of different types of immnudeficent 
mice opened the possibility to use these mice to study the parasite human host throughout 
its life cycle. There has been a huge advance in this field in the past 20 years [34, 131].  
 The election of the immunodeficent mice strain is crucial for the development of the 
correct mouse model for the study of the disease. The first attempts for the study of the P. 
falciparum erythrocytic stages used immunodeficent mice lacking both T and B cells (scid 
and NODscid mice). In these models, an additional depletion of host macrophages using 
liposomes containing clodronate was needed to obtain the correct engraftment with 
human erythrocytes [13, 97, 146]. Afterwards, new immunodeficent mice strains were 
developed that also lack a complete NK cells function were used for the engrafment with 
human erythrocytes without the addition of immunomodulators [5, 71]. With this new 
mice strain, the NODscid m-/- (abreviated 2), the engraftment with human erythrocytes 
had a reproducibilty that reached the 100%. The major limitation of this model is that the 
2 mice develop in a high rate spontaneous lymphomas and thymomas at a certain age, so 
the possibility to perform long lasting experiments with these mice is reduced. 
In this study it is described the use of a new immunodeficent strain, the NOD.Cg-Prkdcscid 
IL2rgtm1Wjl/SzJ mice (abreviated IL2) for the development of a new P. falciparum murine 
model without the use of immunomodulators [63]. The IL2 mice strain has a longer life 
span, compared to 2 mice, and lacks functional T, B and mature NK cells, and also has 
additional deficiencies in the innate immune system that makes these mice able to sustain 
different xenotransplants with human cells [58]. 
To study the suitability of the IL2 mice to be used as P. falciparum mouse model, these 
mice were engrafted with human erythrocytes and infected with the in vivo adapted P. 
falciparum 3D70087/N9 strain following the protocol previously described for the 2 mice 
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[5]. The engrafment with human erythrocytes were done by the daily intraperitoneal 
injection of 1 ml of human erythrocytes at 50% hematocrit (RPMI 1640, 25% 
decomplemented AB human serum, 3.1 mM hypoxanthine). The kinetics for the 
acquisition of the engraftment in IL2 mice was similar to the one obtained in the 2 mice. 
The time required for the achievement of 50% of hEry was also found to be in the same 
range (6.8 ± 0.1 days for IL2 and 6.9 ± 0.4 days for 2). These results confirm that IL2 mice 
are able to sustain the engrafment with human erythrocytes and could be susceptible for 
the infection with the P. falciparum parasite. 
Once a mouse strain is confirmed to accepts xenogenic grafts of human erythrocytes, the 
next step is to study the susceptibility of these mice to be infected by the human P. 
falciparum parasites. To succeed in the infection the first attempts included the use of 
immunomodulators to suppress the innate immune system of immunodeficient 
splenectomized mice in combination of intraperitoneal infections with P. falciparum 
parasites previously adapted to in vitro growth in presence of ascites fluid from mice. In 
these studies, the frequency of successful infections was about 25%, the infected mice 
displayed a variable kinetics of parasitemia and the parasite was only detectable until day 
7 after infection.  Further improvements in the immunosupresion protocol with the 
addition of a monoclonal antibody NIMP-R14, or the addition of inosine to the blood 
injection for mice lead to the obtaining of an increase in the reproducibility of the infection 
and long lasting parasitemias [7, 100]. However, the use of a more immunocompromised 
mice (2 mice) in addition to the use of intravenous infections with a P. falciparum strain 
that was adapted to grow in immunodeficent mice from an  in vitro culture succeeded in 
the achievement of a high reproducible infection with the human parasite in mice [5]. 
In this work, the susceptibility of the NODscidIL2Rnull mice to the infection by competent 
P. falciparum strain (Pf3D70087/N9) was studied. The infection was done with 20x106 
parasite infected erythrocytes by intravenous route in mice with at least an engraftment of 
50% of human erythrocytes in mice peripheral blood. The IL2 mice strain was able to 
sustain the infection with P. falciparum. In addition, several improvements, compared with 
2, were observed during the infection. Firstly, the Pf3D70087/N9 infectious burden in 
engrafted IL2 mice was 10-fold higher than that in engrafted 2 mice. This increment 
makes the IL2 Pf mouse model more suitable for drug discovery studies in which it is 
necessary to have a marked difference in the parasitemias between untreated and treated 
mice to evaluate the effect of different doses of drugs on parasitemia. Secondly, during the 
massive human erythrocytes clearance, the parasitemia is reduced but still detectable by 
flow cytometry. In 2 mice during this phase, the parasitemia is not detectable by flow 
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cytometry. This means, that long lasting experiments in which a minimum parastemia is 
needed can be performed with the IL2 P. falciparum model. 
Once the engraftment and the infection by competent P. falciparum strain with the new 
IL2 mice was confirmed, the IL2 mice was selected as the new model for the testing of new 
chemical drug classes developed in GSK providing a precise analysis of the parasitological 
response to different exposure levels of drugs in vivo. 
The  GSKPfHu mouse model has been widely used to test new antimalarial drugs. The new 
model represented an improved standard for preclinical in vivo studies of blood-stage 
antimalarial drugs. It has also been implemented as a crutial tool in preclinical phases for 
the selection and prioritization of new drug families to be developed in the fight against 
the malaria [64]. However, to the best of my knowledge, little is known about the 
behaviour of the parasite inside the mouse host, or how the mouse respond to the 
xenotransplant and infection with the human parasite. To gain further insights into the 
GSKPfHu mouse model, one of the main objectives was to characterize this P. falciparum 
mouse model, and determine critical points for its improvement. 
When the GSKPfHu mouse model was developed, the main priority was to assess a mouse 
model to test the activity of drugs against multiple stages of the P.  falciparum parasite 
asexual life cycle. All the stages of the eythrocytic cycle (rings, trophozoites and schizonts) 
are present at the same time in mice peripheral blood with no signs of sequestration in 
tissues, as it is observed in humans or the rodent P. berghei infection [5]. The P. falciparum 
growth observed in the mice is different from the described in the human host. In the 
natural infection P. falciparum shows a synchronic growth, in which only young stages 
(rings) are present in peripheral blood, trophozoites and schizonts are sequestered in 
different organs and tissues, mainly spleen, liver and brain. This sequestration has been 
long studied but the exact mechanism responsible of this phenomena is still unkown. 
However, it is widely accepted that the interaction between some parasite proteins and 
host proteins during infection of red blood cells are implicated in the process of 
sequestration [48, 132]. For this reason, it is not strange to understand that the 
sequestration does not take place in the GSKPfHu mouse model. The absence of human 
host proteins in these immunodeficent mice may suspect that the parasite can not be 
recognized by the organism for the sequestration process. 
The asynchronous development of the parasite in the animal model makes difficult the 
study of the intraerythrocytic cycle length in mice, it is not easy to track the parasite from 
ring stage to squizont stage when all the stages of parasite are present at the same time. To 
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overcome this issue, the parasite was synchronized to obtain a higher percentage of the 
same parasite stage, in this work we focus on the synchronization of mature stages. For 
the synchronization of the malaria parasite several methods have been developed and 
used for in vitro cultures in the last years, these methods include the use of reagents like 
sorbitol, plasmion or density gradient methods have been used throghout the last years 
[42, 122, 123, 125]. In this work, the synchronization of the parasite was perfomed  by the 
use of the magnetic separation, firstly to avoid the use of chemical reagents that could be 
injected accidentaly in mice or density gradients that makes difficult to separate 
parasitized erythrocytes from host white blood cells [3], and secondly to obtain the 
highest grade of synchronicity with less manipulation, only one step is needed to obtain 
the synchronic parasite [1]. 
The magnetic separation is based in the magnetic properties that present the haemozoin 
which is the result of haemoglobin metabolism by the parasite. After the magnetic 
separation, the fraction selected for the study of the intraerythrocytic cycle was the 
positive fraction, which is enriched with late thropozoites and schizonts, which are the 
stages that perform the most active metabolism. In previous experiments, this fraction 
was the one that showed the shortest window of synchronization (not shown). After the 
infection with this fraction, the ring infection length was observed from 7 to 21 hours after 
infection, the thropozoite stage is observed from 21 to 42 hours and the schizont stage is 
observed between 42 to 49 hours, these data of stages length are slightly longer than 
previously observed for in vitro cultures [122, 149]. The total length of the 
intraerythrocytic cycle in the Pf mouse model is 49 hours, also slightly longer than what it 
has been observed in natural Plasmodium falciparum infection in human beings, but the 
same length in other in vitro experiments performed with magnetic separation 
synchronization [1]. 
Little efforts have been done to understand what is the host answer inside the mouse 
recipient in the humanized mice models during the engraftment and infection process. 
Both processes take place mainly in the peripheral blood. However, it is in some way easy 
to study what is happening in a model that everything occurs in the peripheral blood. The 
peripheral blood can be easily obtained for study, and erythrocytes can be easily marked 
and monitored. In this work the measurement of red cells life-span (half life) and the 
distribution volume (red blood cells volume) are the parameters calculated for the study 
of the erythrokinetics in the GSKPfHu mouse model. In the Malaria field little has been 
studied regarding erythrokinetics neither in the natural P. falciparum infection nor in 
animal models of this infection. 
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The half life is a pharmacology parameter that can be used for the estimation of the speed 
of clearance of erythrocytes in live animals. In the GSKPfHu mouse model there are two 
kind of erythrocytes at the same time, human and mouse. On the other hand, the 
distribution volumen, in pharmacological terms, is used for the quantification of the 
distribution of a drug after administration. In the GSKPfHu mouse model it is assumed that 
the blood volume is the same as the distribution volume. In order to study this parameter, 
the erythrocytes are injected intravenously, these cells are distributed equally just after 
the injection in the peripheral blood with no retention or sequestration by the tissues or 
organs.  
In order to study these parameters, it is needed the tracking of erythrocytes insice mice, 
this has been investigated by labelling erythrocytes in vitro with subsequent reinjection of 
labeled cells into animals and tracking their distribution in peripheral blood while the 
animal is still alive. To determine the volume of distribution several methods are available 
which include radioactive iron or chrome labelled erythrocytes [19, 124]. However, in 
these methods it is needed the complete bleed of the animals for the estimation of the 
parameter, for this reason these methods are not suitable for long tracking of labelled cells 
in alive animals. Throughout the years, several cell tracking methods had been developed 
to study the cell division, proliferation or cell-based therapies in live organisms. However, 
most of these methods include the genetic manipulation of the cells to introduce in the 
genome a protein tagging system for signal amplification in gene expression and 
fluorescence imaging [70]. Nevertheless, these methods can not be used for the tracking of 
erythrocytes that lack DNA. In addition, there are other labelling methods that are based 
on fluorescence membrane labelling that can be more suitable for erythrocytes labelling. 
This type of labelling include reagents such us PKH26, DiOC6, Dextran, CFSE or Biotin-X-
NHS, that have been widely used for different applications in cell tracking [9, 79, 84, 110, 
121]. All these reagents were tested for erythrocyte labelling and posterior in vivo 
injection into the GSKPfHu mouse model. The best results based in fluorescence intensity, 
with non-toxicity and life span of labelled erythrocytes were obtained with CFSE and 
Biotin-X-NHS dyes. In addition, only a small sampling of peripheral blood from mice is 
needed for the monitoring and quantification of labelled erythrocytes and the 
measurement of distribution volume and half life, this allows to conduct long lasting 
experiments using the same mice. 
 In terms of blood volume, the normal values for a CD1 mouse is around 1.45 ml on 
average [152], 60% of this volume is plasma. The blood volume measured in IL2 naïve 
mice using the CFSE/Biotin method is 1.2 ml. However, with the daily injections of human 
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blood (50% hematocrit), the blood volume in IL2 mice increases 3 times higher (3.5 ml) 
compared with the naïve mice, and part of the plasma volume is mostly occupied by cells 
being reduced to 5-10% of the total volume. As a consequence, these mice showed an 
enlarged spleen and liver, and high irrigated tissues, similar to that found in the 2 
GSKPfHu mouse model in engrafted mice and in transgenic polycytemic mice that 
overexpress erythropoietin [5, 27]. Finally, when the blood volume is determined in the 
anaemia phase where erythrocytes are massively cleared, the value obtained is similar to 
naïve mice, 1.7 ml. Though the increment in organs size still present. 
Regarding to the estimation of erythrocytes half life in the GSKPfHu mouse model it has to 
be taken into account that in the same peripheral blood cohexist erythrocytes from human 
donors and mice host. The life span measured for human erythocytes is 120 days, and the 
half life in healthy people usually is around 50 days [37]. On the contrary, the life span 
determined for mouse erythrocytes is less than half of human, 50 days, this difference can 
be explained due to the more active metabolism showed by mice. The life span in mouse 
erythrocytes can be from 12 to 24 days depending on the method of calculation and the 
age of mice [54, 85]. When the half life is determined using the CFSE/Biotin method in 
GSKPfHu mouse model strong differences can be found depending of which phase of the 
mouse model is studied. 
When estimating the half life of mouse erythrocytes in naïve mice (IL2 mice before 
engraftment with human blood), it is observed that the value obtained, 15 days, is 
included in the range previosuly described for common mice. However, when human 
eythrocytes are injected in naïve mice the half life obtained is 5.4 hours after injection. 
This low value can be explained by a rejection of the xenotransplant that leads to the 
removal of these erythrocytes by spleen and peripheral blood macrophages. Nevertheless, 
when IL2 mice have been engrafted with human erythrocytes during 13 days the half life 
of human erythrocytes determined in this phase increases up to 10 days. In addition, 
mouse erythrocytes half life in this phase decreased and is similar to the one determined 
for human erythrocytes. These results suggest that the initial mechanism in the 
engraftment phase to recognize erythrocytes for removal, is saturated and reconigzes 
indiscriminately both human and mouse erythrocytes for the clearance. Consistently, the 
enhacement of the erythrophagocytosis and the decrease in the half life of mouse 
erythrocytes are factors described in mouse models of polycythemia, as a response of the 
increased level of red blood cells in peripheral blood [27].  
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After the infection, mouse and human erythrocytes half life decreased more than in the 
engraftment phase. Of note, human erythrocytes half life is slightly slower to the one 
determined for mouse erythrocytes (5 and 7 days, respectively). Presumably this 
enhancement of human erythrocytes removal might be due to the increment in the 
phagocytosis by spleen macrophages provoked by the presence of the parasite [72]. 
Finally, the parasite infection ends with the anaemia phase. At this point, human 
erythtrocytes are massively cleared, and the half life of these erythrocytes is slightly 
higher to that found in naïve mice. Also the kinetics of clearance of hEry is exponential, the 
same obtained in naïve mice. On the contrary, half life of mouse erythrocytes is similar to 
the estimated in the infection phase, 7 days. These results suggests that the clearance of 
human erythrocytes, at this phase is specific and it not performed randomly. 
In human beings, during the natural P. falciparum infection a severe anaemia is induced by 
the parasite. However, this phenomena does not seem to be strictely related to the levels 
of parasitemia in blood, it has also been observed in cases of low parasitemia burden [46]. 
This phenomena has been well studied and it is widely acepted that in part is caused by 
the alteration of the innate imflammatory mediators that lead to a massive phagocytosis of 
infected and uninfected erythrocytes [113]. Although multiple mechanisms have been 
proposed to produce the severe malaria anaemia (SMA) a detailed molecular mechanism 
has not been yet elucidated. Thus, what has been widely accepted is the fact that in the 
SMA clearance of uninfected erythrocytes is higher than the infected. Mathematical 
modeling of hematological data from human P. falciparum infections has suggested that up 
to 8.5 uninfected erythrocytes are cleared for every infected erythrocyte [59]. In addition, 
in rodent model of severe anemia with low parasite burden, the rate of 
uninfected/infected erythrocytes clearance obtained is much higher, 30:1 [46]. 
Nevertheless, under our experimental conditions in the GSKPfHu mouse model during the 
anaemia phase the quantity of uninfected erythrocytes cleared for every infected 
erythrocyte is 192. This increase in the rate of uninfected erythrocytes clearance in these 
mice is not strange taking into account that in the GSKPfHu mouse model the 
concentration of total erythrocytes is 12x106 per microlitre, when in a human the normal 
values are around 5x106 erythrocytes per microliter. Of note, the addition of fresh human 
erythrocytes do not avoid the anaemia, these new erythrocytes are also selected for the 
massive clearance. 
Of importance, the presence of the SMA in the GSKPfHu mouse model has revealed that the 
infection with P. falciparum in the mouse model has similarities to the natural infection 
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observed in the human host. These results suggest than the GSKPfHu mouse model can be 
a crucial tool for further studies of the mechanisms that involve this severe anaemia 
phenomena. Some authors suggest that these mechanisms may be driven by an 
immunological response to the parasite infection driven by the response to the RSP2 
protein of the parasite that is transferred to the erythrocyte or a disregulation of the 
innate imflammatory mediators such as IFN, IL12 or TNF [113, 156]. 
In the human host, the immune response to the P. falciparum infection is driven by the 
release of cytokines which leads to complex downstream metabolic changes. Recent 
evidences suggest that the immunological response may be implied in the 
pathophysiology of the disease [87]. By contrast, the immune response in the P. falciparum 
mouse models has been poorly studied, only the cytokines IFN and IL6 have been 
confirmed to be expresed in the presence on the human parasite in NODscid and IL2 mice 
[7]. In this work, several inflammatory cytokines (TNF, IL12p70, IFN, MCP-1, IL10 and 
IL6) have been evaluated to gain insights into the inflammatory process in the different 
phases of the GSKPfHu mouse model. 
In the natural P. falciparum infection TNF  is the molecule typically associated with 
pathology in malaria. It is critical for parasite kiling and preventing parasite replication. 
IFN has also a protective role during early stages of P. falciparum infection, so as IL6. 
However, IL12 and IL10 role is the protection against the development of malarial 
anaemia. Whereas MCP-1 is involved in the immune activation. 
The secretion of TNF in the human host is induced in macrophages by the infected 
erythrocytes and this cytokine can enhance the phagocytosis by the increase of expression 
of Fc in monocytes [87]. It is raised in those patients with severe malaria and has been 
implicated in the pathogenesis of murine cerebral malaria. TNFis also raised in placental 
malaria and is assodicated with low birth weight. Accordingly, the concentration of TNF 
in the serum of GSKPfHu mice increases in the phases where the parasite is present and 
the phagocytosis is enhanced, the infection and anaemia phase. 
The IFN in the human infection, plays an important role in the protection to blood stage 
malaria [87]. This cytokine is secreted by CD4+, CD8+ T lymphocytes and NK cells. By 
contrast, the IL2 mice lack T, B and NK cells, as a consequence, INF is not released in 
response to the infection in the GSKPfHu mouse model. However, this cytokine is detected 
in serum from P. falciparum infected NODscid mice, the parental strain of the IL2 mice that 
have functional NK cells. 
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The interleukine 12 is a immunomodulatory cytokine secreted from dendritic cells, 
monocytes and splenic macrophages, among other cells. The IL12 has been demostrated to 
be very important in malaria in the protection against blood stages [128]. The presence of 
IL12 modulates the macrophage activity and mediates the development of malarial 
anaemia [82, 113]. In the GSKPfHu mouse model it is observed that the IL2 levels increases 
from infection and reaches the peak in the anaemia phase. Of note, the levels of IL2 are 
higher in the phases of the model where the phagocytosis of human erythrocytes is 
enhanced, infection and anaemia. This behaviour correlates with what it is described 
about the stimulation of the IL12 secretion by the phagocytosis process [87]. 
Interleukine 10 is an antinflammatory molecule and it is associated to provide protection 
against SMA by preventing the massive production of pro-inflammatory mediators. It has 
been shown that decreased levels of IL10 is associated to severe anaemia in African 
children [74]. Accordingly, in the GSKPfHu mouse model where the severe anaemia is 
observed, IL10 levels in mice serum can not be detected. Interestingly, this cytokine is the 
only one that is detected during the engraftment phase, probably as an inflammatory 
response to the daily intraperitoneal injections. 
Elevated levels of IL6 has been observed in patients with severe malaria. However, lower 
levels of this citokine have been associated to hyperparasitemia in children with 
falciparum malaria [6, 83]. Therefore, lack of control of the parasitemia might be the 
reason why in the severe pathophysiology is observed  with increased levels of IL6. In the 
GSKPfHu mouse model the maximum peak of IL6 is reached during the infection, but this 
peak is only an isolated point in the different phases of the model and do not show a 
specific pattern. 
The monocyte chemotactic protein (MCP-1) is a chemokine involved in the inflammatory 
process and its effect is to organize the migration of leukocytes. In the malaria disease it 
has been found in children with P. falciparum infection [30]. Correspondingly, in the 
GSKPfHu mouse model, highest levels of MCP-1 are detected in infection and anaemia 
phase, the phases where more phagocytic cells are recruited. 
Most of the cytokines studied are present in the phases of infection and anaemia, and are 
related to the massive erythrocytes clearance. In murine malaria, parasitized and 
unparasitized red blood cells clearance are associated in some cases to induced apoptosis 
and posterior phagocytosis [144]. The recruitment of monocytes and macrophages in 
malaria infection is crutial to overcome the infection. In this study we have focused in the 
role of the spleen macrophages in the different phases of the GSKPfHu mouse model. We 
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have found that the macrophages phagocytosis of erythrocytes is active in all phases and is 
perfomed by F4/80 or GR1 positive cells, being the F4/80+ population more active in the 
phases where human erythrocytes are massively destroyed, infection and anaemia. The 
F4/80 is one of the most specific cell-surface markers for murine macrophages and is 
highly expressed in resident tissue macrophages, including spleen red pulp. In murine 
Plasmodium chabaudi infection it has been described an increment in the number of 
F4/80+ cells in the spleen red pulp [76]. In addition, it has been studied the role of F4/80 
macrophages in P. yoelii infection in a model of CD47-/- mice, the CD47 is a marker of self 
present in red blood cells that it is related to age-dependent phagocytosis. As a 
consequence, CD47-/- has an accelerated clearance of young erythrocytes, and this 
clearance is mainly performed by F4/80 macrophages in the spleen [17]. Accordingly, the 
clearance of human red blood cells in the Pf mouse model might be done as the result of 
the recognition as strange cells in the mouse spleen by F4/80 cells. 
On the other hand, the GR1 (Ly6C) molecule in mice is expresed mostly in neutrophils and 
monocytes. The role of this population in the spleen during the malaria infection is the 
clearance of infected erythrocytes in P. chabaudi infection [137]. In the GSKPfHu mouse 
model the phagocytosis of GR1+ cells is lower than F4/80+ macrophages, this difference 
might be due to GR1+ cells are only phagocytosing infected cells which are cleared during 
anaemia and infection phase, which are cleared in a lower number than uninfected 
erythrocytes. Consitently, the spleen in the malaria infection in the human host plays an 
important role in the clearance of infected erythrocytes so as the modulation of the 
expression of parasite antigens on the surface of infected red blood cells [119]. 
Optimization of the GSKPfHu mouse model 
In previous Pf mouse models described before, the route selected for the injection of red 
blood cells is the intraorbital plexus in mice previously treated with clodronate 
encapsulated liposeomes for the depletion of macrophages [12, 13, 98-101]. In our model 
for drug discovery purposes, the use of clodronate due to potential toxic effects and the 
possible intereference with tested drugs, needs to be excluded. Therefore, the injection of 
human red blood cells, in the GSKPfHu mouse model, is done mainly by intraperitoneal 
route. In addition, the intraperitoneal route for the daily human blood injections increases 
the reproducibility in the acquisition of chimerism [5]. Nevertheless, little is known about 
what happens with the erythrocytes after the injection in the intraperitoneal cavity. For 
this reason, in this work it has been studied the kinetics of the intraperitoneal injection, 
and it has been observed that less than 40% of human erythrocytes injected reached mice 
peripheral blood. In addition, the perfusion of the erythrocytes is slow and it takes 12 
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hours to reach the maximum peak of human red blood cells in mice peripheral blood after 
the injection. In addition, a secondary peak of human erythrocytes is found a 5 hours 
followed by a decrease in the number of hEry in the peripheral blood, this peak might be 
due to a sequestration in organs, as probably the spleen. In addition, the half life of human 
erythrocytes, after reaching tha maximun peak of absorption, was 6 times higher than the 
calculated after the i.v. injection in the erythrokinetics. This results may suggest that, 
although the erythrocytes are being cleared in a high proportion, there might be still 
erythrocytes that are being perfused to the blood stream from the peritoneal cavity. 
Therefore, it was hypothesized that the regime of injections every 24 hours, for the 
engraftment of mice, was suboptimal, human erythrocytes are being cleared from 
peripheral blood before the next injection is performed. Thus, new blood dosing regimes 
needed to be explored in further experiments to overcome this issue. 
One of reasons for the low prevalence of human erythrocytes after the intraperitoneal 
injection, might be due to the enhanced phagocytosis of the human erythrocytes in the 
peritoneal cavity before their perfusion to the peripheral blood takes place. IL2 mice have 
a reduced phagocytic activity due to their deficiencies in the cytokines signaling 
transduction due to the absence of the receptor  chain of the IL2 receptor [58]. Therefore, 
the erythrophagocytosis of peritoneum resident macrophages was determined in the 
GSKPfHu mouse model to confirm the activity of these macrophages. Peritoneal 
macrophages from naïve IL2 mice were extracted and put in a culture plate to study the 
ability of these cells to phagocytose human erythrocytes. It was found that IL2 peritoneal 
macrophages were active and performed the erythrophagocytosis, as well as splenic 
macrophages. Of note, in mice peritoneal cavity occurs erythropagocytosis, and this action 
is considered a rejection of the xenotransplant of human red blood cells by IL2 mice, as 
other authors have previously observed [55]. In addition, this rejection was also observed 
after the intravenous injection in naïve mice during the study of the erythrokinetic in the 
GSKPfHu mouse model where human erythrocytes half life in peripheral blood was only 6 
hours. Consequently, the function of the phagocytic system is active and responsible for 
the rejection of the xenotransplant with human erythrocytes, but this system can be 
saturated as observed before in the erythrokinetics studies. 
To overcome the rejection of the human erythrocytes after the injection, different human 
blood injections regimes were explored based on the results obtained in the kinetic of the 
intraperitoneal injection. For instance, the objective for these injections regimes was the 
saturation of the rejection mechanism to obtain an engraftment period lower than the 10 
days needed in the actual GSKPfHu mouse model [63]. These new regimes were based on 
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the change on the volume of blood injected testing 0.5, 1 and 1.5 ml and the frequency of 
these injections, 24, 48 and 72 hours. Other regimes tested were based in the injection of 
human red blood cells in reduced periods of time, every 12 hours instead 24 hours, to 
saturate the peritoneal erythrophagocytosis and accelerate the perfusion of the human 
erythrocytes through the peripheral blood. 
Regarding the volume of injection, 1.5 ml daily injections of human red blood cells 
decreased the time for engrafment to the half, in only 5 days 50-60% of human 
erythrocytes were in mice peripheral blood. However, these daily injections lead to a 
decrease in the body weight of mice, used as a measurement for animal welfare, for these 
reason this regime was discarded. 
In terms of reducing the period of time of human blood injections needed to obtain 50-
60% of human erythrocytes in mice peripheral blood, the best results were obtained in 
mice injected every twelve hours for two consecutive days. The engraftment period was 
reduced to four days, without altering the body weight of mice. These results suggest that 
the clearance system can be saturated only in two days, and the human erythrocytes can 
be accepted by the mouse immune system as a self erythrocyte. 
Further studies were done for the optimization of the GSKPfHu mouse model, one of these 
studies included the characterization of the growth of different P. falciparum strains, to 
overcome the anaemia phase and the massive clearance of human erythrocytes. Several 
studies have been done to elucidate the molecular mechanisms involved in the selection 
for elimination of uninfected erytrhocytes, one of the most accepted causes of this 
clearance is that these erythrocytes have been in contact with merozoites and marked by 
the transference of the protein RSP-2 present in the ropthry of the merozoite to the 
erythrocyte surface. The presence of this protein in the eythrocyte membrane lead to the 
recognition of the erythrocytes by the spleen macrophages for their elimination [138].  
Different strains were selected based on their characteristics: the parental strain NF54, 
resistant strains as V1/S, FCR3 and K1, and the transgenic strain Rap I which lacks the 
Rophtry proteins 1 and 2, which have been described as the responsibles of the clearance 
of non infected erythrocytes during the P. falciparum infection [75, 138], and its parental 
strain D10. The growth of these strains was compared with the 3D7 in the GSKPfHu mouse 
model and it was observed that the resistant strain V1/S in the same way than the 3D7, 
regarding to the anaemia phase, it was provoked at the same day after infection, although 
the peak of parasitemia found in the V1/S strain was 3 times higher than the control strain 
3D7. However, the RapI and NF54 strain caused a delay of the aneamia phase starting 20 
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or 15 days later than the anaemia phase in 3D7 that occurs at day 10 after infection. The 
parasitemia peak found in these strains is similar to the one observed in the 3D7 strain. 
These results suggest that the anaemia phase may be not related to the amount of parasite 
found in mice peripheral blood. In human SMA is proportional not to circulating 
parasitemia but total parasite mass (sequestered) in the organs. The delay in the anaemia 
phase found with the RapI strain might be due to the absence of the ropthry proteins, but 
although the lack of these proteins, the anaemia phase takes place in the GSKPfHu mouse 
model. Presumably, this anaemia mechanism is crutial for the parasite life cycle and there 
might be redundant routes that lead to the massive clearance of uninfected erythrocytes 
provoking the anaemia. Despite the health importance, all the immunological mechanisms 
involved in the induction of the malaria anaemia remain incompletely understood 
although some efforts in the field has been done [41, 59, 75].  
During the massive erythrocytes clearance and throghout the different phases of the 
GSKPfHu mouse model there is an activation of the inflammatory process leading to the 
release of different anti inflammatory cytokines and the activation of the phagocytosis by 
different populations of macrophages. To study the effect of the inflammatory response 
throughout the different phases of the model, IL2 mice were treated with different anti 
inflammatory drugs. Therefore, three different anti inflammatory drugs were used: i) 
Dexamethasone, which is a synthetic glucocorticoid that inhibits multiple 
immunocompetent cell types such as monocytes and macrophages, that are active in the 
GSKPf mouse model; ii) Acetylsalycilic Acid, which is a non-steroideal antiinflammatory 
drug that inhibits the production of prostaglandine that is secreted during an infection or 
an inflammatory process; iii) Anti GR-1, which is used for the depletion of GR-1 positive 
cells that include monocytes and macrophages. Mice were treated with different doses of 
these drugs, neither a massive growth of the parasite, nor the decrease of the massive 
erythrocytes clearance was found under the treatment that inhibits partially the activation 
of the phagocytic cells. 
One of the main organs implied in the activation of the inflammatory response is the 
spleen. The spleen also serves as a filter that can remove red blood cells from circulation 
because of either physiological senescence or pathological alterations. When studying the 
structure and morphology of the spleen it can be found that the specialized structure of 
the venous system of the red pulp is responsible of the clearance of abnormal and 
senescent erythrocytes, so as the innate immune response by the presence of granulocytes 
and macrophages. Although the spleen has a crutial role in the malaria infection [119], it is 
not clear it is is involved in the rejection of the xenotransplant. Therefore, the engraftment 
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of human erythrocytes by intraperitoneal injections have been studied in IL2 
splenectomized mice. Though the relevance of the spleen, no effect of the splenectomy was 
observed, IL2 splenectomized mice presented the same degree of rejection of the 
xenotransplant with human erythrocytes after the intraperitoneal injection as the non-
splenectomized mice. Therefore, other organs could be involved in the clearance of the 
human erythrocytes in the absence of the spleen, this organ might be the liver, which is 
implied in the clerance of erythrocytes in the cases of polycythemia (incresed number of 
erythrocytes in peripheral blood) [27]. As a consequence, the absence of the spleen it does 
not seem crucial in the rejection of the xenotransplant with human erythrocytes in IL2 
mice. 
It is clear that the rejection of the xenotransplant of human erythrocytes in the IL2 mice is 
mainly driven by the innate immune system, that is the only immune response still 
present in this mice strain. There are several mutations that provoke serious 
immunodeficiency in mice. The most common mutation used is the Prkdcscid, which are 
characteristic for the absence of B and T lymphocytes caused by arresting the lymphocyte 
development [29]. This mutation is present in the IL2 mice strain used in the GSKPfHu 
mouse model. However, the Rag2 and Rag1 mutations prevent the genetic recombination 
required for functional B and T cells receptors, resulting in a similar immune defects. 
These mutations confere increased resistence to radiation, making these mice strain more 
suitable for the study of tumors [89, 95, 134]. The generation of IL2 receptor gamma chain 
knockout produces the absence of NK cell activity in the scid or Rag background, 
increasing the immunodeficiency of the mice. 
Different immunodeficent background were tested to evaluate the ability to sustain the 
xenotransplant with human erythrocytes and the infection with the P. falciparum parasite. 
The mice strains tested were: Rag2 IL2, NOG, NRG and FRG. All the different genetic 
background explored lead to the absence of T and B cells, in addition to NK deficent cells. 
Although the immunodeficency are similar in all strains tested, different results were 
obtained with one strain, the Rag2 IL2. The engraftment with human erythrocytes was not 
possible due to the fast clearance of the erythrocytes after the release of human 
erythrocytes in peripheral blood after the intraperitoneal injection, 24 hours earlier than 
in IL2 mice. However, the rest of the strains studied behaved in the same way as the IL2 
strain, sustaining the P. falciparum infection but being unable to avoid the massive 
clearance of human erytrocytes. 
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Although different efforts have been done for the optimization of the GSKPf mouse model 
regarding to avoid the massive clearance of human erythrocytes none of the efforts 
explored had a positive outcome. Further studies must be done in this field to establish the 
mechanisms that induce the severe anemia associated with the infection caused by human 
parasite P. falciparum. However, in spite of these difficculties the GSKPfHu  mouse model is 
able to sustain the growth of the human P. falciparum parasite and the innate immune 
response found in mice in addition to the severe malarial anaemia are similar to the found 
in human beings during the infection with the falciparum parasite. These evidences 
support the fact that the GSKPfHu model can be considered as a powerful tool of research 
on malaria disease progression. 
The GSKPfHu mouse model as a researching tool 
The establishment of mice with genetic immune deficiencies, such as loss of T and B 
lymphocytes and carrying null mutations in the IL2 receptor common gamma chain has 
allowed the efficient engraftment of different types of human cells [112]. The humanized 
mouse models are crucial for the study of human infectious diseases, cancer biology an 
more recently, regenerative medicine. In the case of malaria , the development of a 
reliable mouse model for the human parasite P. falciparum has been a major 
breakthrough and has circumvented the ethical concerns for the use of non-human 
primates, that were the only alternative for malaria in vivo studies several years 
ago. Indeed, the establishment of a reproducible P. falciparum mouse model have changed 
the drug discovery panorama in the malaria field over the past 10 years. Several 
compounds that actually are in clinical phases of drug development have been tested in 
the GSKPfHu mouse model [61, 103, 117]. 
The main advantages of the GSKPfHu mouse model are based on the feasibility, it is 
needed immunodeficent mice and human blood, and the reproducibility of the P. 
falciparum growth without the addition of immunomodulators that can interfere with 
other drugs when the model is used for drug discovery assays. The use of IL2 mice has 
been crucial for the malaria drug discovery. These mice do not develop thymic 
lymphomas, as the 2 mice used in the first Pf mouse model developed in GSK facilities [5], 
allowing the performance of long term experiments. Besides, these mice are unable to 
clear P. falciparum infection without therapeutic interventions. These characteristics have 
made the GSKPfHu mouse model a reference tool in the development of new antimalarial 
drugs. 
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The use of this model can provide estimates of the efficacy therapeutic parameters in 
terms of efficacy dose and drug exposure by the use of a modified Peters´ 4-day test. The 
main modifications consist on the treatment starting point, in which mice are treated 
during 4 days starting when parasites are detectable in mice blood by flow cytometry. 
Whereas in the original 4-day test mice treatment starts from one to three hours after the 
infection, so parasite growht is not exponential. During the treatment, parasitemia is 
measured everyday to quantify the effects of the drugs on the parasite growth which 
allows to obtain parasite clearance curve. However, in the Peters´ 4-day test parasitemia is 
measured only 24 hours after finishing the treatment. Finally and in addition to the Peters´ 
assay, within the first 24 hours samples of the measurement of the drug levels in blood are 
obtained for each mouse included in the assay. The measurement of parasitemia and drug 
levels in blood is done for each individual mouse included in the assay to explore the 
individual differences. 
The parameters of efficacy obtained from the 4-day test are essentially measurements of 
potency to achieve a biological endpoint. The usual biological endpoins estimated are the 
reduction in parasitemia with respect to the vehicle treated mice, the ED90, which is the 
effective dose that reduce parasitemia by 90%. Additionally, the measurement of the drug 
levels in mice blood can be used for the estimation of another efficacy parameter can be 
estimated, the AUCED90, which is the quantity of compound per hour in blood needed 
every 24 hours of treatment to reduce the parasitemia by 90%. However, the final 
biological endpoint in the efficacy assay and the one that usually is used in the human dose 
prediction and modelling, is the curative dose or the dose that do not have recrudescence 
of parasite up to 28 days after finishing treatment with the drug. 
In this work, two complete efficacy studies are included. Compounds exhibit a different 
inhibition profile. However, although the effect of the Atovaquone is slower, the quantity 
of compound needed to kill the 90% of the parasite (ED90) is less than the needed for a fast 
compound as the Piperaquine (0.05 mg/kg for Atovaquone versus 0.8 mg/kg for 
Piperaquine).  Moreover, the quantity of drug in blood needed to kill the 90% of the 
parasitemia (AUCED90) in the case of Atovaquone is also less (0.03 mg·h/kg) than the 
needed for Piperaquine to kill the same percentage of parasite (0.8 mg·h/kg). These 
results suggests that the speed of clearance of parasite is not the main driver for the 
estimation of the potency of the compound. In this case, the biological endpoint used is the 
ED90 or AUCED90 and do not take into account the parasite clearance rate, but the final 
parasitemia obtained 24 hours after finishing the treatment. For this reason, the 
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Atovaquone, in spite of being considered a slow acting drug is more potent that 
Piperaquine. 
Among the doses tested for the Atovaquone in the 4-day test (0.01, 0.05, 0.1, 1 and 10 
mg/kg), the maximal biological effect or parasite clearance curve is reached at the dose of 
0.1 mg/kg. As a result, the following doses obtain the same biological effect. Paradoxically, 
when the recrudescence study is performed to find the curative dose for Atovaquone it is 
found that the doses of 0.1, 1 and 10 are not curative doses and show different time to 
recrudescence response although having reached the maximal biological effect. 
Consequently, within the development of Atovaquone, when used as a single monotherapy 
agent in the treatment of P. falciparum, was probed to be highly effective, but it was 
associated to high recrudescence rates, and the emergence of resistances were observed 6 
months after treatment [15, 81], concuring with what it has been shown in the 4-day 
efficacy assay in the GSKPfHu mouse model. These results prevented Atovaquone to be 
marketed alone and actually is used in combination usually with Proguanil, which 
synergized with Atovaquoen and provides better results in terms of parasite relapse [80]. 
When Piperaquine was administered to the infected mice, the maximal biological effect is 
found at the dose of 10 mg/kg, among the doses tested (1, 5, 10, 25, 50 and 100 mg/kg). In 
addition, at this dose it is reached the curative dose, none of the mice at this dose and 
higher showed recrudescence up to 28 days after finishing the treatment. The Piperaquine 
treatment in human beings also lead to a fast clearance of parasite, with up to 5 hours of 
parasite clearance half life after starting treatment in patients. In addition, the rates of 
parasite recrudescence are lower compared to Atovaquone, with 100% of cure in the 
patients that received the highest dose of Piperaquine alone in a recently clinical study 
performed [111]. Although Piperaquine is a very effective marketed antimalarial 
compound, it is administered in combination (usually Dihydroartemisinin) to avoid the 
emergence of resistant parasites after treatment [45]. 
The GSKPfHu mouse model has become an unique tool to analyze the properties of drugs 
as future medicines. The use of human pathogen in the model has been crucial to explore 
the translational use of the model for malaria disease [4], and it has been used in multiple 
projects during the discovery and development of new antimalarial drugs inside and 
outside GSK facilities [28, 69]. 
In human beings the efficacy of a drug is measured by the rate at which the parasite are 
cleared from peripheral blood and the rate of cure after treatment [154]. In the 4-day test 
performed with the Pf mouse model, the parasite clearance rate is not used as a 
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measurement of efficacy, but the differences in parasitemia at a given time of the assay 
with respect to the vehicle-treated controls, the daily sampling for parasitemia 
measurement and the non-recrudescence dose (cure after treatment), can be used for the 
modelling of parasite clearance rate in human with different potent softwares used by 
modellers. In addition, the microsampling of mice employed in efficacy studies for the 
measurement of drug levels in blood, can be used for the estimation of the PK/PD 
relationships that drive the efficacy, and parameters such as the quantity of drug needed 
every 24 hours to kill the 90% of parasite (AUCED90) or needed to obtain the maximun 
parasite clearance (MCP) can be estimated and used for human dose predictions in the 
clinical study designs in the first time in human phase [90]. 
The 4-day test with drug levels measurement have been designed to obtain the maximun 
information of a potential antimalarial compound such as potency, speed of parasite 
clearance and time to recrudescence in only one assay. This information can be increased 
depending on the readout technique used for the parasitemia measurement. Several years 
ago, the gold standard for parasitemia assessment was microscopy with Giemsa stained 
smears, and nowadays is usually used in areas in which malaria is endemic. In countries 
where the first time in human clinical trials with healthy volunteers are done, the qPCR is 
an alternative method used for the parasitemia readout [90, 111]. However, the 
introduction of flow cytometry for the detection of the Plasmodium parasite has implied a 
huge breakthrough in the malaria field in pre-clinical phases of drug discovery. Thus, 
previous methodology as microscopy is a very time consuming technique and it is needed 
specialized personnel to obtain a reliable result, and for qPCR usually is needed higher 
content of blood sampling (from 50 to 70 l), that makes difficult the daily sampling of 
mice without provoking an anaemia. However, the flow cytometry technique provides 
higher throughput, statistical power, accuracy in the counting of low parasitemias and it is 
less time consuming, and it is only needed 2 l of blood per sampling point [62]. 
Consequently, the flow cytometry technique for the detection of parasite have been 
implemented in the pre-clinical stages of drug development and has started to be 
implemented for malaria diagnosis in malaria endemic areas in the last 5 years [35]. 
The use of flow cytometry parasite detection can be crucial to obtain more information 
about the drug tested in the 4-day efficacy assay providing further insights regarding the 
mode of action. The incorporation of high-content experimental designs might increase 
the decision-making and translational value of GSKPfHu mouse model. Indeed, a 
phenotypic study of the dying profile and parasite speed of clearance for treated 
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falciparum parasite can be done. This study might give a clue about the mode of action of 
the drugs tested. 
In this work it is described how the YOYO-1 bidimensional analysis combined with the 
monoclonal antibody TER119-PE improve the sensitivity of the flow cytometry technique 
making suitable the characterization of all P. falciparum erythrocytic stages. Once it has 
been validated that the YOYO-1/TER119-PE technique is susceptible for the detection of 
slight differences in terms of complexity and DNA quantity in the different parasiste 
stages, it can be taken a step forward considering the possibility of usign YOYO-1 to 
monitor the morphological changes that parasite suffers under treatment with potential 
antimalarial drugs in the 4-day efficacy assay. Thus, it is proposed that the use of YOYO-1 
technique can elucidate the most likely vulnerable erythrocytic stages to the treatment. 
The addition of phenotypic effect to the in vivo 4-day assay may increase the information 
obtained in this assay. The validation of the phenotypic effect observation was assesed 
using standard commercial antimalarial drugs. There, mice received 4-day treatment and 
samples from peripheral blood were stained with the YOYO-1/TER119-PE technique. The 
used antimalarial drugs belong to different chemical families with different mechanism of 
action to validate our hypothesis, but not all of them are well known. According to the 
results obtained, it has been defined five different dying profiles based on the patterns 
shown in the YOYO-1/TER119-PE patterns found, and four different speed of parasite 
clearance (fast, medium, slow, very slow) depending on the time that parasite takes to be 
cleared from peripheral blood after starting treatment (24-48 hours for fast, 72 hours for 
medium, 96 hours for slow and more for verly slow clearance), which could be 
accountable of mode of actions with a defined delayed phenotype. 
Regarding to the speed of clearance, this phenotypic characteristic might be crutial when 
in early stages of drug discovery it is needed a filter to discriminate different type of drugs 
to target a single dose treatment in clinical studies or slow acting drug to be developed as 
a partner of a fast acting compound in drug combination therapies [104, 130]. In the last 
years, the only study to discriminate this characteristic has been in vitro studies of 
parasite reduction rate [79]. However, in the 4-day assay with the daily parasitemia 
sampling is posible to obtain a complete curve of parasite clearance in a alive host, where 
the pharmacokinetics properties of the drug and metabolism of the host may play a crutial 
role to define the final effect of the drug in the parasite, characteristics that actually can 
not be simulated in in vitro cultures. 
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According to the results obtained, it has been able to define five different patterns of dying 
profile when analyzing YOYO-1/TER119-PE samples from treated mice. For instance, in 
the pyknotic pattern it has been englobed those compounds that produced shrinked 
parasites at the end of the treatment, this pattern is common in compounds that show a 
fast-medium parasite clearance. Compounds enclosed in this group such as Chloroquine, 
Amodiaquine and Piperaquine belong to the same antimalarial class, the 4-
aminoquinolines. By addition, these compounds share the same mechanism of action, 
which is the prevention of biocrystallization of the haeme group in the food vacuole [108]. 
The haeme group is generated from the digestion of hemoglobin in the food vacuole by the 
parasite, it is toxic to the parasite and must be detoxified through polymerization to form 
hemozoin (malaria pigment). Other compounds are included in the pyknotic group but 
neither belong to the same antimalarial class nor have the same mechanism of action of 
the aforementioned compounds. Indeed, Artesunate and Dihydroartemisinin belong to the 
endoperoxide class and their proposed mechanism of action is the production of free 
oxidative radicals, reactive metabolites that can react with free hemin present in 
hemozoin and hemoglobin forming haeme adducts, and the disruption of membrane 
transport [107]. Although the compounds included in the pyknotic dying profile do not 
share the specific mechanism of action, flow cytometry pattern suggest that they have the 
same global final effect on parasite population and the most sensitive parasite stage to 
treatment is the young stages (rings and early trophozoites), due to the fact that there is 
not shown a parasite maturation YOYO-1 pattern at the end of treatment. Whereas, the 
low intensity population showed by YOYO-1 dot plots, suggests apoptotic form of parasite, 
confirmed by microscopy. This fact may reflect a final step in the parasite intoxication as a 
consequence of the treatment with the different compounds that lead to the same final 
fate. 
By contrast, Primaquine belongs to the 8-aminoquinolines chemical class which is derived 
from the 4-aminoquinolines series, but differs in the mechanism of action, that is still not 
completely understood but it is thought to cause an interference with the cellular 
respiration and a dysregulation of the electron transport in the mitochondria [47], showed 
a dying profile that can be defined as shrinked trophozoites, that lead to parasite death in 
a different way as Chloroquine and Piperaquine. Although Primaquine belong to a similar 
chemical class as Chloroquine, it differs in its mechanism of action, these differences may 
explain the discrepancy observed in parasite dying profile and in parasite clearance speed, 
in which Primaquine induces a slow parasite clearance. 
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In the same way, compounds included in another dying profile, the vacuolated, belong to 
different chemical families although they share similar mechanism of action. In this profile 
it is included Atovaquone, that belong to the Hydroxy-1,4-naphthoquinone family, a GSK 
compound, the GSK932121 that is included in the 4(1H)-pyridone chemical family, and 
Primaquine which is a 8-aminoquinolines. When compound GSK932121 was developed, 
little was known about its mechanism of action. However, when this chemical family was 
selected for the progression to clinical phases further studies were performed and 
concluded than shared the same mechanism of action and Atovaquone but it showed 
efficacy against Atovaquone resistant strains [96]. Both compounds block the electron 
transfer chain by binding to parasite cytochrome bc1 at different sites, and prevent the 
transport of H+ to the intermembrane space and block the pyrimidine synthesis needed for 
the replication of DNA required before the schizontal phase [15, 36]. Indeed, treatment 
with these compounds lead to the blockage of parasite replication, as shown in YOYO-1 
pattern, in which parasite is retained in trophozoite stages but showing an altered pattern 
when comparing with the vehicle treated mice. Both compounds, also share a very slow 
parasite clearance profile. In this case, parasite death is caused to an avoidance of 
replication, instead of a direct death provoked by an oxidative stress or loss of the 
metabolism. For this reason, it is needed that parasite reach the trophozoite stage to be 
affected by the treatment. In addition, affected parasite is probably retained in the same 
stage and can still be alive, in some way, until it is cleared by the host immune system, this 
may explain the slower parasite clearance profile. 
Pyrimethamine and Proguanil also affect the trophozoite stage but it a slightly different 
way as Atovaquone and GSK932121. These compounds belong to the type-2 antifolate 
chemical family, which mechanism of action is the inhibition of the dihydrofolate 
reductase enzime (DHFR), leading to the inhibition of the biosynthesis of pyrimidines and 
purines, needed for DNA synthesis, and some aminoacids essential for the parasite 
survival [159]. Consequently, the effect found in flow cytometry pattern is very similar to 
that found for Atovaquone and GSK932121, that also inhibited the pyrimidine synthesis. In 
this case, the parasite dying pattern can be defined as swollen profile. However, the 
parasite stage affected for the treatment is also the trophozoite. However, Pyrimethamine 
and Proguanil parasite clearance is medium-slow, medium for Pyrimethamine and slow 
for Proguanil. This different parasite clearance speed in comparison to Atovaquone might 
be due to Pyrimethamine and Proguanil inhibits other biosynthesis pathways in addition 
to the pyrimidines synthesis, that provokes a faster parasite death. Of note, the differences 
between the Pyrimethamine and Proguanil in the speed of parasite clearance may be due 
to the fact that Proguanil need to be metabolized by the hepatic cytochrome P145 to 
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cycloguanil, that is the dihydrofolate reductase inhibitor [150]. This delay until the 
obtaining of the active metabolite might be the caus of the delay in the parasite clearance. 
Sulfadoxine is another antifolate antimalarial, but belongs to the type-1 subfamily, which 
mechanism of action is the inhibition of the dihydropteroate synthase enzyme (DHPS), 
which is also a enzyme belonging to the parasite folate pathway previous to the DHFR that 
is inhibited by Pyrimethamine and Proguanil [57]. However, in this case the Sulfadoxine 
treatment led to no effect in the parasite reduction. This result might be due to an 
insuficient dose administered to mice (100 mg/kg), nevertheless little is known about the 
monotherapy treatment of Sulfadoxine in vitro or in clinical studies in human beings that 
support the fact that the dose used was inadequate. 
Finally, there is another dying pattern obtained in this phenotypic study, that show 
swollen young stages (young trophozoites) in YOYO-1 staining, but this incovenience is 
not able to stop parasite maturation and parasite reinfection under treatment is possible 
in some way, as a result, parasite clearance is slow. Compounds that cause this pattern 
belong to the same chemical family, the aryl amino alcohol, and compounds tested 
included in this family are Quinine, Mefloquine and Lumefantrine. Although its mechanism 
of action has to been yet well elucidated, they show the same pattern in YOYO-1 staining. 
However, it is said that the mechanism of action is based on preventing the detoxification 
of the haeme group, as a result the toxic haeme and free radicals that are released induce 
parasite death [10, 127]. These mechanism of action can be similar to the 4-
aminoquinolines family (pyknotic profile), but the aryl amino alcohol compounds seem to 
have lower affinity to the haeme group and may prevent the haeme polymerization by 
antagonism instead of clumping. Among the aryl amino alcohol compounds tested, the one 
that showed more effect is the lumefantrine (at the end of the treatment parasite clearance 
is better). Consequently, lumefantrine is metabolized by the cytochrome P450 to desbutyl-
lumefantrine, that have been described to have from 5 to 8 fold higher antiparasitic effect 
than lumefantrine itself [10]. 
Phenotypic studies used in early stages of drug development, when little is known about 
the compounds, can be crutial in the decision making process in terms of compound 
priorization. In addition, this assay that can elucidate the most likely vulnerable 
erythrocytic stage, in addition to a specific dying profile, when added to in vivo screening 
assays may transform this type of assay in High-content High-throughput in vivo screening 
without neither the addition of extra sampling nor the performance of an extra assay. 
These data have important implications for understanding or predicting the clinical 
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efficacy of drug treatment, design of drugs, or combinations with broad activity across 
different developmental stages and for measuring the development of mechanisms of drug 
resistance [65, 148]. 
The fight against malaria includes the search for drugs that can affect the parasite in the 
different stages during the infection of the human host: liver and erythrocytes that include 
asexual and sexual stages. In the recent years the efforts to eradicate the malaria in the 
world has been focus on the asexual erythrocytic stages, that are responsible of the 
pathology of the disease, and the gametocytes (sexual stages), that is the only stage within 
the life cycle of malaria parasite that are able to mediate the transtition from the human 
host to the insect host. The advances in the generation of P. falciparum mouse models have 
been crutial for the development of new potential antimalarials against erythrocytic 
stages. However, actually it is not available a reliable in vivo model to study the efficacy of 
this compounds against sexual stages. 
Gametocytes can be successfully produced in in vitro cultures, and there are available 
assays that can be used to evaluate the efficacy of compounds against the different 
gametocytes stages and also male and female gamete formation, that are the reproductive 
stages of parasite [44, 77, 92]. The current “gold standard” test of the ability of a 
compound to prevent transmission to mosquito is the standard membrane feeding assay 
(SMFA), which permits the feeding of stage V gametocytes in the absence or presence of 
compounds to mosquitoes in a experimentaly controlled manner [78]. 
In vitro studies are very important for the discovery of new antimalarials, but the final 
effect of the compound has to be tested not only in the parasite but also evaluate the 
physiological consequences on the host or the effect of the host metabolism in the drugs 
tested. The lack of small animal models to study the transmission blocking potential of 
drugs is a barrier for the conduction of essential preclinical researching. For this reason, it 
has been studied the ability of the GSKPfHu mouse model to be used as an in vivo tool for 
the study of the transmission blocking potential of new compounds. However, first of all it 
is needed to study the ability of the GSKPfHu mouse model to support the sexual stages of 
the P. falciparum parasite. 
For this purpose, it is studied the instrinsic ability of the P. falciparum NF54 in vivo 
adapted strain to produce gametocytes without the addition of any reactive for the 
induction. It has been described before the presence of gametocytes in other P. falciparum 
humanized mouse models. However, these models are based in the direct injection of a P. 
falciparum parasite grown in an in vitro culture or that comes from a human volunteer to 
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the engrafted mice without previous adaptation to the mouse host [7, 97]. For this reason, 
it is not well known neither the gametocytes detected in mice peripheral blood have been 
developed in the previous recipent nor the induction of gametocytes have been done in 
the humanized mice. Gametocytes need up to 15 days to develop from stage I to stage V, 
which is the one that is infective to mosquitoes [73]. However, in the GSKPfHu mouse 
model it has been studied the gametocytogenesis in a Pf strain adapted to grow in 
humanized mice after several in vivo passages until obtain a reproducible growth, up to 21 
passages were done, with at least 1 passage per week [5]. For this reason, in this case 
there is no doubt that the presence of gametocytes in this mouse model is the result of the 
natural induction and production in the mouse host. 
The gametocytogenesis in the GSKPfHu mouse model was monitored up to 26 days after 
infection. Gametocytes in all stages (form I to V) were detected in giemsa smears. In 
addition, an exflagellation assay was performed to assess the viability of stage V 
gametocytes and it was revealed that the peak of exflagellation is about day 16 that is close 
to the 15 days required in the human host to reach the stage V gametocytes [73]. 
Consequently, a transmission study to mosquitoes was done as a confirmation of the 
viability of gametocytes, it was found that mosquitoes were infected with a prevalence of 
5%, that is much lower to that found in other Pf humanized mouse model, 38% [97]. 
However, it is tha same value as the prevalence obtained in the natural P. falciparum 
infection in the human host [43]. 
Although this value confirms that the GSKPfHu mouse model can mimic what is happening 
in the nature, for the development of a transmission blocking assay it is needed an 
increase in the mosquito prevalence and number of oocysts per mosquito to be able to 
observe the effect in the reduction of this prevalence after the treatment with new drugs. 
For this reason, a new approach was considered to overcome the deficiencies of the 
natural transmission approximation. 
In this new approach, a combination of in vitro/in vivo assay was designed. Stage V 
gametocytes were cultured and purificated, then injected to IL2 engrafted mice, with at 
least 50% of human erythrocytes to avoid the rejection of the gametocytes. At this 
percentage of human erythrocytes no additional blood injections are required throughout 
the experiment, due to the fact that hEry half life is more than 10 days and the experiment 
is designed to last 4 days. Half live of stage V gametocytes in the human host is 2.4 days 
[141], and consequently in the GSKPfHu mouse model the half life of the injected stage V 
gametocytes was measured in 3 days. These results confirms that there is no rejection of 
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stage V gametocytes in the mouse host. The viability of the gametocyes was also studied 
and confirmed by the exflagellation assay. Therefore, a transmission study to mosquitoes 
was assessed to confirm the viability of these gametocytes. It was found that although the 
concentration of gametocytes was higher than in the natural transmission study, the 
prevalence of mosquito infection was similar, 6%. 
These results suggest that the GSKPfHu mouse model can be used to test the ability of 
compounds to block transmission of P. falciparum gametocytes from humanized mice to 
mosquitoes. However, further efforts have to be done in order to set up a reliable and 
reproducible in vivo transmission blocking assay. These efforts may include either to find 
and adapt new P. falciparum strains with a reproducible higher yield of late-stage 
gametoyces and focus the adaptation on the reinforcement of the sexual stages by using 
passages through mosquitoes to mice with human liver (FRG mice) and viceversa if the 
natural transmission strategy is aborded, or to identify the issues that are provoking the 
low prevalence in mosquito infection as may be the high hematocrit that humanized mice 
show or the purification step previous to the injection of the stage V gametocytes, if the in 
vitro/in vivo approach is selected. Actually, these efforts are being done and in few months 
new data will be obtained. 
  
.
  
 
 
 
 
 
 
 
 
 
Conclusions/Conclusiones
  
  
 
165 Conclusions/Conclusiones 
Conclusions 
1.- IL2 mice has allowed the establishment of an efficient and robust P. falciparum 
humanized mouse model in which the xenotransplant of human erythrocytes is 
reproducible and can be optimized by changing the regimes of human blood 
injections to mice. 
2.- The P. falciparum growth is reproducible and the GSKPfHu mouse model can 
sustain the infection with different P. falciparum strains. The P. falciparum erythrocytic 
cycle length in the GSKPfHu mouse model have been demonstrated to be the same as in 
the human host, 48±1 hour. These results suggest that the GSKPf Hu mouse model can be 
used as a good surrogate for the P. falciparum erythrocytic stage. 
3.- The characterization in the GSKPf Hu mouse model of the erythrokinetics of human and 
mouse erythrocytes makes possible the discrimination of three different phases in the 
model: engraftment, infection and anaemia. The anaemia phase is characteristic for the 
massive clearance of infected and uninfected eythrocytes. This pathology has been 
previously described in the P. falciparum infection in the human host and is one of the 
causes of the high mortality of the malaria disease, the severe malarial anaemia. 
4.- The innate immune response to the xenotransplant of human erythrocytes and 
infection with P. falciparum in the GSKPfHu mouse model are mediated by the release of 
inflammatory cytokines by phagocytic cells. The cytokines secretion pattern is similar to 
that found in the natural P. falciparum infection in the human host. 
5.- The GSKPfHu mouse model has been validated for the test of antimalarial drugs and the 
obtaining of the efficacy parameters in the model are crucial for the decission making for 
different drug development projects in preclinical stages. 
6.- The GSKPfHu mouse model can sustain the sexual development of parasite, and the 
transmission to mosquitoes have been demonstrated. These results lay the groundwork 
for the development of a transmission blocking assay to test the abitily of new drugs to 
block the transmission to mosquitoes. 
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Conclusiones 
1.- Los ratones IL2 permiten el establecimiento de un modelo de ratón humanizado 
eficiente y robusto en el que el xenotransplante con eritrocitos humanos es reproducible y 
es susceptible de ser mejorado mediante cambios en la pauta de inyecciones de sangre 
humana a los ratones. 
2.- El crecimiento de P. falciparum es reproducible y el modelo murino GSKPfHu es capaz 
de soportar la infección con diferentes cepas de P. falciparum. Además, se ha demostrado 
que la duración del ciclo eritrocítico en el modelo murino GSKPfHu es la misma que en el 
hospedador humano, 48±1 horas. Estos resultados sugieren que el modelo murino 
GSKPfHu puede ser usado como sustituto para estudiar la fase eritrocítica de P. falciparum. 
3.- La caracterización de las eritrocinéticas de los eritrocitos humanos y de ratón en el 
modelo murino GSKPfHu hace posible la discriminación de tres fases diferentes en el 
modelo: quimerización, infección y anemia. La fase de anemia se caracteriza por la 
eliminación masiva de eritrocitos infectados y no infectados. Este patología ha sido 
descrito en la infección de P. falciparum en el hospedador humano y es una de las causas 
de la alta mortalidad de la malaria, la anemia severa. 
4.- La respuesta inmune innata al xenotransplante de eritrocitos humanos y la infección 
con P. falciparum en el modelo murino GSKPfHu está mediada por la secreción de 
citoquinas inflamatorias por las células fagocíticas. El patrón de secreción de citoquinas es 
similar al encontrado durante la infección de P. falciparum en el hospedador humano. 
5.- El modelo murino GSKPfHu ha sido validado para testar fármacos antimaláricos y la 
obtención de parámetros de la eficacia de estos fármacos en el modelo son cruciales para 
la toma de decisiones en los diferentes proyectos de desarrollo farmacéutico en fases 
preclínicas. 
6.- El modelo murino GSKPfHu es capaz de soportar el desarrollo de las formas sexuales 
del parásito, y la transmisión a mosquitos ha sido demostrada. Esos resultados sientan las 
bases para el desarrollo de un ensayo para evaluar la capacidad de bloquear la 
transmisión a mosquitos de nuevos fármacos. 
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